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This volume of the International Journal of Molecular Sciences contains a collection of articles by
colleagues of Antonius (Ton) Gerardus Rolink (19 April 1953–6 August 2017). Ton had participated
in an FP7 Marie Curie Initial Training Network called DECIDE (decision-making within cells and
differentiation entity therapies), and the DECIDE partners have submitted articles for this Special
Issue. Articles have also been submitted by scientists outside the DECIDE network. We would like to
thank all authors for their valuable contributions to this volume.
The DECIDE (decision-making within cells and differentiation entity therapies) network initially
arose from the shared interests of Drs Ceredig, Brown, and Rolink in the subject of the process of blood
cell formation, or haematopoiesis, and in particular, how progenitor cells differentiate to give rise
to the different blood cell types. Haematopoiesis is an archetype cell-lineage system with which to
study cell-lineage choice. Research in this area is driven by the need to understand this process at the
basic scientific level, as well as abnormal haematopoiesis, in particular, the development of leukaemia.
Based largely upon the sequential appearance of blood cells during ontogeny and the close and
pairwise relationships between the blood cell types, Brown had initially proposed a radically different
(developmental) view of haematopoiesis [1]. In addition, work with cell lines had demonstrated that
the B-cell and myeloid lineages were more closely related than what was envisaged by the “classical”
model of haematopoiesis. In this model, after an early bifurcation, lymphocytes derive from a common
lymphocyte progenitor (CLP), whereas myeloid cells derive from a common myeloid progenitor (CMP).
Clearly, cloned cell lines with both lymphoid and myeloid potential posed a problem for the classical
model. Subsequently, the work by Amanda Fisher from Ceredig’s laboratory [2] showed that cloned
lymphoid tumours arising in an interleukin-7 (IL-7) transgenic mouse line possessed both lymphoid
and myeloid potentials. Finally, the seminal papers from Ton’s laboratory describing cell lines deficient
in the transcription factor Pax-5 and with a multi-lineage (including lymphoid, in this case T-cell and
myeloid) potential also contributed to the need to rethink models of haematopoiesis [3,4].
Thus, after some initial discussions, we three (Ceredig, Rolink, and Brown) decided to put some
ideas into writing, and in 2009, we published an opinion article in Nature Reviews Immunology [5].
Based on ideas expressed in this article, we then decided to apply for funding in order to address
these ideas. After several iterations and the inclusion of chemists and pharmacists interested in using
vitamin D analogues for the control of myeloid cell differentiation and the treatment of leukaemia,
funding for the Marie Curie DECIDE network was finally approved in 2013.
In all of the above processes, Ton showed immense enthusiasm for the science. In the meantime,
his laboratory had identified an apparently homogeneous bone marrow-derived progenitor population
with both lymphoid and myeloid potential, and termed it early progenitor with lymphoid and myeloid
potential, or EPLM. With the help of two early stage researchers employed by the DECIDE network
working in Ton’s laboratory (Audrey Lilly von Münchow and Llucia Alberti Servera) and two in
Brown’s group (Ciaran Mooney and Alan Cunningham), it now transpires that the original EPLM
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population contains four phenotypically distinct subpopulations. At the genotypic level, the earliest
EPLM subpopulation contains individual cells already committed to either lymphoid or myeloid
lineage, with essentially no bipotent cells [6].
It must be mentioned that Ton made a massive contribution to the DECIDE network.
His enthusiasm for the science has already been mentioned, and this continued throughout the lifetime
of DECIDE, even when ill health prevented his full participation. Ton was always prepared to give
advice to other members of the DECIDE consortium on projects that were not necessarily aligned with
his own research interests. This typifies Ton’s immense generosity and profound knowledge of areas
of science outside his immediate domain. His participation in and organization of DECIDE meetings
was much appreciated (Figure 1). All 12 Marie Curie Fellows were in receipt of his encouragement
and advice regarding their projects. Unfortunately, from early 2017, health issues prevented his
participation in the last DECIDE meeting held in Galway.
Figure 1. (L–R) Andrew Kutner, Rhodri Ceredig, Geoffrey Brown, Eva Marcinkowska, and Antonius
(Ton) Gerardus Rolink at the Wroclaw DECIDE (decision-making within cells and differentiation entity
therapies) consortium meeting in April 2014.
All of the DECIDE partners are eternally grateful for having had the privilege of knowing and
working with Ton, and we dedicate this Special Issue to his memory. In this issue, five DECIDE
partners—Brown, Ceredig, Kutner, Sánchez-García, and Marcinkowska—describe some of their
findings from the DECIDE work. In 2009, Brown, Ceredig, and Rolink first published their pairwise
model for haematopoiesis, and this formed the major scientific basis for establishing the DECIDE
consortium [6]. The pairwise model replaces the “classical”, bifurcating lineage tree models with a
continuum-like view of the spectrum of fate options open to each hematopoietic stem cell (HSC). In tree
models, the progeny of HSCs progress through a series of intermediate hematopoietic progenitors,
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progressively closing down the lineage options. In the pairwise model, each HSC either self-renews
or chooses directly from all of the end-cell options, and then “merely” differentiates. HSCs are also
versatile; even soon after their progeny has selected a lineage, they can still step “sideways” to adopt
alternative, closely related fates. In their review article in this issue, Brown and Ceredig examine
the importance of the developmental ancestry and environmental nurture of HSCs, and argue that
stem and progenitor cells are sensitive to lineage guidance by environmental cues. Thus, a cell’s
environmental history is important to the specification of lineage [7].
A proposition by Sánchez-García, developed from studies using in vivo models of
leukaemogenesis and of carcinomas, relates to the role(s) of oncogenes in the leukaemia and cancer
cells-of-origin. He argues that some oncogenes prime the epigenome of leukaemia-initiating cells,
but they need not be active thereafter for tumour progression and maintenance. This oncogene “hit”
programs the HSC epigenome towards a defined leukemic cell fate. All of the progeny of the resulting
clonal leukaemia stem cells (LSCs) then progress towards one leukemic lineage. Vicente-Dueñas,
Sánchez-García, and colleagues review the notion of epigenetic stem cell rewiring as a driver of cancer,
emphasising that this mechanism represents a common mechanism at work in epithelial tumours [8].
In the case of leukaemia, rewiring fixes the identity of leukaemia cells at the level of HSCs. As HSCs
are versatile, an interesting proposition is that the acquisition of a stable oncogene-initiated block to
such lineage versatility is a key initiating step to the generation of LSCs and cancer stem cells. This may
be a cardinal feature of cancer.
1α,25-dihydroxyvitamin D3 (1,25D3)—a physiologically active metabolite of vitamin D—is a
potent differentiating agent for both normal and malignant cells, and vitamin D prevents malignant
transformation and reduces tumour progression in experimental models, and may be important in
human disease. 1,25D3 is also a central regulator of calcium homeostasis, with high doses leading to
hypercalcaemia. During DECIDE, Kutner designed and synthesised a panel of novel analogues of
vitamin D2, which separate the differentiating and calcaemic actions of 1,25D3, and are substantially
more potent differentiating agents. At the DECIDE meetings, Ton often asked the question of
how could this be, with just the one receptor for 1,25D3, namely the vitamin D receptor (VDR)?
Presently, we do not know the answer to this important question. Kutner and Brown outline some
of the rules for eliminating calcaemic action while retaining potency for cell differentiation. A-ring
chair β-conformation and (24E) side geometry are important for differentiating activity, an aromatic
modification of the CD-ring reduces the calcaemic action, and a rigid and straight (24E) sidechain
confers resistance to catabolism [9].
1,25D3 and all-trans-retinoic acid (ATRA), the active metabolite of vitamin A, are both inducers of
myeloid differentiation. Marcinkowska and colleagues have shown that the retinoic acid receptor α
(RAR α, for ATRA) regulates VDR expression, and that the outcome of this interaction depends on the
developmental status of the cells. For KG-1 (stem-like) and NB-4 (pro-myeloid) cells, activated RAR α
upregulates the VDR expression, rendering the KG-1 cells sensitive to 1,25D3-driven differentiation
towards monocytes. HL60 and U937 cells typify later myeloid development and, by contrast,
an activated RAR α down-regulates VDR [10]. The CCAAT/enhancer-binding protein (C/EBP) family
of transcription factors is important for the expression of myeloid-associated genes. Marchwicka and
Marcinkowska report that ATRA induces CEBPB and CEBPE expression; a high level of RAR α results
in a strong and sustained CEBPB expression. A high VDR expression is required for the strong and
sustained upregulation of the CEBPB gene, whereas a moderate level of active VDR is sufficient for
the expression of CEBPD. CEBPB is, therefore, the major VDR- and RAR α-regulated gene among the
C/EBP family [11]. The transcription factor GATA-1 is important for the erythroid differentiation,
which also requires an adequate supply of iron for haemoglobin production. The ferritin heavy subunit
maintains iron in a non-toxic form. The article by Zolea and colleagues reveals that this protein does
not merely act as a mere iron-metabolism-related factor. Instead, in response to the inducer haemin and
via the miR-150 up-regulation and repression of GATA-1, the silencing of the ferritin heavy subunit in
the K562 erythroid/myeloid cells blocks the commitment of these cells to erythroid differentiation [12].
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For many years, Ton worked on B-cell development, providing important information with which
to unravel this process. The review by Sigvardsson brings to attention the developmental trajectories
to B-cell development, the complex regulatory networks, and the targeting of the networks in human
B-lineage malignancies [13]. Nature versus nurture considerations highlight the roles of bone marrow
niches in the development of B-cells from HSCs. Thus, the article by Aurrand-Lions and Mancini
emphasises the importance of the marrow environment in maintaining stem cells, as well as their
differentiation into mature cells. Cross talk between B-cells and the niches for early pro-B, pre-B,
immature B, recirculating B, and plasma cells, either via direct contact and/or secreted specific factors,
all contribute to a dynamic process, which is important for the commitment and differentiation of
hematopoietic stem and progenitor cells towards a particular pathway [14]. Interleukin-7 (IL-7) is
essential for B- and T-lymphocyte development, although there appears to be a species difference in
the dependence of B lymphopoiesis. The article by Kasai and colleagues identifies a cytoplasmic region
of the mouse IL-7 receptor α subunit (IL-7R α) that is essential for B-cell development, as revealed
by a series of deletion mutants of IL-7R α. Amino acids 414–441 in the IL-7Rα chain form a critical
subdomain [15]. Studies of antibody-secreting plasma cells have been continuously hampered by the
lack of surface molecules with which to identify them. The article by Trezise and colleagues reports
mining of the transcriptome of plasma cells to identify novel and cell surface proteins. Three surface
proteins, Plpp5, Clptm1l, and Itm2c, represent potential targets for novel treatments for multiple
myeloma, a tumour of antibody-secreting cells. In this regard, and as revealed by the analysis of
mouse strains with a loss-of-function mutation for each protein, these proteins are dispensable for
normal B-cell development and antibody production by antibody secreting cells [16]. Lastly, the review
article by Urbanczyk addresses an area of pro- to pre-B-lymphocyte development that developmental
biologists frequently neglect, namely the regulation of energy metabolism, specifically glycolysis and
oxidative phosphorylation. The hypoxia-inducible transcription factor HIF1α plays an important role
in early B-cell development by promoting glycolysis in B-cell progenitors. By contrast, Urbanczyk
and colleagues have shown that the cell surface expression of the pre-B cell receptor down-regulates
EFhd1, a Ca2+-binding protein that localises on the inner mitochondrial membrane and that limits
glycolysis in pro-B cells. They therefore speculate on the importance of Ca2+ fluctuation-mediated
mitochondrial flashes (mitoflashes) for the pro- to pre-B-cell transition [17].
Concluding Remarks
Many articles in this Special Issue concern the research interests of Ton. We take this opportunity to
thank all of the DECIDE and non-DECIDE authors for their efforts in preparing these articles. Ton often
commented on whether there was really a need to make a clear distinction between HSCs and their
immediate progeny. HSCs can make an immediate choice of cell lineage, and as we might view HSCs as,
at the very least, lineage affiliated, the distinction between HSCs and their immediate progeny becomes
blurred. Ton and others showed that bone marrow stromal cells play a vital role in B-lymphocyte
development. Appropriately, this issue highlights the increased interest and importance of bone
marrow niches and hematopoietic cytokines in instructing lineage affiliation and cell differentiation,
rather than HSCs and progenitors following a wired/prescribed developmental pathways in a
stochastic manner. Some hematopoietic cytokines, including the ligand for FMS-like tyrosine kinase
3 (FL, myeloid versus lymphoid, as shown by Ton and colleagues), erythropoietin (erythroid),
macrophage colony stimulating factor (CSF; monocyte), and granulocyte-colony stimulating factor
(granulocyte) can instruct the HSC fate. There has been a long debate about whether IL-7 is instructive
for B lymphocyte development. One of Ton’s last papers addressed this matter by showing that
IL-7 and FL enhance the production of already “pre-decided” (committed) B-cell progenitors. IL-7
promoted their survival, whereas FL made these progenitors proliferate [18]. Opinions about IL-7
and B-cell niches and metabolism are also very important for our understanding of normal immunity,
and possibly autoimmunity. For Ton, science was always meant to be fun; he did this by inspiring and
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encouraging his colleagues and students. This is perhaps best exemplified by a group photograph of
Ton’s lab, taken in 2014 (Figure 2).
Figure 2. Ton stands to one side and lets the students take centre stage.
Finally, with new research tools becoming available, in particular single cell transcriptomic
and proteomic analysis, it does seem that we are moving towards an entirely new architecture for
haematopoiesis. This will guarantee that there will be lots of fun in the future trying to dissect this
fascinating cell lineage. As emphasized in the review by Sánchez-García, a new view on normal
haematopoiesis also has important implications for the way we view the initiation of cancer, perhaps
as a fixed lineage-choice in a LSC/cancer stem cell that an oncogenic event wires. When considered in
the context of this view of cancer initiation, understanding how to “normalise” the behaviour of LSCs
and other cancer stem cells might give rise to potentially valuable therapeutic leads.
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Abstract: Evidence from studies of the behaviour of stem and progenitor cells and of the influence
of cytokines on their fate determination, has recently led to a revised view of the process by which
hematopoietic stem cells and their progeny give rise to the many different types of blood and immune
cells. The new scenario abandons the classical view of a rigidly demarcated lineage tree and replaces
it with a much more continuum-like view of the spectrum of fate options open to hematopoietic stem
cells and their progeny. This is in contrast to previous lineage diagrams, which envisaged stem cells
progressing stepwise through a series of fairly-precisely described intermediate progenitors in order
to close down alternative developmental options. Instead, stem and progenitor cells retain some
capacity to step sideways and adopt alternative, closely related, fates, even after they have “made a
lineage choice.” The stem and progenitor cells are more inherently versatile than previously thought
and perhaps sensitive to lineage guidance by environmental cues. Here we examine the evidence
that supports these views and reconsider the meaning of cell lineages in the context of a continuum
model of stem cell fate determination and environmental modulation.
Keywords: blood and immune cells; cell lineage; cytokines; fate determination; hematopoiesis;
stem cells
1. Introduction
In 1983, Sulston and colleagues produced a tree map—a series of bifurcations—that delineated
the origins of the 671 cells of the newly hatched roundworm Caenorhabditis elegans [1]. In this organism,
cell lineages and the fates of cells are largely invariant and ancestry therefore determines the end fate
of a cell. The apparent rigidity of a tree lineage map ensures tissues develop reliably and consistently.
An autonomous lineage programme is also likely to generate the cell types required in a manner
that is both efficient and economical. To add to lessons learned from Caenorhabditis elegans, there is
“unpredictability” in the developmental nature of cells within this organism. Numerous sub-lineages
give rise to various populations of motor neurons, rather than these cells descending from the same
progenitor in the map. Moreover, when one of the progeny of a terminal division is a motor neuron its
“sibling” is unlikely to be a cell of the same type [1].
For over 30 years, tree maps have also been used to describe blood and immune cell
development [2] and the development of other tissues (e.g., neuronal-crest-derived cells) [3].
Accordingly, investigations of decision-making by developing cells have tended to examine how
they make either-or choices. In the case of hematopoiesis, attention focused on how the progeny
of hematopoietic stem cells (HSC) first become common lymphoid progenitors (CLP) and hence
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generate B cells, T cells and natural killer (NK)/innate lymphoid (ILC) cells, or common myeloid
progenitors (CMP), which gives rise to all the other blood cell types [2]. It is then envisaged that later in
development progenitors choose, for example, between the neutrophil and monocyte pathways [4] and
between the megakaryocyte and erythroid pathways [5]. For years, we have defined hematopoietic
cell lineages in terms of just two initial types of oligo-potential cells, CLP and CMP, giving rise to all of
the various end-cell types.
In recent years, descriptions of the architecture of haematopoiesis have been moving away from
the idea of HSC development progressing via: a) a series of intermediate oligo-potent progenitors;
and b) these cells making a series of binary choices that stepwise restrict lineage options, ultimately to
one final fate. In a new scenario, the suggestion is that HSC can make an immediate lineage choice
from a continuum that encompasses all of the end-cell options. Our pairwise model, proposed in 2009,
(Figure 1A) [6], does not prescribe an invariant route to each end-cell type via definitive intermediate
progenitors. It presumes, quite simply, that all of the options are open to HSCs. This is in keeping
with decision-making, regarding lineage affiliation, at the level of the HSC and very different from
HSC making an immediate and binary choice, for example, between the myeloid and lymphoid fates.
In support of this new viewpoint is the recent finding that HSC in mice can undergo restriction to
the myeloid, megakaryocyte/erythroid and megakaryocyte pathways without dividing or entering
S phase of the cells cycle [7]. Previously, we showed that the human promyeloid cell line HL60 makes
a choice between the neutrophil and monocyte fates without dividing and when held in the G1 and
S phases of the cell cycle [8,9]. Cell fate decisions are therefore uncoupled from cell division and
the mechanisms that control fate determination/differentiation and proliferation are at least partly
independent. An inverse relation between cell cycle and differentiation can actually occur, as has been
shown in the case of the transcription factor PU.1 in myeloid differentiation. Increased PU.1 levels can
lead to prolongation of the cell cycle resulting in further accumulation of PU.1 and thus commitment
of progenitors to the macrophage lineage [10].
The concept of a continuum of developmental options is important and applies to the description
of various changes to the status of cells. A longstanding viewpoint is that embryonic stem cells make
a binary choice between pluripotency and specification to a germ cell layer. However, the stem cell
compartment of human embryonic stem cell cultures is significantly heterogeneous and Hough and
colleagues have argued that a continuum of states spans pluripotency and lineage commitment of these
cells [11]. Moreover, the existence of self-renewal as a canonical state is debatable: cells progressively
decrease their likelihood of self-renewal as the expression of stem cell- and pluripotency-related genes
decreases and that of genes encoding differentiation attributes increases [11]. Epiblast cells of the
early mammalian embryo are able to make mesoderm, endoderm or ectoderm fate decisions and as
development progresses they mature through a continuum of lineage potency states [12]. Additionally,
a continuum best describes the progression of cell differentiation. For example, early studies revealed
gradual changes in the expression of a large number of surface antigens during the different stages
of neutrophil development [13]. Similarly, maturation changes occur along a continuum during
erythropoiesis [14]. To return to Caenorhabditis elegans, a continuum framework has been used to model
epithelial morphogenesis and elongation of the embryo to a worm [15].
The pairwise model also emphasizes that there are particular nearest neighbour relationships
between the various cell lineages. The known sets of fates of cells termed lymphoid-primed
multipotent progenitors (LMPP), early progenitors with lymphoid and myeloid potential (EPLM)
and common myeloid progenitors (CMP) and of other downstream progenitors (see Figure 1A,B),
guided the construction of the relationships of progenitors in the pairwise model. However, recent
genotypic studies have revealed that LMPP, EPLM and CMP although phenotypically relatively
homogenous are not homogeneous populations and instead are mixtures of cells with different lineage
affiliations [16–20]. We have examined the affiliations of EPLM, which were originally described as
a population of cells that could generate B and T lymphocytes, NK cells, dendritic cells (DC) and
macrophages but that lacked megakaryocyte and erythroid potentials [21]. Thus, by using the surface
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markers Ly6D, SiglecH and CD11c and by RNA sequencing single cells, we separated EPLM into four
subpopulations each with lineage biases. We divided the most primitive EPLM, lacking these markers,
into cells that already have myeloid, DC or lymphoid signatures [16]. Likewise, Naik and colleagues
have similarly divided LMPP into lymphoid-, myeloid- and DC lineage-biased cell populations [18].
Hoppe and colleagues used RNA expression data to classify CMP into granulocyte/monocyte and
megakaryocyte/erythroid progenitors [17] and Paul and colleagues have assigned bone marrow
progenitors into seven groups with transcriptional characteristics of neutrophils, basophils, eosinophils,
monocytes, DC, erythrocytes and megakaryocytes [20]. Figure 1B shows the sub-populations of LMPP,
EPLM and CMP as cells added to their arcs of potentials. The particular close relationships between
cell lineages remain the same as lineages adjacent to one another share the usage of transcription
factors and cell responsiveness to promiscuous cytokines [6,22]. This fits with the notion of visualising
cell specification as a continuum and infers that adjacent elements are less different from each other
whereas the extremes are quite distinct.
Figure 1. A continuum or pairwise model for hematopoiesis. (A) The model envisages a continuum of
fates is available to hematopoietic stem cells (HSC), with pairwise relationships between the various
cell fates. The pairwise model, replaces a rigid and bifurcating lineage tree with a spectrum of fate
options open to HSC. In the “classic” model, HSCs progress stepwise through a series of intermediate
progenitors, to close down developmental options in a binary manner. In the new scenario, HSC make
an immediate lineage choice from all of the end-cell options. The figure is, with permission, from [6]
©Macmillan Magazines Ltd. HSC, hematopoietic stem cell; DC, dendritic cell; NK cell, natural killer
cell. (B) The partial arcs represent the close relationships between cell lineages that we inferred from
the different groups of fates that are available to known intermediary progenitor cells (marked with an
asterisk). Investigators initially described Lymphoid-primed multipotent progenitors (LMPP), early
progenitors with lymphoid and myeloid potential (EPLM) and common myeloid progenitors (CMP) as
homogeneous population of cells. However, they are a mixture of cells with the lineage affiliations
shown as cells added to the arcs for LMPP, EPLM and CMP. Affiliations include B lymphocyte (B),
DC, monocyte (Mo), eosinophil (Eo), basophil (Ba), erythroid (E) and megakaryocyte (M) [16–20].
HSC are shown to include the following: lymphoid biased cells (Ly) [23,24] that express the fms-like
tyrosine kinase 3 receptor (Flt3+) [25]; myeloid biased or committed cells (My) [26,27] that express
Flt3+ [25] and/or the receptor for thrombopoietin (TpoR+) [28]; cells committed to the erythroid
pathway [19] and affiliated as to expression of the receptor for erythropoietin (EpoR+) [25,29]; and cells
that express the receptor for macrophage colony stimulating factor (M-CSFR+) and monocyte-affiliated
(Mo) [25,30]. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; DC/Pro-B,
dendritic cell and B lymphocyte progenitor; Eo/B-CFU, eosinophil and basophil progenitor; EPLM,
early progenitor with lymphoid and myeloid potential; GMP, granulocyte and macrophage progenitor;
LMPP, lymphoid-primed multipotent progenitor; MEP, megakaryocyte and erythrocyte progenitor;
Mon/B/DC?, monocyte, B lymphocyte and dendritic cell? progenitor; Mon/DC, monocyte and
dendritic cell progenitor, NK/T, natural killer cell and T lymphocyte progenitor and NK/ILC, natural
killer cell and innate lymphoid cell progenitor.
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There is good evidence to support the view that the lineage affiliations seen in recent investigations
of LMPP, EPLM and CMP become apparent earlier during development, even as early as in HSC.
In 2010, Ichi and colleagues reported that the transcriptional profiles of individual HSCs show
considerable variation and some HSCs are poor precursors of lymphocytes whilst others generate a
balanced output of cell types [31]. Subsequently, investigators examined the progeny of single cells
transferred into irradiated mice and described myeloid- and lymphoid-biased mouse HSC [24,26,32,33].
Notta and colleagues have shown that the progenitor cell compartment of human bone marrow is
a mixture of cells with uni-potent myeloid or erythroid potential alongside multipotent cells [19].
The Jacobsen group described a sub-set of murine HSC with a bias towards platelets and myeloid cells,
requiring thrombopoietin for their maintenance [28]. Similarly, sub-sets of murine HSC express the
receptor for macrophage colony-stimulating factor (M-CSF), mRNA for the erythropoietin (Epo)
receptor [25,29,30] and the fms-like tyrosine kinase 3 (Flt3) receptor, for Flt3 ligand (Flt3L) [25].
The selective expression of these receptors is suggestive of a predisposition and/or affiliation of
some HSC to a lineage because the corresponding cytokines (M-CSF, Epo and Flt3L) can instruct
end-cell fate ([30,34] and see later).
2. The Mature End-Cell Populations Are Not Homogeneous
The variety of end-cell types is more complex than is usually shown in models. For example,
the DC family includes Langerhans cells (LC), two types of interstitial DC (iDC) [35,36], CD8+ DC [37]
and CD8− conventional DC (cDC) [37] (Figure 2A). The delineation of these DC sub-populations
depends on their precise functions. They include antigen transport, immune regulation and the control
of infections e.g., yeast. In addition, there are type 1 interferon-producing plasmacytoid pDC [38]
and monocytes that are a form of pre-DC [39] and both are classified within mononuclear phagocytes
(see later). The local environments in which DC precursors reside may be important for their fate
specification (Figure 2). Satpathy and colleagues have highlighted the importance of various cytokines
to DC development, including whether their actions within distinct stromal niches influence fate
choice [40].
Figure 2. Heterogeneity of dendritic cells. (A) Surface markers are used to describe the various end-cell
DCs and their nature is a matter of gradations. (B) Where each population resides is important to
their function within the immune system and the local environment may determine the fate of DC
precursors [41]. HSC, hematopoietic stem cell, ILC, innate lymphoid cell, Mon, monocyte; Neut,
neutrophil; Eos, eosinophil, Bas, basophil; Ery, erythrocyte; Meg, megakaryocyte, DC, dendritic cells,
iDC, interdigitating dendritic cell; LC, Langerhans cells; Lg, Langerin.
There is heterogeneity among cells of the mononuclear phagocyte system [42]. Human monocyte
sub-populations are discriminated on the basis of CD14 and CD16 expression and those in mice
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by the use of markers such as F4/80, Ly6C (Gr-1), CD11b, CD43 and the chemokine receptor
CX3CR1 [43]. Following trans-endothelial migration, monocytes enter the tissues where they give
rise to macrophages. There is debate about how best to distinguish macrophages from DCs: is there
any real difference between the capacity of some macrophages and DCs to present antigens [44]? Live
imaging studies have not provided clear evidence for a distinction [45]. Additionally, a population of
cutaneous Langerin+ve DC develops from blood monocytes, rather than from Langerhans cells [35,46].
The markers used to define macrophage sub-sets include the macrophage scavenger receptors
(CD36, CD14, signal-regulatory protein family (SIRP)), Toll-like receptors, various integrins, epidermal
growth factor-seven transmembrane (EGF-TM7) proteins, other immunoglobulin superfamily receptors
(Siglecs) and multiple C-type lectins. Our perception of the assortment of these markers is that it is
apparently random [47]. The use of quantitative flow cytometry (FC) profiles reveals a spectrum of
phenotypic variability, rather than precisely defined sub-sets of cells [42]. Some of this phenotype
noise may be due to stochastic fluctuations in the levels of expression of transcription factors. Even so,
the different macrophage sub-sets, as defined by different combinations of markers, provide distinct
signals to T cell sub-sets and are therefore important physiologically.
Macrophages encounter multiple signals in the various tissues that are important for shaping
their phenotype [48]. For example, macrophages that reside in the lung and in the peritoneum
have distinct gene expression profiles and chromatin landscapes. Lavin and colleagues transferred
macrophages that had been isolated from the mouse peritoneum into the alveolar cavity, whereupon
they upregulated the macrophage-specific genes that typify lung macrophages and downregulated the
peritoneal macrophage-specific genes. Expression profiling confirmed this transition: the transferred
cells resembled lung macrophages more than peritoneal macrophages. So, the originally peritoneal
macrophages had adapted to their new environment [49]. Further evidence of macrophage adaptability
is that CD8+ve and CD8−ve antigen-presenting cells in the spleen that arise from the same progenitor
are interconvertible [50]. These findings both highlight the adaptability of differentiated cells and show
that the microenvironment can influence cell specialization. Signals from the tissue environment may
modulate the chromatin landscape that, in turn, prescribes a tissue-related gene expression pattern
within macrophages.
3. Some End-Cells Are Interconvertible
CD4+ve effector cells include T helper 1 cells (Th1), T helper 2 cells (Th2), interleukin (IL)
17-producing T helper cells (Th17), follicular T helper cells (Tfh) and regulatory T cells (Treg).
These sub-types have different functions. They include the control of bacterial, helminth and fungal
infections and B cell maturation in germinal centres and the suppression of immune responses.
CD4+ve effector cells produce many different cytokines, including IL-2, IL-3, IL-4, IL-13, IL-17, IL-21
and granulocyte-macrophage colony-stimulating factor (GM-CSF) and to a lesser extent interferon
g (IFNγ) [51]. The nature of the cytokines produced is indicative of the type of CD4+ve helper cell.
CD4+ve cell types arise in multiple environments and the prevailing cytokine environment is important
for their differentiation. For example, IL-12 is required for Th1 cell differentiation and IFNγ amplifies
this process, whereas IL-4 drives the differentiation of Th2 cells [52].
The characteristics of some of the mature CD4+ effector cells are interconvertible (Figure 3).
IL-21 is produced by Th2 cells [53] and TFh cells [54] and Th2 cells can give rise to Tfh cells [55].
Induced regulatory T cells (iTreg) can convert to pro-inflammatory Th17 [56] and when transferred into
T cell-deficient CD3−/− or Rag2−/− mice respectively give rise to Tfh cells in Peyer’s patches [57] and
Th2 cells in the spleen [58]. Memory Th2 cells convert in vitro to iTreg, in response to treatment with
transforming growth factor β (TGF-β) and blockade of IFNγ and IL-4 signalling [59]. In all of these
examples, the switching between the different types of CD4+ cells requires an external set of signals,
suggesting that environmental signals may underlie the adaptability of CD4+ cells to the type of the
immune response required. Eizenberg-Magar and colleagues have constructed mathematical models
that predict how different cytokine inputs to CD4+ T cells determine their differentiation state [60].
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Figure 3. The heterogeneity and interconversion of CD4+ve helper T lymphocytes and innate lymphoid
cells. CD4+ve effector cells and innate lymphoid (ILC) cells include various sub-populations. For both
of these types of cells, the characteristics of some of the mature effector cells are interconvertible (A) The
arrows connecting the sub-types of CD4 T cells show interconversions. (B) The arrows connecting the
sub-types of ILC show interconversions. HSC, hematopoietic stem cell, iTreg, induced-regulatory T
cells; Th17, Interleukin 17 producing T helper cells, Th1, T helper 1 cells; Th2, T helper 2 cells, Tfh,
follicular helper T cells; NK, natural killer cell, Mon, monocyte; Neut, neutrophil; Eos, eosinophil, Bas,
basophil; Ery, erythrocyte; Meg, megakaryocyte, DC, dendritic cells.
The sub-types of ILC have natural killer and helper-like functions that are important as a first
line defence against pathogens, the genesis of lymphoid organs and tissue modelling [61]. There are
three main groups of ILC. Group 1 includes natural killer cells and helper-like ILC and groups 2 and 3
are helper-like. The the expression of transcription factors defines two populations within groups 1
and 2. The developmental relationship between the various ILC populations is presently unclear and
their characteristics are interconvertible (Figure 3). Expression of master regulators of transcription,
surface receptors and the ILs produced define group 3 sub-types. There are cells that either: (1) express
the transcription factor retinoid-related orphan receptor γt (RORγt), CD4 and the cytokine receptor
CCR6 at their surface and produce IL-17 and IL-22 (lymphoid tissue inducer (LTi)-like ILC3) or (2)
express the transcription factor T-bet, the NK receptors NKp46 and NK1.1 at their surface and produce
IFNγ and TNFα. However, LTi-like ILC3 (RORγt+, CCR6+) cells express T-bet when exposed in vitro
to a Notch stimulus [62]. There may be a true bi-directional plasticity of ILC3 as NKp46+ ILC3 may
downregulate NKp46 in vivo giving rise to NKp46− ILC3 [63]. The relative levels of expression of
RORγt and T-bet may determine the effector functions of group 3 ILC3 and underlie the plasticity of
the phenotype of these cells. However, there is controversy on this matter as the subsets of group 3
ILC3 may be separate lineages that develop from different progenitors [64]. To add to the plasticity of
ILC, mouse studies have shown that ILC2 that reside in the lung become ILC1 in response to infection
by influenza virus and Staphylococcus aureus and by cigarette smoke [65].
4. How Might We Classify the Types of Cells?
One purpose of classifying blood cells is to aid the understanding of their development: we have
no hope of understanding cell diversification without categorizing a cell’s identity. The conventional
use of the term cell lineage and cell type, refers to the developmental history of a cell. For example,
a progenitor cell that is committed to the B lymphocyte developmental pathway gives rise to cells
we denote as a B lymphocyte. However, ancestry does not always resolve cell identity where there is
inconsistency between the attribution of cells to a lineage and classification with regard to a phenotype.
For cells viewed collectively as ILCs, there are two separate origins; a progenitor that gives rise
to the NK precursor and NK cells and another for all the helper-like ILC [61]. Similarly, it is not
clear to what extent there are separate progenitors for the different DCs. They appear to arise from
two separate -lymphoid and monocytic- origins but the surface phenotypes and gene transcription
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profiles of DCs derived in vitro from purified CLPs or purified CMPs are indistinguishable [66].
A Common Dendritic cell Progenitor (CDP) with the ability to give rise to both cDC and pDC has been
identified [67,68]. Several other phenotypically distinct cells have been proposed as progenitors of
different DC sub-populations [67,69–71]. However, it appears that multiple developmental pathways
are at play in generating the different DCs, and, in some cases, they converge into phenotypically
homogeneous but transcriptionally and functionally distinct mature DC [72,73]. The delineation
of cell type with regard to ancestry is also confounded if we accept that HSCs predispose to a
lineage by expressing, for example, the receptor for M-CSF but might step sideways and adopt
a different trajectory.
In the case of the mature immune cells, an answer to the problem of their classification,
their attributes or conversely the absence of a characteristic(s), is the unique function of each type of cell.
In other words, members of a cell type serve a function that is different from members of another cell
type. However, immune cell types can share functional attributes that confounds ascribing cell identity
on this basis and blurs the boundaries between cell lineages. A cytotoxic capacity brings together some
T cells and some ILC, whereas macrophages, DC and B cells can phagocytose, pinocytose, process and
present foreign antigens. Additionally, cells of the immune system cooperated to perform their role and
it is therefore not too surprising that different types of cells share, for example, the chemokine receptors
that dictate the location of cells to a particular environment and the cytokine receptors for survival.
5. What Are the Differences between Types of Cells?
So, what are features that allow us to specify a population of immune cells? Distinguishing one
cell type from another is in essence a matter of how many phenotypic markers we use to define a cell
type. The use of two surface markers can clearly differentiate one type of cell from another. However,
and as mentioned above, use of additional surface markers reveals substantial heterogeneity regarding
mononuclear phagocytes and investigators must rely on their judgment as to how best to classify cell
populations. Traditionally, the basis for the identification of early progenitors, in particular, is the use
of a limited number of cell surface markers, which appear in many cases to have a graded, rather than
discontinuous expression pattern. Examples of graded expression are the markers used for FC-based
identification of Lineage-negative, CD117+ (kit), Sca-1+ cells (LSK), LMPP and CLP populations.
CD117, Sca-1 and Flt3 show a graded, continuous expression, thus making the identification and
isolation of cells with “high” or “intermediate” expression of markers almost arbitrary and dependent
on the staining prowess and judgement of the investigator (Figure 4). This problem becomes even
larger for genetically modified mice, where it might prove difficult to distinguish between true changes
in the proportions of gated cells (representing progenitor stages) and any potential alterations, caused
by the genetic modification to the mice, in the expression level of markers that are used to “ring-fence”
these cells. Modern and comprehensive analyses, particularly of single cells, have revised the approach
to categorize cell types. Tools currently available for the examination of cellular heterogeneity include
global gene expression analysis and mass cytometry where the number of individual surface markers
analysed is extremely large. This leads to an even more detailed consideration of how finely to draw
lines between different cell types and perhaps this becomes arbitrary for some of the different types of
immune cells.
Regarding the use of global gene expression analyses, the conceptual problem is how fine should
the criteria be that we use to distinguish one type of cell from another? A caveat is that it is impossible
to be certain that two cells that, using a set of phenotypic attributes are ring-fenced as identical,
are identical genotypically [77]. A simple reason is that cells of any given end-cell type are not all
interacting with just one environment: some will be inside a particular environment and some left
outside. Even within an environment, a graded input of signals might well lead to a graded output
regarding the level of acquisition/stabilization of a phenotype. Moreover, a population of cells, even if
clonal, is heterogeneous. Chang and colleagues have shown that cells of cloned populations of mouse
hematopoietic progenitors express different levels of Sca-1. This relates to a state that fluctuates
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but is meaningful because cells that express extremely high or low levels of Sca-1 have distinct
transcriptomes and different leanings towards the myeloid or erythroid lineage [78]. Heterogeneity of
cloned cells is also the case for neuronal stem cells whereby in vitro subsets have distinct developmental
commitments [79]. The heterogeneity of cloned stem cells presumably reflects the inherent versatility
of multipotent cells. Of particular interest to lineage-predisposition of these cells are the events that
regulate the expression of transcription factors. It would thus seem that none of the classically accepted
features alone is reliable enough to unequivocally define a particular lineage or cell type. Rather,
we should consider a combination of several attributes, including morphology, phenotype, function
(for mature cell types), genetic signature and developmental ancestry.
Figure 4. Markers used to identify hematopoietic progenitors display graded, rather than
discontinuous, expression. CD117, Sca-1 and Flt3 show a continuous expression making the
identification of cells with “high” or “intermediate” expression of markers almost arbitrary. Figure
shows a typical gating strategy for the identification of LSK (red), LMPP (green) and CLP (blue)
progenitor populations based on the expression of CD117, Sca-1, Flt3 and CD127 (IL-7Rα). LSK are
identified as Lineage-CD117highSca-1high [2] and LMPP as the LSK with the highest expression of
Flt3 [74]. CLP are gated as Lineage-CD117intSca-1intFlt3+CD127+ [75,76]. LSK: Lineage-negative,
Sca-1-positive, kit-positive cells; LMPP: Lymphoid-primed Multi-Potent Progenitors; CLP: Common
Lymphoid Progenitors.
For years, the issue of delineation has applied for how to best classify organisms into species,
such as Darwin’s many finches. One solution is that each species of finch breeds true. In a similar vein,
whether cells can or cannot readily, even when “pushed” in vivo or in vitro, interconvert provides
a way of resolving the delineation of cell types. The matter of definition of cell type and lineage,
if we view this a synonymous, is simple if both refer to a cell that has progressed along a pathway
to a stage of development and a phenotype that is irreversible. For example, and to the best of our
knowledge, a cell, including its phenotypically identifiable progeny in the bone marrow, destined to
generate mature B cells does not normally give rise to a mature T cell. Interestingly, the importance
of the extent of developmental progression to irreversible lineage affiliation is exemplified by the
finding that the Double Negative 2 T cell progenitor population that have already progressed some
way along the T cell pathway can still give rise to NK and myeloid cells when “pushed” using the right
conditions [21,80]. Nevertheless, and by applying the rule of irreversibility of phenotype, we would
view the different ILC and CD4+ T cells that can interchange/reverse mature fates under the right
conditions as sub-types of cells belonging to the ILC and CD4+ T cell lineages respectively, rather than
as separate lineages. As to their taxonomy, we might view their differentiation and end phenotype as a
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much more flexible and continuous process that circumvents the need to draw overly strict boundaries.
In this case, there is a continuum of intermediate states between cell sub-types.
6. Does the Environment That Cells Reside in Instruct Cell Fate?
As mentioned above, cells and their genes, do interact with and respond to their environment.
The environmental history of a cell is therefore important to the specification of phenotype. Whilst for
cell identity we have attached prime importance to developmental history, namely who begat whom,
this might merely serve to keep offspring within a particular nurturing environment. In some instances,
we might have mistakenly read environmental nurture as developmental history.
Some hematopoietic cytokines are important for shaping hematopoiesis. Generally, we accept
that they are essential for the survival and proliferation of hematopoietic cells at all stages of their
development. However, in some cases they are also important for the differentiation of hematopoietic
lineages. Thus, their function as merely survival and/or proliferation agents (permissive role)
or inducers of differentiation (instructive role) has been a matter of debate for long time [81–83].
Several investigations have provided evidence in support of both modes of cytokine action, with the
data in some cases being contradictory (reviewed in: [84–86]). Genetic deletion of cytokines or
their receptors has resulted in a reduced production of immune cells whose generation is subject to
regulation by the cytokine in question but even though the disruption in developmental output can be
quite severe, it has never led to the complete absence of the lineage. This indicates either a permissive
role of these cytokines or some level of redundancy, with other cytokines compensating for the absent
instructive signal. Furthermore, over-expression of anti-apoptotic signals, such as B-cell lymphoma
2 (Bcl2), in order to provide a strong survival signal to cells, has been on some occasions sufficient
to rescue the affected lineage, suggesting a permissive cytokine function. Thus, whilst the absence
of IL-7 signalling severely disrupts T cell development, Bcl2 over-expression can significantly rescue
T cell output in these mice [87–89], suggesting a survival role of IL-7 in early T cell development.
Similarly, the B cell defect observed in mice lacking Stat5 (the crucial signalling mediator for IL-7)
can be fully recovered by Bcl2 over-expression [90], while sustained and increased Flt3L levels can
rescue B cell development in Il7-/- mice [91], thus demonstrating the permissive role of IL-7 in both
T and B cell development. Moreover, early in vivo studies with chimeric receptors provided further
evidence for a permissive role of hematopoietic cytokines. The replacement of the intra-cellular part
of the TPO receptor (mpl) with that of G-CSF [92] or the signalling domain of G-CSF with that of
Epo-R [93] did not result in any lineage skewing, as would be expected regarding an instructive role of
the corresponding cytokines.
Other transgenic approaches, mainly by ectopic expression of cytokine receptors,
have nevertheless suggested instruction of lineage fate by cytokines. Thus, expression of M-CSF
receptor in multi-potent hematopoietic cell lines resulted in skewing of their developmental
output [94,95], while ectopic GM-CSF receptor expression on CLP or pro-T cells increased their myeloid
differentiation potential [96–98]. Similarly, Flt3 expression in MEP up-regulated myeloid-specific
transcription factors and promoted their differentiation towards granulocyte/macrophage lineages [99].
More recently, investigators have provided in vitro and in vivo evidence for an instructive role
of cytokines in lineage fate. Our studies support an instructive role of Flt3L at an early stage
of hematopoiesis [34]. Transgenic mice over-expressing Flt3L ubiquitously are anemic and
thrombocytopenic. Investigation of the progenitor cell populations in these mice revealed that Flt3L
acts to skew hematopoiesis towards the myeloid and lymphoid lineages, as there is a lack of generation
of erythroid and megakaryocyte progenitors. The cells diverted lack expression of cell lineage markers
(Lin-) but express the Sca-1 antigen and the receptor for the stem cell factor CD117 or c-kit and are
termed LSK. Likewise, increasing the level of Epo in vivo, by transgenesis, has revealed an instructive
role for this cytokine in erythropoiesis [29]. In 1982, Metcalf and Burgess provided evidence supporting
the view that G- and GM-CSF instruct bi-potent granulocyte-macrophage colony forming cells in their
choice between granulocyte and macrophage pathways respectively [4]. Rieger and colleagues added
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to these finding by showing that G- and M-CSF instruct granulocyte and macrophage progenitors to
follow each of the pathways respectively [100].
Overall, there is evidence to support the view that some of the hematopoietic cytokines can
instruct cell fate and therefore guide the generation of a particular type(s) of cell as required. The effect
of cytokines seems to be cell-context dependent, highlighting the interplay between extra-cellular
signals from the environment and intra-cellular fate-determining factors, such as transcription factors
and the epigenetic landscape [86]. Additionally, some level of promiscuity in the use of cytokines
by hematopoietic cells makes the identification of their specific mode of action challenging. In that
context, studies at the single cell are necessary. As evident from the data discussed above, most of the
experimental evidence for an instructive role of hematopoietic cytokines comes either from in vivo
over-expression of cytokines and/or their receptors or from in vitro culture systems. It is conceivable
that, depending on the strength of the signal, a particular cytokine may act to provide a signal for
survival, to proliferate or to instruct lineage choice. The response elicited within a cell, as to which
of the three outcomes is undertaken, would accord with an increasing level of signal intensity. Thus,
in order to demonstrate their instructive role, it is necessary to use a high level of cytokine in in vitro
experiments. A graded response of cells to cytokines may be important for steady state versus
hematopoiesis under stress conditions, such as infection, whereby the different requirements are
survival/expansion versus survival/expansion coupled to a rapid and emergency, diversion of cells
towards a required end cell type [101]. Recent evidence to support this viewpoint is that Singh and
colleagues have observed that during chronic erythroid stress, in Epo transgenic mice, HSC exhibit a
vastly committed erythroid progenitor profile together with enhanced cell division [102].
This makes physiological sense when one considers that the hematopoietic system is extremely
flexible, responding rapidly to situations of stress, infection and blood loss. Whilst there is debate
as to how this operates, it is important to bear in mind that cells we identify as HSC that can
reconstitute the entire hematopoietic/immune system long term (LT-HSC) express the receptors for
the proposed instructive cytokines. These include the receptors for Epo, M-CSF and Flt3. Around 19%
of LT-HSC express the receptor for M-CSF on their cell surface and ~5% express cell surface Flt3,
with ~12% expressing Flt3 mRNA. Around 13% express mRNA for the Epo receptor and the level
of surface protein expression is unknown due to the lack of a suitable antibody reagent. These are
essentially sub-populations of LT-HSC [25]. We might assume that engagement of the cytokine with
the receptor provides a signal for survival and proliferation. We do not know whether the presence of
the appropriate cytokine instructs LT-HSC to adopt either a macrophage, myeloid or erythroid fate.
7. The Events That Shape Cell Identity
It is reasonable to conclude that the nature of immune cell diversity is not merely a matter
of affiliation to an ancestral pathway but that environmental nurture is important. A mixture of
(i) predisposition towards/affiliation of HSC to a lineage and (ii) nurture at a later stage of development,
by environmental cues, appear to govern the end-fate of a cell (Figure 5). This perhaps explains the
many sub-types of a number of different immune cells. Nurture is also important for HSC. It is likely
that the localization of HSC within diverse and supportive bone marrow niches and their exposure to
different development growth factors and morphogen gradients plays an important role in driving
their heterogeneity [103].
Waddington’s epigenetic landscape has provided a longstanding model for the general nature of
the events that shape cell identity [104]. Cells roll down bifurcating valleys and once a cell has chosen
a fate there are ridges that help maintain this fate. Changes to the epigenome dictate the hills and
valleys that exclude other fates and which the microenvironment might impose. Ferrell has proposed
an alternative landscape whereby at the start there are numerous valleys and ridges, commitment
to a fate relates to the disappearance of some of the valleys and ridges and new valleys and ridges
arise from cell-cell competition [105]. Sieweke examines a landscape that he likens to a small group
of Pacific islands—Captain Cook’s Islands—in the middle of an ocean. These can be reached from
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many directions such that the routes to a fate are flexible [106]. Waddington’s landscape and the
alternative landscape both involve stepwise bifurcations but there does not seem to be the need for
HSC to undergo this progressive restriction. These models and a “small group of islands” model
mean that there are close relations between particular cell lineages, as envisaged in the pairwise model.
A “small groups of islands” model is more in keeping with the pairwise model except that each island
can be approached separately rather than by Captain Cook’s route from island to island and from east
to west.
Figure 5. The developmental versus environmental history of cell types. A continuum of options is
open to HSC and they are able to choose a fate without having to progress stepwise through a series of
intermediate progenitors in order to close down developmental options. There is good evidence to
support the viewpoint that environmental nurture is important to the generation of diversity of some
of the mature cell types.
8. Implications for Leukemia
Normal HSCs and their immediate progeny are versatile in their choice of developmental pathway.
If we accept that HSC can commit themselves directly to one pathway, we might presume that each
pathway is equally available. Versatility is also the case for the progeny of HSC. The colonies observed
for the progeny of HSC, particularly multipotent HPC, grown in semi-solid agar or methylcellulose
medium contain many different cell types. We have argued that these findings are misleading as
to how HSC and HPC behave in vivo, because single cells dispersed in agar are not in their normal
social environment and lack the influence of niches, the extracellular matrix and the appropriate
cytokines [101]. Nevertheless, the findings from colony assays support the notion of inherent versatility
of HPC and perhaps indicate that environmental influences in vivo are important for guiding and/or
narrowing the trajectories of HSC. HSC are versatile in the pairwise model, because they can step
sideways to adopt alternative, closely related, fates, even after they have “made a lineage choice.”
The making of the architecture of leukemia and lymphoma, is very different because the lineage
output of the transformed counterparts is restricted to a particular pathway [107–109]. In contrast
to the flexibility of HSC, the transformed counterpart essentially dumps cells down a particular
pathway. The rationale for this and perhaps the cardinal aspect of cell transformation in cancer is that
a genetic insult fixates the epigenome to a lineage. Sanchez-Garcia has proposed that the contribution
of oncogenes to leukemia is via epigenetic priming of the cells that initiate leukemia and the initial
oncogenic insult(s) is/are then dispensable for tumour progression and maintenance [109]. In other
words, there appears to be an insult-wired block to versatility in the leukemia stem cell.
9. Concluding Remarks
In the pairwise model, HSC can immediately predispose towards or affiliate to a single lineage,
yet retain the ability to divert to an adjacent lineage. We might view the adjacent options as easily
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accessible or latent in some way. In this case, predisposed or affiliated HSC are essentially progressively
differentiating towards an outcome, including narrowing their trajectory from the continuum of
options. In the original diagram for the pairwise model, we showed DC, monocytes and NK cells
as a single population. Each of these cell types is clearly a heterogeneous population and, therefore,
it seems that some cells have a lifelong capacity to differentiate and diversify. Questions that are
perhaps more important than lineage affiliation are (i) what channels a cell towards a particular
phenotype and (ii) how does a cell stabilize a pattern of attributes, some of which are shared by
different cell types. Perhaps the signals they receive from the environment in which they reside,
that “mark” the epigenome, are as important as developmental history. Our view of the architecture
of haematopoiesis has important implications to our understanding of the initiation of leukaemia.
Whereas HSC are versatile, an insult(s) appears to wire the epigenome of HSC regarding lineage choice
to a fixed leukaemia cell fate [109].
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Abstract: Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same
leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity.
However, the latest findings have shown that the mode of action of oncogenes is not homogeneous
throughout the developmental history of leukemia. Studies on different types of hematopoietic
tumors have shown that the contribution of oncogenes to leukemia is mainly mediated through the
epigenetic reprogramming of the leukemia-initiating target cell. This driving of cancer by a malignant
epigenetic stem cell rewiring is, however, not exclusive of the hematopoietic system, but rather
represents a common tumoral mechanism that is also at work in epithelial tumors. Tumoral epigenetic
reprogramming is therefore a new type of interaction between genes and their target cells, in which
the action of the oncogene modifies the epigenome to prime leukemia development by establishing a
new pathological tumoral cellular identity. This reprogramming may remain latent until it is triggered
by either endogenous or environmental stimuli. This new view on the making of leukemia not only
reveals a novel function for oncogenes, but also provides evidence for a previously unconsidered model
of leukemogenesis, in which the programming of the leukemia cellular identity has already occurred
at the level of stem cells, therefore showing a role for oncogenes in the timing of leukemia initiation.
Keywords: leukemia; oncogenes; reprogramming; stem cells; cancer therapy; leukemia stem cell;
mouse model
1. The Making of Leukemia: The Concept of Epigenetic Reprogramming
In spite of the enormous amount of data that we have gathered in the last four decades about the
biology of tumor cells, our capacity to control the development of the disease is still very limited [1,2].
We still do not know how to prevent the conversion of a precancerous cell into a tumor, mainly due to
the fact that the early events triggering the tumoral fate and the commitment to a new cancerous lineage
remain basically unknown [3]. This lack of knowledge is sadly illustrated by the cases of women
carrying BRCA1 or BRCA2 mutations, whose only chance to reduce their probability of developing
breast cancer is to undergo prophylactic tissue amputation [4]. It is clear that the most crucial point
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in the biological history of a cancer is the transition from a normal target cell to a cancerous one.
However, the developmental mechanisms controlling the establishing of a tumoral cellular identity,
which are essential for the cancer to arise in the first place, have received little attention. The main
focus of both basic and translational research has been the altered controls of cellular proliferation
in malignant cells. This has been reflected in the therapeutic approaches used to treat the patients:
in general, most of the anti-cancerous treatments are directed against the mechanisms behind the
abnormal proliferation of cancerous cells. However, these therapies are unspecific, with many side
effects caused by their high toxicity and, in the end, unable of eradicating the disease in a large
percentage of the cases. Therefore, an unmet need in cancer research is to understand how to neutralize
the mechanism(s) that convert a normal cell into a cancerous one in the first place.
Douglas Hanahan and Robert Weinberg condensed the complex biology of cancer cells into nine
hallmarks, “nine essential alterations in cell physiology that collectively dictate malignant growth” [5].
Cancer cells are the basis of the tumoral disease: they give rise to the tumors and drive the progression
of the disease, carrying the oncogenic and tumor suppressor mutations that define cancer as a genetic
disease [5]. In spite of their importance, we still do not fully understand the mechanisms that lead
to their appearance, or at least we do not know enough so as to have a significant impact on cancer
mortality [6]. As a consequence, our advances in cancer treatment are incremental and mainly empirical,
with successive clinical trials leading to slightly better therapeutic options that, although they might
provide some benefit, do not bring an end to the disease [7].
Therefore, an in-depth understanding of cancer requires a more detailed knowledge of the
mechanisms triggering malignant growth, and it is essential if we want to identify the molecular
culprits of cancer maintenance [3]. Despite this, all the aspects related to the deregulation of the
normal developmental mechanisms that take place in tumorigenesis have received little attention
when trying to define the main features of cancer. However, this is a key aspect since, if cellular fate
could not be changed, cancer would be impossible, since only normal, non-pathological cell types
would exist. Therefore, the mechanisms establishing and regulating cellular identity play an essential
role in allowing the appearance of aberrant cancerous cell types; hopefully, the understanding of these
mechanisms might be the key to the total elimination of cancer cells in the patients. In this review, we
discuss the importance that oncogenes have in establishing the identity of the tumor cells, and how
reprogrammed cells participate in the disease evolution. A deeper knowledge of this, so far largely
neglected, mode of action of the oncogenes should help us to develop new ways to attack cancer.
2. Oncogene Addition versus Reprogramming Leukemia Predisposition
Many years of research have shown that oncogene expression is necessary not only at the earliest
stages of cancer development, but also for the posterior maintenance of the disease. Therefore, since
the discovery that human cancers carry mutated oncogenes, these have been regarded as primary
potential therapeutic targets. Indeed, in mouse models in which the expression of the oncogenes is
driven by tissue-specific promoters, tumors arise frequently, but they regress when the oncogenic
stimulus is switched off [8–10], suggesting that cancer cells are oncogene-addicted [11]. These findings
seem to point to a homogeneous mode of action of oncogenes throughout tumor life, since the removal
of the cancer-inducing oncogene will lead to tumor regression in these models (Figure 1). This model
is fitting with the fact that, in human cancers, due to the clonal nature of the disease, all cancer cells
carry the same initiating oncogenic lesions.
However, human cancers also present a very high degree of cellular heterogeneity [12], an
indication that, in the oncogenic process, the nature and identity of the target cells suffering the action
of the oncogene can be of great importance, especially since therapies based on the aforementioned
current working model of cancer are incapable of eradicating cancer in humans [7]. On the contrary,
the observations suggesting that the mode of action of oncogenes is not homogeneous throughout all
the different cancer cell types would explain why anti-oncogene targeted therapies present different
efficiencies against the different cellular stages of cancer evolution [7].
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Figure 1. Oncogene addition versus reprogramming cancer predisposition. (A) In physiological
conditions, the survival of a cell is determined by a specific survival pathway that needs to be
activated by a vital ligand recognized by a specific receptor. If this vital ligand is removed from
the niche/environment, the cell will die. (B) The oncogene addition hypothesis implies that a tumoral
cell is able to grow independently of the survival signals because the oncogene activates survival
pathways that maintain the tumor cell alive without vital ligands in the niche. The oncogene addition
model implies that the inhibition of the oncogene in the tumor cells leads to the tumor cell death,
as the survival pathways are no longer active. But under this scenario the evidence from the clinic
indicates that only non-CSCs die. (C) The tumor reprogramming model of cancer initiation suggests
that tumor stem cells are not oncogene addicted because there is a different function for oncogenes
within CSCs. In this model, the target cancer cell of origin is not addicted neither to the oncogenes nor
to the environmental signals.
This concept fits well with a model of cancer in which the tumor is generated and maintained
in a hierarchical manner similar to that of the normal stem cell-driven tissues, like the hematopoietic
system (Figure 2). In such a tissue, genetic programming of the stem cells is all what is required to give
rise to all the differentiated cells forming the tissue, and the genetic information responsible for the
stem cell programming does not need to be anymore present within those mature cells that form the
tissue. When extrapolated to cancer formation, this concept would imply a potentially different role
for the oncogenes at the level of the cancer stem cells (CSCs) [3,13]. Indeed, if cancer is generated by a
malignant stem cell reprogramming process, the oncogenes initiating tumor formation might not be
required for tumor progression [14,15].
This model also explains how, in the evolution of several human tumors, a pre-cancerous lesion
can be stably maintained as the only proto-oncogenic alteration in an abnormal cell population that
will only give rise to a full-blown tumor in response to secondary hits [16,17]. This initiating lesion is
the driving force in the reprogramming process, essential for the acquisition of a tumoral phenotype.
However, once its function in oncogenic reprogramming has been performed, this initiating hit would
become just a passenger mutation within the CSC, having either no function or even performing
26
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a different one, unrelated to the initial reprogramming one, for example in tumor proliferation.
This reprogramming model would explain why targeted therapies focused on the oncogenes can fail
in eliminating all cancer cells, in spite of their initial efficacy against the cells composing the main
tumor mass; a good example of this apparent paradox is imatinib, that fails to kill BCR-ABL+ CSCs
because somehow it cannot block the reprogramming capacity of the fusion oncogene in the stem cell
compartment [15,18,19].
Figure 2. Proposed model for the role of human cancer gene defects in the making of a leukemia. (A) In
the development of every normal tissue, a small pool of multipotent stem cells maintains multiple
cell lineages. (B) Traditionally, human cancer genetic defects have been thought to act on cells already
committed to a differentiation program. Hence, the cancer phenotype closely resembles that of the
initial differentiated target cell. (C) Normal uncommitted stem and progenitor cells are the targets
for transformation in some human cancers, and the human cancer-gene defects into these cells are
the instigators of lineage choice decisions, which are therefore dictated by the oncogene and not by
the cell-of-origin phenotype. Consistent with this is the finding that forced expression of these genes
in stem cells can select or impose a specific cancer-lineage outcome. This explains why specific gene
defects are usually found only in one type of cancer (see text for details). Dotted lines depict cell lineage
choices that were not imposed by the oncogene.
In tumoral cells from human patients it is impossible to separately study the potential different
roles of the oncogenes at the different stages of tumor development, due to the advanced stage of
the tumors at diagnosis and the accumulation and superposition of numerous driver and passenger
mutations. Indeed, in order to reveal the existence of a lack of homogeneity in the action of oncogenes
throughout the biological history of the tumor, we need a system that allows us to isolate the function
that the oncogene is playing in the first steps of cancer, in the cancer cell-of-origin. Ideally, one would
need a system in which the oncogene expression was restricted to the stem/progenitor compartment
in order to demonstrate that the posterior expression of the oncogene (as happens in human tumors) is
in fact not necessary for tumor progression once the tumoral reprogramming has already taken place,
and is therefore dispensable for cancer progression or maintenance (Figure 2).
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This conceptual framework has recently given rise to experimental settings in which different
oncogenic lesions, each linked to a specific type of hematopoietic cancers, have been targeted
to the hematopoietic stem/progenitor cellular compartment of genetically engineered mice by
using the locus control region of the Sca1 (“Stem cell antigen-1”) gene. It is a mouse glycosyl
phosphatidylinositol-anchored cell surface protein (GPI-AP) of the LY6 gene family. It is the common
biological marker used to identify hematopoietic stem cell (HSC) along with other markers and plays
a role in hematopoietic progenitor/stem cell lineage fate. In this setting, it has been shown that the
different lesions can epigenetically re-program the targeted stem cells and create a differentiation
state from which tumor cells with different properties emerge heterogeneously [15,20–24] (Figure 3).
Overall, this new view on oncogenesis not only reveals a novel function for oncogenes in cancer,
but also provides evidence for a previously unconsidered model of tumorigenesis, in which the
programming of the cancerous cellular identity has already occurred at the level of stem/uncommitted
cells, therefore showing a role for oncogenes in the timing of cancer initiation.
Figure 3. Driving of cancer by a malignant epigenetic stem cell rewiring. Different types of
mesenchymal (A) and epithelial (B) malignancies have shown that the contribution of oncogenes to
cancer development is mainly mediated through the epigenetic reprogramming of the cancer-initiating
target cell. As illustrated, specific genotype alterations associated to human cancer (medium circle) give
rise to specific phenotypes (outer circle) when targeted to the stem cell/progenitor compartment (see
text for details). Chronic Myeloid Leukemia (CML), Activated B-Cell Diffuse Large B-Cell Lymphoma
(ABC-DLBCL), precursor B-cell Acute Lymphoblastic Leukemia (pB-ALL), N-butyl-N-4-hydroxybutyl
nitrosamine (BBN).
3. Restriction of Lineage Options during the Making of Leukemia
A conceptually clarifying example of the power of the aforementioned experimental setting to
recapitulate the characteristics of human cancers is chronic myelogenous leukemia (CML), a widely
accepted stem cell disorder characterized by the presence of the chimeric BCR-ABLp210 oncogene.
When the expression of BCR-ABL is restricted to the Sca1+ cells in mice, the animals develop CML [15].
This model is designed so that the oncogene expression is switched off in the differentiated cells
that form the main mass of the tumor, although leukemia initiation has taken place within the stem
cell/progenitor population. The fact that CML arises in mice under these circumstances indicates that
the absence of BCR-ABL expression is not required for the generation of differentiated tumor cells
(Figure 2). These results connect tumorigenesis with the reprogramming of early progenitors and
strongly support the existence of a reprogramming-like mechanism in cancer development.
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CML is a paradigmatic stem-cell-driven cancer in humans, but we reasoned that, assuming the
tumoral reprogramming theory as we have previously mentioned, a similar experimental approach
as the one used to model BCR-ABLp210+ CML could also be used to reproduce in the mouse the
genotype-phenotype correlation (specific oncogene/specific tumor) found in other human cancers.
A challenging system to test this hypothesis would be a tumor whose main cell type is a mature
differentiated cell, like in the case of multiple myeloma (MM) or mature B-cell lymphoma. In fact, it has
been shown that both MM (induced by the MafB oncogene) and B-cell lymphoma (induced either by
the MALT1 or the BCL6 oncogenes) phenotypes and biology can be accurately mimicked in mice with
the same Sca1-mediated stem cell targeting system described before [20–23] (Figure 3). These results
implicated for the first time the stem cells in the pathogenesis of MM and B-cell lymphoma. Also, the
fact that both hematopoietic tumors can be generated in mice by limiting oncogene expression to
hematopoietic stem/progenitor cells (HS/PCs) implies that eliminating oncogene function beyond
the stem cell stage does not interfere with the generation of later tumoral developmental cell types,
and suggest that the oncogene is programming in the stem cells an epigenetic program that in some
way persists during differentiation and will finally lead to a mature tumoral phenotype of MM or
B-cell lymphoma [21–23,25,26]. Therefore, we postulate that cancer-initiating oncogenes epigenetically
modify target genes that remain in this “poised” state in the mature tumor even when the oncogene is
not present anymore (Figure 2).
4. Epigenetic Reprogramming in Non-Hematopoietic Tumors
Other examples of tumoral stem cell reprogramming, in which the induction of a new tumoral
fate by the oncogene takes place at the stem cell level (as opposed to reprogramming to pluripotency,
which is initiated from a differentiated cell) have been described for other types of non-hematopoietic
tumors. For example, the EWS-FLI-1 fusion gene, associated with most Ewing sarcoma tumors, triggers
the expression of the embryonic stem cell genes OCT4, SOX2, and NANOG when present in human
pediatric mesenchymal stem cells but not in adult ones, and it reprograms them to give rise to Ewing
sarcoma cancer stem cells [27]. Similarly, the synovial sarcoma-associated oncogene SYT-SSX2 can
reprogram mesenchymal stem cells by promoting their differentiation towards a pro-neural lineage,
in what most likely constitutes the primary tumorigenic event in this type of cancer [28]. A similar
scenario has recently been described in the genesis of chondroblastomas [29].
This driving of cancer by a malignant epigenetic stem cell rewiring is, however, not exclusive
to mesenchymal-derived cancers, but rather represents a common tumoral mechanism that is also
at work in epithelial tumors like lung carcinomas [30], bladder cancer [31], skin carcinomas [32],
ovarian carcinomas [33], pancreatic carcinomas [34], brain tumors [35,36], and prostate carcinomas [37]
(Figure 3).
These results prove that, when oncogenic proteins are expressed in stem or progenitor cells, they
can have a highly selective impact in differentiation. This, in turn, helps explaining the strikingly
consistent associations between each given chromosomal translocation, its resulting chimeric oncogene
and the final phenotype of the cancer it triggers. Altogether, the evidence supports a new vision of
cancer mainly as a disease of cellular differentiation, much more than just a proliferative disorder,
and asks for a reconsideration of the function of oncogenes. We should also insist on the fact that
this ‘hit-and-run’ reprogramming model for oncogene activity is not something happening only in
pathological conditions. Indeed, during normal hematopoietic development, for example, molecular
cues such as IL7 and erythropoietin are required to trigger specific differentiation programs but are
not required once the programs have been established.
This new conceptual framework, supported by the experimental findings and by the frequent
therapeutic failures in cancer human patients, also has important implications in the clinical
management of cancer. Certainly, if cancers develop through a reprogramming mechanism, then
the oncogenes, although necessary to initiate the tumor, might be dispensable for posterior tumor
survival and/or progression. Oncogenes would then have a driving role in the reprogramming
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process, but be only passenger mutations afterwards, or have a secondary, unrelated role in more
evolved tumor cell clones. For example, in human CLL, the susceptibility to generate malignant B
cells is already present at the hematopoietic stem cell (HSC) stage, long before the cells become B
cells [38]; consequently, patient-derived HSCs show an abnormal expression of lymphoid-related genes,
reflecting their cell-autonomous aberrant priming into the B-cell lineage. These findings, therefore,
have important implications for the therapeutic targeting of tumoral cells.
For example, in the case of CML, with one of the most commercially successful oncogene-targeted
therapies so far, the data from Sca1-BCR-ABLp210 animal models showed that the survival of CML
stem cells was independent on the kinase activity of BCR-ABL, therefore indicating that curative
approaches in CML should most probably focus on kinase-independent mechanisms of resistance [15].
These results on the failure of imatinib to eradicate CML in Sca1-BCR-ABLp210 mice have been later
confirmed in human patients [39–43], and this is a clear example of how a good preclinical model
can anticipate the human CSC-therapeutic response. These results on the role of BCR-ABLp210
in CML development show that leukemia stem cells might not be oncogene-addicted (Figure 1),
and are most likely relevant to many other cancers (multiple myeloma, MALT lymphoma, CLL,
etc.). Furthermore, these findings challenge the current accepted/working model of the role of
oncogenes and support the hypothesis that mature hematological malignancies may be initiated by an
inappropriate lineage-decision making process at the HSC level.
5. Hematopoiesis and Leukemia Are Both Lineage Decision-Making Processes
The most important functional characteristics of HSCs are their capacity for self-renewal and
their multilineage differentiation potential. Traditionally, the generation of differentiated cells from
HSCs was thought to occur through a series of dichotomic branching steps diverting into mutually
exclusive stable progenitor states. However, recent work has shown that hematopoiesis occurs through
a mechanism of continuous lineage priming [44] and therefore the architecture of the system is much
less compartmentalized than previously considered, and also more versatile in terms of lineage
plasticity, since developing progenitors can use different unusual pathways and/or have hidden
potentials, so that it could very well be that “defined” progenitor populations are in fact mixtures of
cells with several differentiation capabilities. This vision also changes our idea of cellular commitment,
if developing hematopoietic cells are in fact being gradually biased towards a certain fate without
sudden black-or-white developmental steps. A very important element of this vision is that these
progressive developmental biases are physiological rules that can be bent or even broken by both
intrinsic and extracellular factors in pathological conditions, a fact that has clear implications to the
understanding of the origins and progression of malignant transformation in a setting in which, as we
have stated, cancer would mainly be a disease of cellular differentiation (Figure 2).
This new point of view deepens our understanding of the biology of leukemia and its origins.
In several types of leukemia it has been shown that the pre-leukemic stem cell (pre-LSC) possesses
multilineage potential; this is the case in CML, where pre-leukemic BCR-ABLp210+ stem cells can give
rise to all different blood cell types (Figure 4). This is also the case for CMLs associated with a mutant
RAS allele, in which this mutant RAS can be found in all mature lineages [45]. In myelodysplastic
syndromes, a multipotent malignant stem cell is behind the development of refractory anemia (RA),
RA with ringed sideroblasts or RA with excess blasts [46]. In all these cases, the existence of a
pre-LSC with multilineage differentiation potential suggests that initiating mutations arise in a normal
HSC and that afterwards, through the acquisition of additional mutations triggered by secondary
events, the initiated clone will evolve to produce a sub-clone of lineage-restricted malignant blasts
(Figure 4). This two-hit model of leukemogenesis relies on the stepwise acquisition and collaboration
between two main groups of mutations: (i) those affecting genes of transcriptional or epigenetic
regulators that can modify or restrict lineage options (e.g., generation of chimeric oncogenes such
as RUNX1-RUNX1T1 or PML-RARA, BCR-ABLp190, ETV6-RUNX1 or mutations in CEBPA, PAX5 or
NPM1) and, (ii) those activating signal-transduction pathways that confer survival or proliferative
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advantages (e.g., mutations in FLT3, RAS or KIT). Therefore the pre-leukemic oncogenic lesion is stably
maintained as a single alteration in an abnormal cell population, but will only progress to an open
leukemia when secondary hits occur [16,17]. Therefore, although the cells that suffer the initiating
leukemic hit possess multi-lineage potential, LSCs are reprogrammed by this oncogenic hit and their
lineage decision-making becomes restricted or biased.
Figure 4. Schematic representation of the emergence of LSCs in the making of a leukemia. A mutation
occurs in HSCs leading to the emergence of aberrant pre-leukemic HSCs. These aberrant pre-leukemic
HSCs self-renew and expand within the HSC compartment. Pre-leukemic HSCs give rise to a high
number of lineage-committed progenitors harboring this identical mutation. This leads to an increased
chance of acquiring the additional oncogenic/environmental events, which finally transform the
aberrant progenitor cells from pre-leukemic HSCs into the leukemic stem cells (LSCs). Loss of
differentiation potentials is essential for the emergence of LSCs. LSCs are reprogrammed by an
oncogenic insult to an invariant cell lineage. Hematopoietic stem cell (HSC), Multipotent progenitor
cell (MPP), Lymphoid-primed MPP compartment (LMPP), Common myeloid progenitor (CMP),
Common lymphoid progenitor (CLP), Early progenitor with lymphoid and myeloid potential (EPLM),
Granulocyte-macrophage progenitor (GMP), Monocytes (Mon), Eosinophil-granulocyte-macrophage
(EoGM), Granulocyte-macrophage progenitor-colony forming unit (GM-CFU), Dendritic cell (DC),
Megakaryocyte-erythroid progenitor (MEP), Natural Killer cell (NK), Eosinophil/Basophil-colony
forming unit (Eo/B-CFU).
It seems therefore that tumoral reprogramming and aberrant lineage-programming are crucial
characteristics at the root of cancers including leukemia. The neural stem cells from malignant
glioblastoma can be reprogrammed to induced-pluripotent stem cells (iPSC). These iPSC can then
be differentiated into mesodermal lineages, and along this developmental pathway they lose
their malignant nature, but they maintain it when they are differentiated into neural cells [47].
Similarly, primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia
(B-ALL) cells can be reprogrammed into non-leukemic macrophages, overriding the malignant
differentiation block into the B cell lineage [48]. These findings underscore the fact that the cancerous
condition is in some way linked to the fact that the cells have been programmed to adopt a specific
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given lineage. Then the key questions are: Which is the normal developmental stage that is being
programmed? and at what stage does this occur within the leukemic development itself?
The leukemic conversion is only possible if the normal cell that gives rise to the leukemia,
the leukemia cell-of-origin (LOC), has the necessary developmental plasticity to tolerate the
reprogramming and react to it by changing its fate. On the other hand, the oncogenic event(s)
triggering LOC malignant conversion cancer must also have a reprogramming capacity to be able to
promote such a change in cellular identity [49].
It is generally accepted that tumoral progression is a multi-hit process and, also from a tumoral
reprogramming perspective, the different aspects of normal cellular biology must be progressively
altered to finally give rise to a full-blown tumor [5]. Under normal conditions, HS/PCs are slowly
moving towards lineage biases, diversifying and differentiating towards their final cellular identities.
The requirement of multiple hits for full tumor development is in relationship to the fact that the
changes required to revert or deviate cells from their normal non-pathogenic fate are inherently
disfavored developmentally, and biological barriers are in place to ensure that cells do not easily
change their identity in order to minimize the risk of malignant transformation.
This biological reluctance of the cells to being reprogrammed by an oncogene to a tumor
phenotype is illustrated by recent studies on stem-cell-based animal models of human cancer.
The loss of the p53 tumor suppressor is a frequent occurrence in malignancy, and it has a clear
function in facilitating pathological reprogramming to a malignant phenotype. In a stem-cell-based
transgenic model of multiple myeloma, the loss of p53 accelerates the appearance of the disease
by allowing the MafB oncogene to drive a much more efficient malignant transformation [22,25].
Something similar happens in the case of mucose-associated lymphoid tissue (MALT) lymphoma
driven by the MALT1 oncogene [21]. In a stem-cell-based model of CML [50], the restoration of p53
activity in already established cancers slowed the progression of the disease and prolonged the survival
of diseased animals by causing the apoptotic death of leukemic progenitors, one more demonstrating
the importance of reprogramming in lineage decision-making towards a tumoral fate.
6. The Importance of Environmental Signals in the Making of Leukemia
We have seen that precancerous lesions can exist as stable single alterations maintained in an
abnormal, but not cancerous, cell population that will only progress to full-blown cancer as a result of
secondary hits [16,17]. One of the best examples of this is childhood B-ALL, in which the first oncogenic
hit, through a stem cell tumoral epigenetic reprogramming mechanism, gives rise to a preleukemic
clone that remains harmless until its carrier is exposed to common infections [24,51,52]. This infection
exposure would never cause leukemic development in healthy individuals (i.e., persons not carrying a
preleukemic clone). Also, human epidemiological studies show a positive association between body
weight at birth and the risk of developing childhood leukemia. This implies that, although some
epigenetic reprogramming can be observed immediately after exposure to exogenous or endogenous
agents, both aberrant epigenetic programming and altered disease susceptibility may manifest only
later in life, long after the exposure took place. However, there are not known differences in epigenetic
reprogramming between childhood and adults with leukemia. Together, these data lead us to propose
that leukemia as a result of epigenetic reprogramming is a type of gene–environment interaction that
can cooperate with a genetic predisposition, not by inducing mutations, but by reprogramming the
epigenome to modulate gene expression in order to promote leukemia development. By dissecting
how epigenetic reprogramming increases leukemia risk, we may not only be able to better identify
who has an increased risk of developing leukemia from early life environmental exposures, but may
also be able of developing interventions that can reverse the epigenetic effects of the tumor epigenetic
reprogramming to decrease leukemia risk associated with this type of gene–environment interaction.
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7. Therapeutic Intervention in Leukemia and the Prospect of Modifying the Making of Leukemia
The understanding of cancer as a LSC-dependent aberrant tissue has deep implications for cancer
treatment. Obviously, under the LSC conceptual framework, the LSCs should the primary targets
of anti-cancerous therapy. However, since LSCs share most of their basic biological properties with
normal, non-pathologic stem cells, therapies directed against LSC pathways might also unintentionally
eliminate normal resident stem cells.
We have seen how the main contribution of oncogenes to tumor development is not their
proliferation-inducing capability, but rather their capacity for reprogramming the LSC epigenome.
This capacity of making leukemia in such a way that the maintenance of oncogene expression is not
required for the posterior generation of differentiated tumoral cells seems to be a common mechanism
of determination of cancerous identity and, as such, it should change our understanding of how the
“hallmarks of cancer” are acquired during tumor development. In this sense, it has recently been
shown that epigenetic reprogramming can be the driving force behind intra-tumoral heterogeneity [53],
and can also be the mechanism used by tumors to evade CD19 CAR immune therapy [54,55] (Figure 5).
Figure 5. Epigenetic reprogramming and cancer therapy. (A) Epigenetic reprogramming can be the
mechanism used by tumors to evade CD19 CAR immune therapy. (B) Epigenetic reprogramming can
be exploited in therapy to kill leukemia/cancer stem cells. Recent findings indicate that rewiring the
epigenetic programming of tumor cells is a viable prospect (see text for details).
With the new animal models generated within this stem cell reprogramming paradigm, we can
now study how different cancerous stages develop from the very beginning, and we could unlock
the potential to provide great advances in human cancer medicine. Since assessing the effects of
therapies on the rare LSCs that are the responsible for relapse is almost impossible in the patients, the
development of these treatments will have to heavily rely on the use of accurate preclinical models
and preclinical assays.
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The key factor in this new view of cancer specification is the setting of a new regulatory circuitry
by epigenetic reprogramming. This opens a new door for therapeutic opportunities since in these last
tears we are learning more and more about how to genetically or pharmacologically manipulate the
epigenetic status of cells. In fact, epigenetic therapeutic protocols have already been incorporated in
some cases to standard chemotherapy regimens as a potential improvement in the treatment of, for
example, relapsed pediatric acute lymphoblastic leukemia [56].
Also, in more experimental settings, cancer cells have been reprogrammed to non-tumoral
fates, losing their malignancy. For example, it is possible to produce even mouse embryos from
brain-tumor-derived cells [57] and to reprogram embryonal carcinomas [58] or melanoma cells by
using nuclear transplantation [59]. Similarly, B-ALL cells have been reprogrammed to an alternative
lineage cell fate without a malignant phenotype [56]. Also, it has recently been shown that epigenetic
reprogramming can be exploited in therapy to kill leukemia stem cells [60] and can also be used to
treat pediatric brain cancer [61,62]. These findings support the underlying theory and indicate that
rewiring the epigenetic programming of tumor cells is a viable prospect. Also, it is not unreasonable to
expect that LSCs from different cancer types will share many similarities, so that similar LSC-based
therapeutic approaches could be successfully employed against different cancer types (Figure 5).
In any case, like for any other type of therapy, a detailed understanding of the epigenetic rewiring is a
prerequisite for any potential intervention.
8. Future Opportunities and Challenges
The new perspective of leukemia that is arising from the most recent results from advanced
animal models is leading us to a better understanding of the biology of the disease and, at the same
time, is forcing us to question long-standing beliefs about the role of oncogenes in leukemia generation.
We have seen that the exposure of plastic stem cells to the epigenetic reprogramming capacity of
some oncogenes works as a new type of gene–target cell interaction in which oncogene exposure poises
the epigenome to induce leukemia development [20–24]. In this model of action, oncogene-activating
mutations would have a driving role in the reprogramming process at the leukemia cell-of-origin, but
may become passenger alterations (or have a different, secondary role) at later stages. To increase
the complexity of the problem, the phenotypic consequences of the epigenetic reprogramming can
remain silent until triggered by later exposures (genetic and/or environmental) [24,51,63–65]. Of great
importance is the fact that the setting of the epigenetic circuits that lead to tumor cell development is
unidirectional. This implies that even brief exposure to an environmental agent can disrupt the normal
epigenetic developmental programs and alter the epigenome for life [66]. Now we have the ability to
model tumor stem cell generation in vivo for different types of cancer, with their respective inducing
oncogenes. This opens up new possibilities for studying how the different cancer stages develop from
the start. If we can understand how the oncogene–target cell interaction is regulated, then we might
learn how to manipulate tumoral cellular identities and stages experimentally, a knowledge that could
lead to tremendous advances in human cancer medicine.
Looking into the future, we are faced with the paradox that we still do not understand how the
balance is regulated between cell intrinsic and environmental agents in developmental processes.
Cellular pluripotency is a pre-requisite for the versatility of the organisms, giving them the capacity of
evolving different types of specialized cells to face different challenges. However, pluripotency is a
force that needs to be tamed in order to give rise to an adult organism composed of highly differentiated
(and not therefore pluripotent) cells. In the last decade, we have learnt that the architecture of adult
tissues is much more versatile and plastic than previously thought, and this is particularly important,
for example, when responding to the demand triggered by infectious agents as to the specialized cells
required to fight them.
New findings open new questions. For example, is the decision to initiate leukemia made at one
single time point during the tumoral differentiation process, or is composed by a series of consecutive
decisions required to switch to a leukemia cell fate? What is the precise nature of the epigenetic
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pathway triggered by the leukemia-initiating gene defect(s)? Last but not least, these findings on the
mechanisms of cellular commitment to a tumoral fate are relevant not only to the understanding of
the stem cell properties of leukemia and the development of new therapies, but also to regenerative
medicine, since in this context it will be essential to have full control over the potential malignancy of
reprogrammed cells.
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Abstract: The most active metabolite of vitamin D is 1α,25-dihydroxyvitamin D3, which is a central
regulator of mineral homeostasis: excessive administration leads to hypercalcemia. Additionally,
1α,25-dihydroxyvitamin D3 is important to decision-making by cells, driving many cell types to
growth arrest, differentiate and undergo apoptosis. 1α,25-Dihydroxyvitamin D3 regulates gene
transcription by binding to a single known receptor, the vitamin D receptor. Rapid intracellular
signals are also elicited in vitro by 1α,25-dihydroxyvitamin D3 that are independent of transcription.
There are many aspects of the multiple actions of 1α,25-dihydroxyvitamin D3 that we do not fully
understand. These include how a single receptor and provoked rapid events relate to the different
actions of 1α,25-dihydroxyvitamin D3, its calcemic action per se, and whether a large number of genes
are activated directly, via the vitamin D receptor, or indirectly. A strategy to resolving these issues
has been to generate synthetic analogues of 1α,25-dihydroxyvitamin D3: Some of these separate
the anti-proliferative and calcemic actions of the parent hormone. Crystallography is important
to understanding how differences between 1α,25-dihydroxyvitamin D3- and analogue-provoked
structural changes to the vitamin D receptor may underlie their different activity profiles. Current
crystallographic resolution has not revealed such information. Studies of our new analogues have
revealed the importance of the A-ring adopting the chair β-conformation upon interaction with the
vitamin D receptor to receptor-affinity and biological activity. Vitamin D analogues are useful probes
to providing a better understanding of the physiology of vitamin D.
Keywords: cell differentiation; vitamin D; vitamin D receptor; vitamin D analogues; crystallography
1. Introduction
1α,25-Dihydroxyvitamin D3 (1,25D3, calcitriol, Figure 1) is the most active metabolite of vitamin D
(vitD, cholecalciferol). This seco-steroid hormone has many biological roles [1]. A key physiological role
of 1,25D3 is to regulate the absorption and transportation of essential minerals, particularly calcium,
phosphorus, and magnesium, which are important to the maintenance of bone [2,3]. 1,25D3 also plays
a key role in decision-making by cells because it can elicit events that result in many types of cells
arresting their growth, differentiating, and undergoing apoptosis. The anti-proliferative action of
1,25D3 extends to malignant cells, leading to interest in its use for differentiation therapy of leukemia
and other cancers. However, a substantial limitation to this use of 1,25D3 is that its calcemic action
restricts achieving an effective therapeutic dose [4]. Many of the immune cell types express the receptor
for vitamin D (VDR): 1,25D3 has an important role in their function and is, therefore, important to
good health [5,6]. A related interest is the therapeutic use of 1,25D3 as an anti-inflammatory agent.
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Figure 1. The structures of 1α,25-dihydroxyvitamin D3 (1,25D3) and 1α,25-dihydroxyvitamin
D2 (1,25D2).
2. The Modes of Action of Vitamin D
Some of the biological effects of 1,25D3 result from the direct activation of target genes [7,8]. In this
case, 1,25D3 binds to its single known receptor VDR. The VDR forms a heterodimer with the retinoid X
receptor to regulate gene transcription. 1,25D3 regulates a large number of genes, including ones that
link to the growth and differentiation of cells and diseases that include cancer, diabetes, and arthritis.
At least 229 genes are subject to regulation by 1,25D3, as revealed by ChiP-seq analysis [9,10]. We do
not understand whether the VDR activates all of the envisaged number of genes directly or indirectly.
For some cells, 1,25D3 treatment leads to the activation of non-genomic signaling pathways.
The delineation of these events is from in vitro studies, and they occur within seconds or minutes after
treating cells with 1,25D3 [11,12]. In this scenario, 1,25D3 initiates signals at the plasma membrane
or in the cytosol. The mitogen-activated protein kinases and phosphatidylinositol 3-kinase signaling
cascades mediate this rapid response to some extent [13–15]. There are putative receptors for 1,25D3
at the cell membrane that include the membrane-associated rapid response steroid-binding protein
(MARRS, ERp57, or PDIA3), megalin, and cubilin, and the latter two transport vitamin D, complexed
to its serum binding protein [16]. Additionally, 1,25D3 binds to the VDR in an alternative VDR-binding
pocket through a 6-cis-1,25D conformation as proposed by Mizwicki and Norman [17]. Endocytosis
of this and other putative membrane receptors can generate immediate intracellular signals via the
Rab5/PI3-kinase pathway. A shift in the balance between VDR-provoked gene transcription and rapid
signaling events might underlie the anti-proliferative versus calcemic actions of 1,25D3. However,
the structure-calcemic activity relationship for most of the known vitamin D analogues is not clear
to date.
3. Vitamin D Analogues
Over recent years, investigators have generated and studied hundreds of vitD analogues and
several metabolites. Their structures are important to biological activity. A total of 17 crystal structures
of 1α-hydroxylated vitDs are at the Cambridge Structural Database, and there are structures of 63 vitD
analogues bound to the engineered VDR. Despite all of this, we still do not understand the molecular
events that force an analogue to adopt the A-ring slightly distorted chair β-conformation per se and
when bound to the VDR. It remains a mystery as to why the three hydroxyls (1, 3, and 25) that mediate
analogue binding to the VDR are almost overlapping and why analogues have very different structures
and activities.
The most important parts of vitD and analogues regarding the affinity for the VDR,
and consequently activity profile, are the A-ring, the side-chain, and the CD-ring system.
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Recently, we divided double point modified (DPM) analogues of vitDs [18] into structural
groups. We introduced the new classification system for semi-quantifying the biological activities of
DPM analogues and outlined new directions for structural modifications. Based on this overview,
we designed new analogues of 1α,25-dihydroxyvitamin D2 (Figure 1, 1,25D2) to study the active
conformation of the A-ring. We used a panel of closely related analogues of 1,25D2, [19] with solved
crystal structures [20], rather than just a single analogue. For reference, we used a new compound (not
shown) with all the functional groups (C-25 carboxy and 1- and 3-hydroxyl) protected and, therefore,
deprived of electrostatic interactions [20]. The correlation of the structures of the new analogues with
their biological activities [21,22] allowed us to solve a long-lasting enigma [23,24] surrounding the
1α-hydroxylated analogues of vitD. We have proposed a new general rule (see below), confirmed by
theoretical calculations, which applies to all of our crystallographic data and which has been obtained
for 1α -hydroxylated analogues of vitD over the last 25 years.
We investigated the side-chain structure by generating (24Z) geometric isomers [25] of our
hypocalcemic analogues of 1,25D2. We examined their binding affinities for the VDR, the potency
regarding inhibition of cell growth, and the regulation of stem cell-related gene expression in colon
cancer cells [26]. Resistance to hCYP24A1-metabolism, which deactivates 1,25D3 by enzymatic
hydroxylation [25], relates to a preferred side-chain geometry. An extended and rigidified side-chain
of 1,25D2 is responsible for the longer-term biological effects of vitD (see below). We used human
AML cell lines to examine the correlation between the side-chain geometry of 1,25D2 and potency in
arresting cell growth and inducing cell differentiation [27].
The original principle of CD-ring modified analogues [28] was that the entire CD-ring system of
an analogue was not required for activity [29]. The hydrindane CD-ring moiety originates from the
biotransformation of sterols into 9,10-seco-steroids (vitD), and it was not specifically biosynthesized for
vitD. Additionally, the CD-ring is the only part of the vitD molecule that does not participate in the
metabolic transformations of vitD. Moreover, molecular modeling revealed that des-C,D analogues
relate structurally to the biotransformation product [29] of all-trans-retinoic acid (ATRA), a potent
differentiating agent. Des-C,D analogues combine aspects of both the vitD and retinoid structures,
and we call them retiferols. Our original concept of retiferols led to the synthesis of a substantial variety
of CD-ring modified analogues, including other des-C,D analogues [30], des-D,C-ring analogues [31],
and des-C,D-ring homo analogues [32], and their biological activity was evaluated [30–32]. Our first
retiferol (Figure 2) RAD2 became a synthetic target [33]. Roche researchers [30] obtained 19-nor RAD2
and reported that this analogue was useful in the treatment of hyper-proliferative skin diseases in vivo.
Here, we discuss how CD-ring modifications affect activity.
Figure 2. The structure of RAD2, the first des-C,D analogue of 1α,25-dihydroxyvitamin D3 and of
(20S)-13,13-dimethyl-des-C,D-1,25-dihydroxy-2-methylene-19-nor-vitamin D3.
Below, we examine the use of various classes of new analogues of vitD to unravel some of the
issues relating to structure and biological activity. Of particular importance is that new analogues
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separate the anti-proliferative and calcemic actions of the parent hormone more effectively than
previous analogues (see below), and how might this be the case?
4. The Vitamin D A-Ring Conformation
To investigate the correlation between the A-ring conformation and activity, we conceived and
synthesized, by a novel convergent strategy, a panel of DPM analogues of 1,25D2 coded PRI-1730,
PRI-1731, PRI-1732, PRI-1733, and PRI-1734 (Figure 3) [19]. Our modifications included new 5,6-trans
(5E,7E) geometry of the A-ring per se or combined with the further modifications in the side chain.
These included an additional (22S)-hydroxyl, 22,23-single bond, and a reversed absolute configuration
(24-epi) at C-24. All our analogues induced differentiation of the VDR positive A375 and VDR negative
SK-MEL 188b human malignant melanoma cell lines [22]. As expected, 5,6-trans modification of the
A-ring was advantageous to enhancing the anti-proliferative activity of the analogues but not as a
single point modification. Very unexpectedly, the additional 22-hydroxyl in the side-chain, conceived
to enhance VDR binding, reduced significantly the anti-proliferative activity of both the natural and
5,6-trans series of analogues [21].
Figure 3. The structures of double point modified analogues of 1α,25-dihydroxyvitamin D2.
PRI-1731 and PRI-1733 increased translocation of the VDR to the nucleus of HL60 cells but to a
lesser extent than provoked by 1,25D2 and 1,25D3. 5,6-Trans modification contributed substantially to
the increased stability of the PRI-1731 and PRI-1733 against enzymatic hydroxylation by hCYP24A1,
produced by expressing recombinant protein in Escherichia coli. Unexpectedly, reversing the chirality at
C-24 from the natural (24S) in PRI-1731 to the (24R) in PRI-1733 did not affect metabolic resistance.
The conversion remained at the high level of only 12% for both analogues, compared with 44% and 35%
for 1,25D3 and 1,25D2, respectively. The addition of 22-hydroxyl and the saturation of the 22,23-double
bond resulted in a dramatic loss of metabolic stability from 12% for PRI-1731 to a 52% conversion for
PRI-1732. We used fluorescence polarization-based competition assay to measure the binding affinity of
our analogues for the VDR. Only the 5,6-trans analogue of 1,25D2 (PRI-1731) showed a binding affinity
comparable to that of both 1,25D2 and 1,25D3. Very intriguingly, a combination of all four structural
modifications resulted in a complete loss of activity in the case of PRI-1734. This analogue showed
weak binding to the VDR [21] and failed to agonize the VDR. However, its structure might be a good
starting point for the design of a vitD antagonist, once the binding is improved [21]. The modifications
introduced have not led to an increase in differentiation-inducing potency for the above new panel of
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analogues. However, they have resulted in a very divergent group of analogues that have provided
very important data regarding structure versus activity relationships.
VitD analogues are resistant to crystallization due to a high flexibility over the number of rotated
single bonds in the side-chain and in the triene system. Therefore, we were very fortunate to obtain
single crystals of as many as three analogues (PRI-1730, PRI-1731, and PRI-1732), out of a panel of
our five analogues [19], suitable for X-ray diffraction. For our structure–activity relationship, it was
also of key importance to obtain a single crystal of the synthetic intermediate with all the functional
groups (1,3, and 25-hydroxyl and 25-carboxyl) protected and, therefore, deprived of electrostatic
interactions [25]. Very interestingly, we observed that the A-ring of PRI-1730 and PRI-1731 exists in
a crystal state in a chair β-conformation, and that of PRI-1732 and of the totally protected synthetic
intermediate in a chair α-conformation [20]. Using this unusually large collection of solid-state
structures, our crystallography study revealed the new general rule regarding the solid-state A-ring
conformation. We concluded that the direct hydrogen bond between 1-hydroxyl and 3-hydroxyl of the
neighboring molecule forces the A-ring of 1α-hydroxylated analogues of vitamin D to adopt the chair
β-conformation. According to our rule, the analogues adopting an A-ring chair β-conformation exhibit
higher biological activity than the structurally related analogues existing in the chair α-conformation.
This is due to the possibility of stronger electrostatic interactions of the chair β-conformation with the
VDR. This explains why PRI-1730, which adopts the chair β-conformation, shows much higher activity
(e.g., in nuclear translocation of the VDR) than PRI-1732, which has the chair α-conformation, and why
PRI-1730 shows a much higher metabolic stability (31% conversion) than PRI-1732 (52% conversion).
Contrary to the common understanding, our crystallographic studies demonstrated that the structure
of an analogue in a solid state very much relates to its structure in a solution and when interacting with
the VDR, predicts its biological activity as high or low. We should consider testing only the analogues
existing in a solid state in A-ring chair β-conformation for biological activity.
5. Modifications to the Vitamin D Side-Chain
In our studies of the relationship between the side-chain structure and activity, we developed
another new convergent strategy to modify our leading 1,25D2 analogues, PRI-1906 and PRI-1907
(Figure 4). We extended and rigidified the side-chain and obtained new analogues, PRI-1916 and
PRI-1917, with the previously unknown geometry at C-24 [(24Z), instead of (24E)]. The binding affinity
of PRI-1916, with two methyl at the terminus of the side-chain at C-25, for the full-length human VDR
in a fluorescence polarization assay was substantially higher than that of the previously obtained
PRI-1906. However, the affinity of PRI-1917, with two ethyl at C-25, was much lower than that of the
parent PRI-1907. This finding indicated that terminal alkyls at C-25 strongly influence the binding
affinity of analogues for the VDR. Our PRI-1906 and PRI-1907 have a very high resistance to metabolic
conversion (2.3% and 0.8% for PRI-1906 and PRI-1907, respectively, compared with 44% and 35%
for 1,25D3 and 1,25D2, respectively). Our new PRI-1916 and PRI-1917 showed a somewhat lower
resistance to conversion, although still higher than that of 1,25D3 and 1,25D2. From these findings we
proved that a rigid and straight (24E) geometry of the side-chain is preferred for metabolic resistance,
and in keeping (24E), (24-trans) analogues elicit long-term biological effects against cancer cells [25].
(24Z) Modification of the side-chain of 1,25D2 analogues has a contrasting effect on the differentiating
activity of PRI-1906 and PRI-1907. Although the VDR affinity of the (24Z) analogue PRI-1916 was
lower than that of (24E) analogue PRI-1906, the potency of PRI-1916 was slightly higher than that of
PRI-1906 when tested against the human AML cell lines KG-1a, HL60, U937, and MOLM-13, which
typify different stages of myeloid maturation [27] However, PRI-1917 was significantly less potent
than PRI-1907. We, therefore, finally concluded that the (24E) side-chain geometry combined with
selected modifications of the A-ring is preferable in terms of generating potent anti-proliferative and
differentiating vitDs. Evaluation of the differentiating activity and calcemic action of newer analogues
of 1,25D2 has shown they are more potent differentiating agents than 1,25D3 and have a reduced
calcemic action (see Table 1).
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Figure 4. The side-chain extended and rigidified analogues of 1α,25-dihydroxyvitamin D2 (PRI-1906
and PRI-1907) and their (24Z) geometric isomers (PRI-1916 and PRI-1917).
Table 1. Differentiating potency, calcemic action, and binding to the receptor for vitamin D (VDR) of
PRI analogues of 1α,25-dihydroxyvitamin D2.
Analogue
Differentiation
EC50 m × 10−11
Calcaemic Action
Ca2+ (Serum) m × 10−6
VDR Binding
IC50 m × 10−10
1,25D3 53 107 23
PRI-1907 6 75 62
PRI-5100 113 86 6
PRI-5101 118 90 5
PRI-5201 3 93 11
PRI-5202 2 81 36
The values obtained for 1α,25-dihydroxyvitamin D3 (1,24D3) are shown for comparison. The EC50
for differentiating potency is the value that drives half-maximal differentiation of the promyeloid
cell line HL60 towards neutrophils. Calcium levels are the mean of the values obtained for five mice
treated with 0.3 μg/kg of 1,25D3 or an analogue every other day for 3 weeks and measured on day
21. The serum calcium level in ethanol-treated mice was 62 μM. The analogues PRI-1907, PRI-5201,
and PRI-5202 are more potent differentiating agents than 1,25D3 and have a lower calcemic action.
Quite unexpectedly, both (24E) and the new (24Z) analogues are equipotent in decreasing the
cloning capacity and the proliferative activity of the human colon cancer cells HT-29 [26]. These cells are
refractory to the anti-proliferative action of the chemotherapeutic agent 5-flurouracil. Both of the C-25
diethyl analogues, PRI-1907 and PRI-1917, decreased the level of expression of stemness-related genes,
while both dimethyl analogues, PRI-1906 and PRI-1916, were not able to downregulate these genes.
Therefore, the new geometric analogues, PRI-1907 and PRI-1917, are good candidates for further studies
to examine the benefit to preventing cancer relapse. In this regard, they act to decrease the proliferative
capacity of cells that initiate tumor regrowth, by virtue of downregulating stemness-related genes.
The analogues might be useful in post-treatment of cancer patients with conventional reductive
chemotherapy, particularly regarding the reduced calcemic action of PRI-1907 and the newer analogues
of 1,25D2 (see Table 1) [26].
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6. CD-Ring Modifications of Vitamin D
There is evidence to support the viewpoint that methyl substituents at C-13 of 13,13-dimethyl-
des-C,D-1,25-dihydroxy-2-methylene-19-nor-vitamin D3 mimic the C-ring of 1,25D3. The 13,13-
dimethyl des-C,D-analogue of (20S)-1α,25-dihydroxy-2-methylene-19-nor vitamin D3 (Figure 2) still
retains much of the activity of vitD [34]. As predicted [29] and confirmed recently [35], even an
extensive modification of the CD-ring does not affect the functional activity of vitD as long as the
three-dimensional (3D) arrangement of the three 1α, 3, and 25 hydroxyls, responsible for VDR binding,
is preserved. As expected, a number of CD-ring modifications resulted in a lowering or complete
loss of the undesired calcemic action regarding the development of a potent agent that selectively
drives differentiation [30]. A lowering of calcemic activity is also the case for a novel class of five
des-C analogues with the CD-ring fragment partially replaced by an alkyl chain to mimic the C-ring
and an aromatic m-phenylene ring replacing the D-ring (Figure 5). Docking studies to the human
ligand-binding domain of the VDR led to the design of these analogues. The analogue with an
ethyl substituent to mimic the missing C-ring is active against breast cancer cells and, as expected,
has negligible calcemic action [36]. These analogues provide important information about the
structure–activity relationships regarding CD-ring modifications. This novel class of aromatic-based
vitamin D analogues also confirmed that retaining the network of hydrogen bonds of 1,25D3 is
crucial for transactivation activity and that aromatic modification of the CD-ring fragment abolishes
calcemic activity.
Figure 5. The des-C-m-phenylene-D-21-nor-analogues of 1α,25-dihydroxyvitamin D3 (R = Et, n-Pr, n-Bu,
n-Hex, n-Hept).
7. Future Directions
As described, various modifications to vitD underlie the search for a new drug candidate.
Beneficial modifications are those to the A-ring, the triene system, the CD-ring fragment, and the
side-chain. An old viewpoint was to make very subtle and single modifications. The current
understanding to obtaining the most potent VDR agonist is to combine several modifications at
various parts of the molecule. However, the number of possible combinations is numerous. The route
to the best combinations remains elusive, because the ultimate outcome of combinations is quite
unpredictable. They might result in enhancement or in a complete loss of activity. Even so, several
vitamin D super-agonists have been rationally designed and synthesized.
Intuition has mostly driven the design of new vitamin D analogues, coupled with trial and error.
A crystal of the full-length native VDR that is suitable for X-ray diffraction study is presently not
available. In this case, a classical model [37] that makes use of a truncated VDR protein remains the
only available approach to examining the interactions of vitDs with the VDR. This artificial VDR
protein has the flexible hinge region cut off to improve the ability of the residual VDR to crystallize.
45
Int. J. Mol. Sci. 2018, 19, 2119
The accumulating of more and more data leads to the viewpoint that the standing model might
be of limited significance, because the resulting solid-state structures of various analogues show
overlapping of the functional hydroxyls. Very recently, a study of a panel of five analogues of very
different structures recorded no detectable differences regarding binding to the VDR [36].
A common understanding is that crystallography plays the major role as the only direct method for
studying analogues per se and their protein complexes to reveal structure versus activity relationships.
Relative spectroscopic methods, such as high frequency nuclear magnetic resonance (900 MHz) [38], are
still of a very limited use, as not enough data have been accumulated for a complete signal assignment.
Up to now and for complexes of vitDs and the VDR, there is only low-resolution crystallographic
data, usually well above 2 Å. We might expect that high-resolution crystallographic data, below
0.5 Å, will give a much better insight into the structural differences between the VDR complexed with
various analogues.
However, to make substantial progress and ensure the design of analogues in a truly rational
manner an entirely new crystallographic approach is required. It is highly desirable to obtain single
crystal high-resolution data of the native VDR, other than for a truncated model protein. Considering
the recent developments of crystallography, the time is right to make a concerted effort to obtain
the crystal structure of the full-length human VDR per se and complexed with vitDs. Automated
high-throughput robots now crystallize proteins up to three times larger than the VDR. Additionally,
consideration of modern cryo-electron microscopy as a tool for examining a native VDR-retinoid X
receptor (RXR) complex is worthwhile. Success in the above directions will open a new era that should
reveal the real relationships between the structure and the biological activity of vitDs.
To understand the various biological roles of the VDR there is a need to develop an antagonist of
the VDR. The rational design of a potent antagonist is much more difficult than designing an agonist,
because there are only few antagonistic structures for use to examine correlations between structure
and function. Additionally, computerized docking approaches are especially useful for designing
agonists, and the same method is useful to the design of antagonists. The crystal structure of the
full-length VDR will be valuable to the design of an antagonist.
8. Concluding Remarks
As outlined, the precise nature of modifications to the structure of vitD is important to the gain
and loss of particular biological actions. The modified analogues, in turn, are important to developing
a better understanding of how vitD can mediate a variety of different biological roles. Of particular
interest is the generation of vitDs that are potent differentiating agents and lack calcemic action, for use
in studies of cell differentiation and as potential anti-cancer agents. Work over a number of years
has generated a range of analogues with very different modifications to the structure of vitD and has
correlated their structures with biological actions. A number of important structure–activity rules
have emerged (see Figure 6). Analogues with an aromatic modification of the CD-ring fragment have
a reduced calcemic action. The hydrogen bonds of the natural 1,25D3 are crucial for transactivation
activity, and vitDs with the (24E) side-chain geometry combined A-ring modifications are potent
anti-proliferative and differentiating agents. Too many structural modifications, a combination of
four in the case of PRI-1734, led to a complete loss of biological activity. A rigid and straight (24E)
geometry of the side-chain confers resistance to catabolism via enzymatic hydroxylation by hCYP24A1.
The provision of a better understanding of how vitD and analogues bind to VDR is also essential to
unraveling function. In this regard, the existence of the vitD A-ring in the β-chair conformation, rather
than the α-chair conformation, is essential to the differentiating activity of analogues. The application
of the rules to activity gained so far should allow analogues to be refined further regarding potency
and selectivity.
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Figure 6. Map of the relationships between structural modifications to 1α,25-dihydroxyvitamin D2
and biological actions.
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Abstract: All-trans-retinoic acid (ATRA) and 1α,25-dihydroxyvitamin D (1,25D) are potent inducers
of differentiation of myeloid leukemia cells. During myeloid differentiation specific transcription
factors are expressed at crucial developmental stages. However, precise mechanism controlling
the diversification of myeloid progenitors is largely unknown, CCAAT/enhancer-binding protein
(C/EBP) transcription factors have been characterized as key regulators of the development and
function of the myeloid system. Past data point at functional redundancy among C/EBP family
members during myeloid differentiation. In this study, we show that in acute myeloid leukemia
(AML) cells, high expression of vitamin D receptor gene (VDR) is needed for strong and sustained
upregulation of CEBPB gene, while the moderate expression of VDR is sufficient for upregulation
of CEBPD in response to 1,25D. The high expression level of the gene encoding for retinoic acid
receptor α (RARA) allows for high and sustained expression of CEBPB, which becomes decreased
along with a decrease of RARA expression. Expression of CEBPB induced by ATRA is accompanied
by upregulated expression of CEBPE with similar kinetics. Our results suggest that CEBPB is the
major VDR and RARA-responsive gene among the CEBP family, necessary for expression of genes
connected with myeloid functions.
Keywords: nuclear receptors; CCAAT-enhancer-binding proteins; CEBP genes; vitamin D receptor;
retinoic acid receptor α; differentiation; acute myeloid leukemia
1. Introduction
CCAAT/enhancer-binding proteins (C/EBPs) are transcription factors that activate the expression
of target genes through interaction with response elements within their promoters [1]. There are six
members of C/EBP family, and they regulate differentiation process in various tissues [2]. The first
transcription factor in this family, C/EBPα, was isolated from the rat liver and it appeared to be
important for adipocyte differentiation [3]. C/EBPs are modular proteins consisting of an activation
domain, a DNA binding domain, and a leucine-rich dimerization domain that is responsible for
forming dimers with other members of the family [4]. In order to activate transcription, the C/EBP
dimers bind to the consensus sequence 5′-TT/GNNGNAAT/G-3′ in promoter regions of target genes.
For three out of six genes encoding C/EBP family members, alternative protein products are translated,
due to a leaky ribosomal scanning mechanism. Some of them lack the N-terminal activation domains
and exert inhibitory functions, presumably by a dominant negative mechanism [5].
Hematopoiesis is a process in which all blood elements are formed from multipotential
hematopoietic stem cells (HSCs). In the process of hematopoiesis, the HSCs and their progeny
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interact with the bone marrow stromal cells and they are stimulated by the numerous growth factors
that are secreted in the bone marrow environment. The eventual cell fate during hematopoiesis is
governed by spatiotemporal fluctuations in transcription factor concentrations, which either cooperate
or compete in driving target gene expression [6]. Some members of C/EBP family of transcription
factors are important at certain steps of hematopoiesis [7]. C/EBPα appears in differentiating cells
at the stage of early progenitors with lymphoid and myeloid potential and then reappears only in
the cells that are differentiating into granulocytes [8]. C/EBPα-deficient mice show disturbances
in monocyte and neutrophil development [9,10]. High level of C/EBPβ leads to monocyte and
macrophage development [11,12], while high level of C/EBPε leads to neutrophil differentiation [13].
The role of C/EBPδ in blood cells development is less defined, since CEBPD−/− mice did not reveal
any blood disturbances [14]. It has been documented that C/EBPδ regulates expression of genes
important for granulocyte function [15].
However, the most important factors that drive blood cells development are cytokines [16], some
ligands for nuclear receptors can also modulate cell fate during hematopoiesis [7]. The best described in
this respect are ligands for retinoic acid receptors (RARs). Active metabolites of vitamin A are natural
ligands for RARs. A dominating retinoic acid (RA) metabolite is all-trans-RA (ATRA), which binds
with high affinity to all RARs (α, β, and γ) [17]. During embryogenesis, ATRA causes the appearance
of hematopoietic progenitors from the hemogenic endothelium [18], while in adults, it is important for
the differentiation of granulocytes, as well as B and T lymphocytes [19]. This activity of ATRA has
been used in clinics. The most clinically significant application of ATRA is to treat a rare subtype of an
acute myeloid leukemia (AML), called acute promyelocytic leukemia (APL). At the first description
this subtype was considered the most difficult to treat [20], while it is now considered as highly curable
using the combination of ATRA and anthracycline-based chemotherapy [21]. Another ligand for the
nuclear receptor which influences hematopoiesis is an active metabolite of vitamin D. The correct
physiological concentrations of 1,25-dihydroxyvitamin D (1,25D), which is a natural ligand for
vitamin D receptor (VDR), are necessary to induce markers of monocytic differentiation in HSCs [22].
The expression of the VDR gene is higher at the early steps of hematopoiesis than at later stages and
in mature blood cells [23]. However, both these ligands do not seem indispensable for blood cells
development since RARα-deficient and VDR-deficient mice show no defects in hematopoiesis [24,25].
The possibility that these nuclear receptors can, in some aspects, functionally compensate each other
should be considered.
It has been documented in the past that members of C/EBP family of transcription factors can be
upregulated in blood cells by an exposure to RA, 1,25D, or to their active analogs. For example, the
expression of C/EBPε mRNA and protein increases in AML cells exposed to 9-cis–RA or 1,25D analog
(KH1060) [26]. The gene encoding C/EBPβ has been shown to be a target for VDR regulation [27] and
all isoforms of this transcription factor are increased in AML cells exposed to 1,25D or to analogs of
1,25D [11,28]. This gene is also strongly upregulated in AML cells that were exposed to ATRA [29].
1,25D induces a transient increase of C/EBPα [11], which also participates in the ATRA-induced
differentiation of AML cells [30].
In this study, we addressed a question of whether the lack of one of the nuclear receptors
mentioned above could be compensated by the other in terms of CEBP activation. Therefore, we
used four cell lines in our study, with different expression of retinoic acid receptor α (RARA) or VDR.
In HL60 cells, VDR expression is on a high level and RARA is moderate [31]. For the purpose of
this study, we silenced the expression of VDR in HL60 cells using shRNA. In contrast to HL60 cells,
KG1 cell express high levels of RARA, but low of VDR [31]. The effects of RARA silencing were studied
using a sub-line KG1-RARα(−).
51
Int. J. Mol. Sci. 2018, 19, 1918
2. Results
2.1. Activation of Expression of CEBP Transcription Factor’s Genes in AML Cells with High Level of VDR and
Low Level of RARα
In previous studies, we have shown that different AML cell lines have variable sensitivity to
1,25D− and ATRA-induced differentiation [32]. HL60 cell line responded to 1,25D with robust
monocytic differentiation and to ATRA with moderate granulocytic differentiation. That corresponded
to high basal level of expression of VDR and low basal level of expression of RARA [31]. In view
of demonstrated regulation of differentiation of myeloid leukemia cells by these two compounds, it
was of interest to determine the expression profiles of CEBP genes in response to 1,25D and ATRA in
HL60 cells. Therefore, the expression of CEBPA, CEBPB, CEBPD, CEBPE, and CEBPG in HL60 cells
that were exposed to 1 μM ATRA or to 10 nM 1,25D for different time periods was tested. As depicted
in Figure 1a, transient upregulation of CEBPA was detected in HL60 cells stimulated with 1,25D,
followed by fast decline. This was in concordance with an earlier observed transient upregulation
of C/EBPα protein in HL60 cells after exposure to 1,25D [11]. The increase in expression of CEBPB
was more sustained, with a peak at 24 h and more gradual decline. As presented before, protein
level of C/EBPβ follows this sustained expression pattern and it peaks between two and three days
of exposure to 1,25D [11]. CEBPD, CEBPE, and CEBPG were not upregulated in response to 1,25D
exposure of HL60 cells. As presented in Figure 1b in HL60 cells that were exposed to ATRA, CEBPA
was upregulated weakly and transiently. Expression of CEBPB and CEBPE was stimulated by ATRA
stronger and in a sustained manner. Modest upregulation of CEBPD was observed at 96 h from
exposure to ATRA. Again, no stimulation of CEBPG was observed. Values of mRNA expression
obtained using comparative quantification algorithm are presented in Table A1.
Figure 1. Regulation of CEBP genes in HL60 exposed to 1,25D or all-trans-retinoic acid (ATRA).
HL60 cells were exposed to 10 nM 1,25D (a) or 1 μM ATRA (b) and after desired time the expression
of CEBP genes was measured by Real-time PCR. The bars represent mean values (±standard error
of the mean (SEM)) of the fold changes in mRNA levels relative to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA levels. Expressions in control cells were treated as calibrators.
Values significantly different from those obtained from respective controls cells are marked with an
asterisk (* p < 0.05).
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2.2. Activation of Expression of CEBP Transcription Factor’s Genes in AML Cells with Low Level of VDR and
High Level of RARα
In contrast to HL60 cells, KG1 cells are not responsive to 1,25D and they have a low level of VDR
protein, whilst being susceptible to ATRA-driven granulocytic differentiation [33]. This corresponds with
the high basal level of expression of RARA gene and high constitutive content of RARα protein [31].
In the next series of experiments, KG1 cells were exposed to 1 μM ATRA or to 10 nM 1,25D for different
time periods. In KG1 cells, the transcript levels of CEBP genes remained unchanged after exposure to
1,25D (Figure 2a). In contrast, significant changes in expression of CEBP genes after exposure of KG1 cells
to ATRA were observed. Modest upregulation of CEBPA was detected at 3 h and 96 h from exposure.
CEBPB was the most responsive to ATRA out of the genes studied, the expression upregulation was fast
and long-lasting. The second ATRA-responsive gene was CEBPE, where the expression peaked at 24 h.
The expression of CEBPD and CEBPG was modest with a peak at 96 h (Figure 2b). Values of mRNA
expression that were obtained using comparative quantification algorithm are presented in Table A2.
Figure 2. Regulation of CEBP genes in KG1 exposed to 1,25D (a) or to ATRA (b). KG1 cells were exposed
to 10 nM 1,25D or 1 μM ATRA and after desired time the expression of CEBP genes was measured by
Real-time PCR. The bars represent mean values of the fold changes (±SEM) in mRNA levels relative to
GAPDH mRNA levels. Expressions in control cells were treated as calibrators. Values significantly different
from those that were obtained from respective controls cells are marked with asterisk (* p < 0.05).
2.3. Effects of Silencing High RARA on Expression of CEBP Transcription Factor’s Genes in KG1 Cells
In an attempt to elucidate whether the lack of one of the nuclear receptors VDR and RARα
could be compensated by the other in terms of CEBP activation, we used KG1 sublines with silenced
RARA gene (KG1-RARα(−)) and KG1 control cells (KG1-CTR), which were obtained before [31].
These cells have substantially reduced level of RARA gene expression and RARα protein, but also
exhibit the increased expression of VDR gene and VDR protein, when compared to wild-type KG1 and
KG1-CTR [31]. It should be noted that the expression of VDR gene in KG1-RARα(−) is still lower
than in HL60 cells (Figure 3a), and it was not sufficient to induce antigen CD14 typical for monocytes
(Figure 3b). The KG1 sublines were stimulated with 1,25D or ATRA in a similar manner as before.
As presented in Figure 3e, KG1-RARα(−) cells started to be responsive to 1,25D, however in a manner
that was different from HL60 cells. Only CEBPD gene became responsive to 1,25D in RARA silenced
KG1 cells, and the expression of CEBPB remained at a control level. As expected, expression levels
of CEBPA, CEBPB, and CEBPE were reduced in KG1-RARα(−) when compared to KG1-CTR cells
after ATRA stimulation, especially at the early hours from stimulation (Figure 3c–f). Values of mRNA
expression that were obtained using comparative quantification algorithm are presented in Table A3.
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Figure 3. Responses to 1,25D and to ATRA in KG1 cells with silenced retinoic acid receptor α (RARA)
gene. Expression of vitamin D receptor (VDR) gene in KG1-RARα(−) cells compared to HL60 cells,
which were treated as calibrator (a). Differentiation of KG1 sublines in response to 1,25D. KG1-CTR
and KG1-RARα(−) cells were stimulated with 10 nM 1,25D for 96 h and then the expression of
CD14 differentiation marker was detected using flow cytometry (b). Expression of CEBPA (c), CEBPB
(d), CEBPD (e), and CEBPE (f) genes in KG1-CTR and KG1-RARα(−). Cells were stimulated with
10 nM 1,25D or 1 μM ATRA and after desired time the expression of CEBP genes was measured by
Real-time PCR. The bars represent mean values of the fold changes (±SEM) in mRNA levels relative
to GAPDH mRNA levels. Expressions in control cells were treated as calibrators. Values that are
significantly different from those obtained from respective controls cells are marked with asterisk
(* p < 0.05); values that differ significantly from those obtained from respective KG1-CTR control cells
are marked with hash (# p < 0.05).
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2.4. Effects of Silencing High VDR on Expression of CEBP Transcription Factor’s Genes in HL60 Cells
Having shown that KG1-RARα(−) cells demonstrate an altered CEBP expression profile, we decided
to silence the expression of VDR gene in HL60 cells. The gene silencing was performed using shRNA
plasmid and the scrambled shRNA plasmid, as described before [34]. This way, two HL60 sublines were
generated: HL60-VDR(−) and HL60-CtrA. In order to validate whether the expression of VDR gene was
indeed efficiently knocked down in HL60-VDR(−) cells, the mRNA and protein levels were compared
to HL60-CtrA cells. Unfortunately, the silencing was far from complete and mRNA level was reduced to
approximately 80% of the initial level (Figure 4a). In order to verify whether this reduction would lead to
VDR-dependent effects, the expression of the gene that encodes 24-hydroxylase of 1,25D (CYP24A1) was
tested in both HL60 sublines exposed to 10 nM 1,25D. CYP24A1 is the most strongly regulated out of all
1,25D-target genes and is the best measure of VDR’s activity [35]. 1,25D-induced expression of CYP24A1
was significantly reduced in HL60-VDR(−) cells when compared to HL60-CtrA cells. Figure 4c shows that
VDR protein content was also significantly reduced in the nuclei of HL60-VDR(−) cells to 77% in control
cells, and to 39% after 1,25D treatment when compared to HL60-CtrA cells.
Figure 4. Generation of HL60 cells with reduced VDR expression. Constitutive expression of VDR
gene in HL60-CtrA and HL60-VDR(−) cells. Expression in HL60-CtrA was treated as calibrator (a).
Expression of CYP24A1 was measured in both cell lines exposed to 10 nM 1,25D for different times (b).
The levels of VDR protein were determined in the cytosol and nuclei of HL60-CtrA and HL60-VDR(−)
cells by western blots after 10 nM 1,25D stimulation for 24h (c). Cell lysates were tested while using
anti-VDR. Proper cell fractionation was revealed using anti-histone deacetylase 2 (anti-HDAC2), while
proper lane loading using anti-Hsp90 and anti-actin. Values below the blots are means (±SEM), as
obtained from five experiments. The bars represent mean values of the fold changes (±SEM) in mRNA
levels relative to GAPDH mRNA levels. Values that are significantly different from those obtained
from respective controls cells are marked with asterisk (* p < 0.05); values that differ significantly from
those obtained from respective HL60-CtrA cells are marked with hash (# p < 0.05).
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Even though HL60-VDR(−) subline was not entirely devoid of VDR, the cells were exposed 1 μM
ATRA or 10 nM 1,25D in order to examine the expression of selected CEBP genes. CEBPA and CEBPB
have been selected, since they are direct targets of VDR-dependent transcriptional regulation [36,37].
As presented in Figure 5a,b, the limited decrease of VDR expression level resulted in a reduced CEBPA
and CEBPB expression levels in response to 1,25D when compared to HL60-CtrA cells. Interestingly, the
response to ATRA in HL60-VDR(−) cells was different than in HL60-CtrA cells, and upregulated
regarding CEBPA expression, while downregulated regarding CEBPB expression. Values of mRNA
expression that were obtained using comparative quantification algorithm are presented in Table A4.
Figure 5. Expression of CEBPA (a) and CEBPB (b) genes in HL60-CtrA and HL60-VDR(−). Cells were
exposed to 10 nM 1,25D or 1 μM ATRA and after desired time the expression of CEBP genes was
measured by Real-time PCR. The bars represent mean values of the fold changes (±SEM) in mRNA
levels relative to GAPDH mRNA levels. Expressions in control cells were treated as calibrators.
Values that are significantly different from those obtained from respective controls cells are marked
with an asterisk (* p < 0.05); values that differ significantly from those obtained from respective
HL60-CtrA cells are marked with hash (# p < 0.05).
3. Discussion
The process of hematopoiesis leads to the acquisition of immune functions by terminally
differentiated cells. Lineage selection within hematopoiesis depends on the appropriate levels of
key transcription factors, which are regulated in response to numerous hematopoietic cytokines
and interactions with bone marrow environment [38]. Transcription factors C/EBPα, C/EBPβ, and
C/EBPδ have been demonstrated in granulocytes, monocytes, and eosinophils, as well as in myeloid
progenitor cells [39]. C/EBPε has been identified as a critical regulator of terminal granulopoiesis [13].
Many genes that are important for myeloid functions contain in their promoters binding sites for
C/EBP transcription factors [5]. In normal hematopoiesis, C/EBP transcription factors are produced
in response to coordinated actions of cytokines and upstream transcription factors, and their activity is
further modulated by posttranslational modifications [5].
C/EBPα seems to be the most important for normal blood development, since mutations in
CEBPA gene lead to AML. CEBPA is mutated in around 13% of all AML patients [40], and mutations in
this gene appear early, indicating at the driver role in leukemogenesis [41]. This is why the expression
of CEBPA in AML patients has been extensively studied, and it has been shown to be downregulated
by another driver of leukemogenesis, namely the AML-ETO fusion protein, which is present in 5–10%
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of patients with AML [42]. Later studies have documented that the downregulation of CEBPA also
accompanies AML cases with inv(16), which creates CBFB-MYH11 gene fusion and occurs in about
10% of AML patients [43]. All together, the above data show that more than 30% of patients with AML
exhibit disturbances in expression of CEBPA.
It has been shown that both 1,25D and ATRA are able to upregulate expression of C/EBP factors
without the addition of hematopoietic cytokines [11,26,27,29]. Whether all the CEBP genes are direct
targets for either RARα or VDR is not clear. Retinoic acid response elements (RAREs) have been found
in the promoter of CEBPE gene, and not in other genes of this family [44], but at present, we know
that RARα can bind to big variety of RAREs [45], which are sometimes located in a long distance from
the transcription start [44]. CEBPA and CEBPB are direct targets of VDR-dependent transcriptional
regulation [36,37], but it is not sure whether such a mechanism occurs also for CEBPD.
We thus wanted to find out how variable levels of VDR and RARα proteins affect the expression
of CEBP genes, and whether the lack of one of the nuclear receptors that are mentioned above, could
be compensated by the other. In the first place, we determined the expression profiles of these genes
after stimulation with 1,25D or ATRA in HL60 and KG1 cells. These cells differ in basal levels of
expression of VDR and RARα, and in susceptibility to 1,25D-induced differentiation. The basal levels
of VDR and RARA mRNA expression in all of the cell lines that were used for the purpose of this
research is presented in Table A5. HL60 cells, which have high level of VDR protein, respond to 1,25D
with transient upregulation of CEBPA, and strong and sustained upregulation of CEBPB. It appeared
that KG1 cells that have low level of VDR protein do not express CEBP genes in response to 1,25D at
all. After the silencing of the RARA gene in KG1, these cells reduced the responsiveness to ATRA,
but started to be responsive to 1,25D, most probably because of an increased expression of VDR [31].
The restored VDR expression level was not high enough to upregulate the expression of CEBPB, but
it was sufficient to upregulate CEBPD. As presented here, the upregulation of CEBPD alone was
not sufficient to complete the myeloid differentiation process. KG1 cells and HL60 cells are both
responsive to ATRA, however, due to higher basal expression of RARA, KG1 cells respond stronger
than HL60. In KG1 cells, the upregulation of CEBPB and CEBPE is approximately two times higher
than in HL60 cells in response to ATRA; however, the kinetics of expression is similar.
Our results suggest that the ability of 1,25D or ATRA to effectively force the final myeloid
differentiation of AML cells strongly depends on effective levels of nuclear receptors for these
compounds. It also seems that expression of CEBPB is indispensable for the final effect of myeloid
differentiation, and that VDR and RARα do not compensate each other in terms of the induction
of CEBP expression. Our data are in agreement with the earlier findings that strong and sustained
expression of CEBPB, when accompanied by transient expression of CEBPA leads to the differentiation
towards monocytes [11], while, when accompanied by the sustained expression of CEBPE, it leads the
differentiation process to granulocytes [46].
4. Materials and Methods
4.1. Cell Lines and Cultures
HL60 cells were from the local cell bank at the Institute of Immunology and Experimental Therapy
in Wrocław, and KG1 cells were purchased from the German Resource Center for Biological Material
(DSMZ GmbH, Braunschweig, Germany). The cells were grown in RPMI-1640 medium with 10% fetal
bovine serum, 100 units/ml penicillin, and 100 μg/mL streptomycin (Sigma, St. Louis, MO, USA), and
maintained at standard cell culture conditions.
4.2. Chemicals and Antibodies
1,25D was purchased from Cayman Europe (Tallinn, Estonia) and ATRA was from Sigma-Aldrich
(St. Louis, MO, USA). The compounds were dissolved in an absolute ethanol to 1000× final
concentrations, and subsequently, diluted in the culture medium to the required concentration.
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4.3. cDNA Synthesis and Real-Time PCR
Total RNA was extracted from the cells treated with 1 μM ATRA or 10 nM 1,25D for different
time points (3 h, 24 h, 96 h). Briefly, the isolation of total RNA, reverse transcription into cDNA, and
Real-time PCR reactions were performed as published before [33], using CFX Real-time PCR System
(Bio-Rad Laboratories Inc., Hercules, CA, USA). The sequences of GAPDH, CYP24A1, VDR, and RARA
primers, and the reaction conditions were described previously [31,47]. The CEBPA, CEBPB, CEBPD,
CEBPE, and CEBPG primers were obtained from RealTimePrimers.com (Real Time Primers, LLC, PA,
USA). Their sequences are as follows: CEBPA: forward 5′-TTGGTGCGTCTAAGATGAGG-3′, reverse
5′-GGCAGGAAACCTCCAAATAA-3′; CEBPB: forward 5′-AACTCTCTGCTTCTCCCTCTG-3′, reverse
5′-AAGCCCGTAGGAACATCTTT-3′; CEBPD: forward 5′-ATCGACTTCAGCGCCTACAT-3′, reverse
5′-GCCTTGTGATTGCTGTTGAA-3′; CEBPE: forward 5′-GAGGAGGTTGCTCAGAGTGG-3′, reverse
5′-TCCTGGCCTATTCAGCAGTT-3′; CEBPG: forward 5′-GAACAACCCATTTTGCACTC-3′, reverse
5′-TGAAAGCCAGGAACAAAAAG-3′; APDH: forward 5′-CATGAGAAGTATGACAACAGCCT-3′,
reverse 5′-AGTCCTTCCACGATACCAAAGT-3′. Quantification of gene expression was analyzed
with either the ΔCq (to present comparative quantification of expression levels) or with the ΔΔCq
(to present changes in expression induced by treatment) methods using GAPDH as the endogenous
control Primers efficiencies were measured in all of the cell lines using Real-time PCR reaction based
on the slope of the standard curve. The results were normalized to primer efficiencies to compare gene
expression in different cell lines [48]. Real-time PCR assays were performed at least in triplicate.
4.4. Flow Cytometry
The expression of CD14 was determined by flow cytometry. The cells were incubated with
10 nM 1,25D for 96 h, then washed, and stained with 1 μL of Phycoerythrin labeled antibody (or the
appropriate control immunoglobulins; both from ImmunoTools, Friesoythe, Germany) for 1 h on ice.
Next, they were washed with ice-cold PBS supplemented with 0.1% BSA and suspended in 0.5 mL of
PBS supplemented with 0.1% BSA prior to analysis on FACS Calibur flow cytometer (Becton–Dickinson,
San Jose, CA, USA). Experiments were repeated at least three times. The acquisition parameters were
set for an isotype control. Data analysis was performed with the use of WinMDI 2.8 software (freeware
by Joseph Trotter).
4.5. Western Blotting
In order to obtain cytosolic and nuclear extracts, 5 × 106 cells/sample were washed and lysed
using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific Inc., Worcester,
MA, USA), according to the user’s manual. Lysates were denatured by adding 5× sample buffer
(1/4 volume of the lysate) and boiled for 5 min. 25 μL of each lysate were separated in SDS-PAGE and
then electroblotted to PVDF membrane. The membranes were then dried and incubated sequentially
with primary and a horseradish peroxidase-conjugated secondary antibody. The protein bands were
visualized with a chemiluminescence. Then, the membranes were stripped, dried again, and probed
with subsequent antibodies. Western blots were repeated five times.
4.6. Gene Silencing Reagents and Procedure
The RARA gene silencing in KG1 cells was described before [31]. The VDR gene silencing in
HL60 cells was performed using shRNA plasmids and Neon® Transfection System (Invitrogen™,
Carlsbad, CA, USA) using control shRNA plasmid-A (sc-108060) and the VDR shRNA plasmid
(sc-106692-SH; both from Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The procedure of
electrotransfection by Neon® Transfection System was described before [49].
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4.7. Statistical Analysis
For statistical analysis one-way ANOVA was used to test the null hypothesis that the samples
in two or more groups are drawn from populations with the same mean values. When the ANOVA
test had shown that the null hypothesis is not true, the Student’s t-test for independent samples was
used to analyze the differences between the pairs of groups (Excel, Microsoft Office and free ANOVA
Calculator: http://www.danielsoper.com/statcalc3/calc.aspx?id=43).
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RARs retinoic acid receptors
AML acute myeloid leukemia
HSCs hematopoietic stem cells
APL acute promyelocytic leukemia
VDR vitamin D receptor
GAPDH glyceraldehyde 3-phosphate dehydrogenase
SEM standard error of the mean
Appendix A
Table A1. Comparative quantification of CEBP genes related to a reference GAPDH gene in HL60 cells.
HL60 CEBPA SEM CEBPB SEM CEBPD SEM CEBPE SEM CEBPG SEM
control 0.16 0.06 0.07 0.02 0.004 0.001 0.004 0.002 0.068 0.026
1,25D
3 h 0.33 0.07 0.19 0.03 0.003 0.001 0.003 0.002 0.085 0.051
24 h 0.22 0.03 0.27 0.03 0.003 0.001 0.004 0.002 0.072 0.042
96 h 0.15 0.05 0.18 0.02 0.003 0.001 0.004 0.001 0.046 0.030
ATRA
3 h 0.18 0.04 0.06 0.03 0.003 0.001 0.002 0.002 0.058 0.014
24 h 0.25 0.07 0.30 0.14 0.002 0.000 0.007 0.008 0.061 0.020
96 h 0.13 0.04 0.25 0.07 0.004 0.001 0.006 0.0071 0.055 0.012
Table A2. Comparative quantification of CEBP genes related to a reference GAPDH gene in KG1 cells.
KG1 CEBPA SEM CEBPB SEM CEBPD SEM CEBPE SEM CEBPG SEM
control 0.025 0.016 0.039 0.000 0.0006 0.000 0.00003 0.0000 0.0037 0.0009
1,25D
3 h 0.035 0.022 0.060 0.000 0.0006 0.000 0.00003 0.0000 0.0041 0.0010
24 h 0.032 0.015 0.063 0.000 0.0008 0.000 0.00003 0.0000 0.0031 0.0009
96 h 0.031 0.058 0.053 0.000 0.0009 0.002 0.00002 0.0000 0.0034 0.0018
ATRA
3 h 0.026 0.011 0.039 0.000 0.0006 0.000 0.00002 0.0000 0.0023 0.0011
24 h 0.063 0.030 0.496 0.000 0.0003 0.000 0.00009 0.0000 0.0023 0.0012
96 h 0.050 0.027 0.284 0.000 0.0011 0.000 0.00013 0.0001 0.0031 0.0018
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Table A3. Comparative quantification of CEBP genes related to a reference GAPDH gene in KG1-CTR
and KG1-RARα(−) cells.
KG1 CTR CEBPA SEM CEBPB SEM CEBPD SEM CEBPE SEM
control 0.0061 0.0022 0.0199 0.0016 0.00002 0.0000 0.00003 0.0022
1,25D
3 h 0.0056 0.0019 0.0197 0.0013 0.00002 0.0000 0.00003 0.0018
24 h 0.0048 0.0011 0.0282 0.0008 0.00002 0.0000 0.00002 0.0012
96 h 0.0106 0.0017 0.0373 0.0012 0.00003 0.0000 0.00002 0.0016
ATRA
3 h 0.0153 0.0056 0.1484 0.0040 0.00001 0.0000 0.00003 0.0056
24 h 0.0133 0.0080 0.1242 0.0056 0.00002 0.0000 0.00008 0.0079
96 h 0.0134 0.0007 0.0577 0.0005 0.00003 0.0000 0.00005 0.0007
KG1
RARα(−) CEBPA SEM CEBPB SEM CEBPD SEM CEBPE SEM
control 0.0082 0.0023 0.0261 0.0016 0.00003 0.0000 0.00002 0.0022
1,25D
3 h 0.0123 0.0034 0.0377 0.0024 0.00003 0.0000 0.00003 0.0033
24 h 0.0102 0.0034 0.0548 0.0024 0.00003 0.0000 0.00003 0.0033
96 h 0.0120 0.0042 0.0660 0.0030 0.00007 0.0000 0.00002 0.0041
ATRA
3 h 0.0140 0.0038 0.0729 0.0027 0.00002 0.0000 0.00002 0.0037
24 h 0.0135 0.0025 0.1457 0.0018 0.00003 0.0000 0.00004 0.0025
96 h 0.0154 0.0036 0.0619 0.0025 0.00004 0.0000 0.00005 0.0034
Table A4. Comparative quantification of CEBP genes related to a reference GAPDH gene in HL60-CtrA
and HL60-VDR(−) cells.
HL60 CtrA CEBPA SEM CEBPB SEM HL60 VDR(−) CEBPA SEM CEBPB SEM
control 0.06228 0.0214 0.0753 0.0125 control 0.09500 0.0318 0.08958 0.0099
1,25D
3 h 0.05003 0.0089 0.3774 0.2312
1,25D
3 h 0.07767 0.0227 0.28449 0.0147
24 h 0.07403 0.0172 0.2351 0.0788 24 h 0.12883 0.0455 0.41116 0.2031
96 h 0.14063 0.0437 0.1749 0.0622 96 h 0.17163 0.0468 0.24263 0.0734
ATRA
3 h 0.06025 0.0180 0.1710 0.0118
ATRA
3 h 0.09056 0.0082 0.24728 0.0580
24 h 0.05366 0.0167 0.2221 0.0188 24 h 0.09029 0.0166 0.40953 0.0871
96 h 0.13521 0.0491 0.6720 0.0612 96 h 0.24610 0.0229 0.358334 0.2188
Table A5. Comparative quantification of VDR and RARA genes related to a reference GAPDH gene in
all cell lines used in this study.
Cell Line VDR SEM RARA SEM
HL60 0.00048 0.00001 0.0679 0.001
HL60 CtrA 0.00045 0.00003 0.0600 0.003
HL60 VDR(−) 0.00035 0.00006 0.0638 0.003
KG1 0.00002 0.00001 0.1241 0.008
KG1CTR 0.00005 0.00000 0.1792 0.002
KG1 RARα(−) 0.00018 0.00003 0.0563 0.003
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Abstract: Erythroid differentiation is a complex and multistep process during which an adequate
supply of iron for hemoglobinization is required. The role of ferritin heavy subunit, in this process,
has been mainly attributed to its capacity to maintain iron in a non-toxic form. We propose a new role
for ferritin heavy subunit (FHC) in controlling the erythroid commitment of K562 erythro-myeloid
cells. FHC knockdown induces a change in the balance of GATA transcription factors and significantly
reduces the expression of a repertoire of erythroid-specific genes, including α- and γ-globins, as well
as CD71 and CD235a surface markers, in the absence of differentiation stimuli. These molecular
changes are also reflected at the morphological level. Moreover, the ability of FHC-silenced K562
cells to respond to the erythroid-specific inducer hemin is almost completely abolished. Interestingly,
we found that this new role for FHC is largely mediated via regulation of miR-150, one of the main
microRNA implicated in the cell-fate choice of common erythroid/megakaryocytic progenitors.
These findings shed further insight into the biological properties of FHCand delineate a role in
erythroid differentiation where this protein does not act as a mere iron metabolism-related factor but
also as a critical regulator of the expression of genes of central relevance for erythropoiesis.
Keywords: ferritin heavy subunit; differentiation; K562; miR-150; GATA-1
1. Introduction
Megakaryocytic and erythroid progenitors that give rise to platelets and red blood cells,
respectively, derive from a megakaryocyte-erythroid common precursor (MEP) [1]. The MEPs
differentiation fate is dynamically determined by the coordination of different molecular events,
including the progressive loss of differentiation potential, the expression of lineage-specific markers,
and the acquisition of specialized morphological features and functionalities [1,2]. During erythroid
maturation, MEPs undergo a progressive decrease in cell size, nuclear condensation, and activation
of the transcription of globin genes with the consequent accumulation of hemoglobin [3].
Immunophenotypic studies also highlighted the acquisition and/or the increase in the expression of
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surface markers such as CD71 (Transferrin receptor protein 1, TfR1) and CD235a (Glycophorin A),
now considered erythroid-specific hallmarks [4,5].
The MEPs fate is orchestrated by thecoordinated action of specific transcription factors.
The dynamic exchange of GATA-1 with GATA-2, the so-called “GATA factor switch”, in which
GATA-1 levels increase during the terminal erythroid maturation while GATA-2 is turned off, is one of
the best-known examples [6,7].
This scenario is even more complex when taking into account the role played by microRNAs
in the fine-tuning of haematopoiesis [8,9]. MicroRNAs are a class of small non-coding RNA whose
activity as post-transcriptional inhibitor of gene expression belongs to the biological process, known as
RNA interference [10]. Almost all of the stages of the haematopoietic lineage specification, from the
maintenance of the haematopoietic stem cell pool to the generation of lineage-committed progenitors
and of specific mature cells, are controlled by miRNAs [11]. Indeed, monocytopoiesis is regulated by
miR-17/92 cluster while erythropoiesis is driven by miR-451, miR-16, and miR-144 and inhibited by
miR-150, miR-155, miR-221, miR-222, and miR-223 [11]. MiR-125b supports myelopoiesis while B-cells
maturation is promoted by the down-regulation of miR-34a [11]. Several reports indicate that miR-150
is involved in the control of multiple haematopoietic cell fates [12]. miR-150 is very highly expressed
during advanced stages of both B and T cell maturation in bone marrow and thymus, respectively,
and its premature expression leads to severe defects in B cell development through the down-regulation
of target genes, such as Myb and Foxp1 [13]. Within the myeloid lineage, a constant repression of
miR-150 ensures the normal terminal erythroid development; on the contrary, its increased expression
induces MEPs toward megakaryocytic maturation [14–16]. The role of miR-150 has been supported by
several in vitro analyses: it has been shown that overexpression of miR-150 promotes the generation of
colony-forming unit megakaryocyte (CFU-Mk), while its antagomiR-mediated suppression induces
colony-forming unit erythrocyte (CFU-E) [17]; furthermore, forced expression of miR-150 significantly
reduces hemin-dependent erythropoiesis, commitment to hemoglobinization and CD235a expression
in the bipotent megakaryocyte/erythroid K562 human leukemia cells [18]. K562 cells can be terminally
differentiated in vitro toward the erythroid and megakaryocytic lineages; thus, they are considered as a
useful in vitro model for studying MEP commitment [1,2]. The molecular mechanisms underlying the
effects of miR-150 on MEPs fate-decision are not fully elucidated. Different models have been proposed
either associated with differentiation-related or proliferation-related pathways [15]. Moreover,
gene expression profiling suggests that forced miR-150 expression in hemin-induced K562 cells
suppress the activation of ErbB-MAPK-p38 and ErbB-PI3K-AKT pathways [18]. However, the upstream
regulators of miR-150 have not yet been determined.
The MEPs function and fate are also affected by metabolic perturbations [19–21]. In particular,
iron metabolism and erythropoiesis are intimately linked. An adequate supply of iron is indeed
necessary to ensure sufficient hemoglobin synthesis and thus for the correct maturation of red blood
cells [20,21]. However, an excessive amount of intracellular free iron may be harmful to the cells
since it can trigger the generation of reactive oxygen species (ROS) through the Fenton reaction [22].
Ferritin, the main intracellular iron storage protein, tightly regulates iron levels by storing it in a
nontoxic and bioavailable form for supply upon metabolic requirement of hemoglobinization [23].
Ferritin is a multimeric protein composed of a total of twenty-four subunits of two types, the ferritin
heavy subunit(FHC, FTH) and the ferritin light subunit (FLC, FTL), assembled to form a shell that
is able to sequester up to 4500 iron atoms [19,20]. FHC has a ferroxidase activity through which
it converts Fe(II) to Fe(III) and protects cells against oxidative stress [24,25]. Indeed, we have
recently demonstrated that FHC-silencing results in a significant increase in intracellular ROS in
erythroleukemia K562 cells [25] as well as in other cell types [26]. At the same time, a growing
body of experimental evidence has shed light on new and intriguing roles for FHC in the control of
proliferation and migration of several cancer cell lines as well as in the regulation of many oncogenes
and oncomiRNAs [24–27].
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The role of FHC in the haematopoietic differentiation has been so far mainly explored in
relation to its function in the iron intracellular metabolism. To date, the gene expression profiling
after the hemin-mediated erythroid differentiation of K562 cells highlighted the occurrence of both
transcriptional and translational up-regulation of the ferritin gene [23,28]. This results in an increase
in ferritin synthesis that ultimately enhances the cellular capacity of iron storage for hemoglobin
synthesis [23].
In this study, we investigated the role of FHC in K562 cells erythroid differentiation by
exploring the effects of the perturbation of its intracellular amount on cell morphology, expression
of representative genes and lineage-specific markers. Our results revealed that FHC knock-down
induced a significant arrest in the erythroid commitment of K562 cells that was mostly mediated
by the up-regulation of miR-150 and the parallel repression of GATA-1, and uncovers a new role of
FHC in the lineage choice of the erythro-megakaryocytic K562 cells through the fine tuning of key
regulatory molecules.
2. Results and Discussion
The K562 leukemia-derived cell line represents a useful in vitro model of MEP since they are
situated at the common progenitor stage of erythroid and megakaryocytic lineages differentiation [1,2],
and can be induced toward either of the above cell fates by a number of chemical agents, such as
hemin and phorbol 12-myristate 13-acetate (PMA), respectively [29].
Ferritin is the main iron storage protein within the cell and is localized in cytoplasm, nucleus,
and mitochondria [27]. The erythroid differentiation is accompanied by an enhanced expression of its
heavy subunit (FHC), which has a ferroxidase activity, and this induction has been mainly attributed
to the necessity for the cell to store in a non-toxic form the high amounts of iron required for optimal
hemoglobinization [23,28]. On the other hand, in particular in K562 cells, FHC might play other roles
besides the control of iron metabolism; it has been proposed that FHC, in its nuclear form, represses
β-globin transcription [30], while its silencing modulates the expression of a repertoire of genes during
hemin treatment [28]. Collectively, these data suggest that FHC might play multiple and key roles in
erythropoiesis, however the underlying mechanisms are not fully elucidated.
2.1. Ferritin Heavy Subunit (FHC) Knockdown Negatively Regulates the Erythroid Fate of K562 Cells
We have previously found that FHC silencing strongly reduces the hemin-mediated induction
of γ-globin synthesis in K562 cells [28]. Here, in order to more clearly define the role of the
ferritin heavy subunit in K562 erythroid differentiation we extended the analysis to key molecules
associated with erythroid development and functions, such as α-globin, transferrin receptor-1 (CD71),
and the glycophorin A (CD235a) erythroid-lineage specific marker. Pools of stably FHC-silenced
(K562shFHC) and of control cells (K562shScr), as previously described [24,28], were treated with 50μM
hemin for 48 h. The FHC amounts, evaluated at both mRNA and protein levels, of hemin-treated
and untreated K562shFHC and K562shScr cells are shown in Figure 1a,b, respectively. FHC was
significantly downregulated in the K562shFHC cells as compared to the control K562shScr cells at both
mRNA and protein levels; hemin treatment consistently increased FHC amounts both in the control
K562shScr(50 μM hemin) and in the K562shFHC(50 μM hemin) cells when compared to their relative untreated
cells (Figure 1a,b). As expected, hemin treatment strongly up-modulated the expression of α-globin,
γ-globin, CD71, and CD235a mRNAs in K562shScr control cells (Figure 1c). Notably, FHC-silencing
was able, per se, to significantly reduce the expression of all four markers; moreover, FHC-silencing
almost completely counteracted the effects of hemin treatment and effectively inhibited the induction
of α-globin, γ-globin and CD71 (Figure 1c). CD235a displayed a relatively different behaviour since
its mRNA was the most sensitive to FHC knockdown and, in parallel, the only one still responsive
to hemin treatment in FHC-silenced cells. We also performed fluorescence-activated cell sorting
(FACS) analysis of CD235a in FHC-silenced and control cells, treated and untreated with hemin.
FHC knockdown substantially reduced the CD235a positive cells as shown by the substantially lower
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values of both the mean fluorescence intensity of CD235a and the percentage of CD235a-positive
cells in Figure 1d (FLH-2 mean: 79 vs. 26.7; % CD235a+: 85.4 vs. 27.3); after hemin treatment
K562shScr became nearly completely positive (FLH-2 mean: 97.1; % CD235a+: 94.3) while the CD235a+
K562shFHC appeared almost completely unaffected (FLH-2 mean: 23.8; % CD235a+: 31.4). Along with
the modifications of marker expression, microscopic analyses highlighted considerable alterations in
the morphology of K562shFHC cells as assessed by May-Grünwald-Giemsa staining, which included
features typically not associated to an erythroid phenotype such as increased size, vacuole-rich
cytoplasm, and polylobulated nuclei (Figure 1e). After 48 h of culture in the presence of hemin,
K562shScr cells showed a globular shape morphology with round nuclei eccentrically located and the
cell pellet developed a distinctive red color; conversely, no morphological changes have been observed
in K562shFHC cells and the cell pellets became barely pink upon hemin treatment.
Figure 1. FHC silencing inhibits hemin-induced erythroid differentiation of K562 cells. (a) qRT-PCR
and (b) Western Blot analyses of FHC mRNA and protein levels, respectively, in the control K562shScr
and FHC-silenced K562shFHC cells untreated (nt) and treated with 50 μM hemin for 48 h; (c) Relative
expression of α-globin, γ-globin, CD71 and CD235a of K562shScr and K562shFHC cells untreated or
treated with hemin. All data represent mean ± SD (n = 3). * p < 0.05 compared with K562shScr cells,
◦ p < 0.05 compared with K562shScr cells, § p < 0.05 compared with K562shFHC cells, N.S.: not significant;
(d) Flow cytometry analysis of CD235a-positive cells in K562shScr and K562shFHC cells untreated or
treated with hemin. Data are reported both as mean fluorescence intensity of CD235a (FL2-H) and as
percentage (%) of CD235+ cells; (e) May-Grünwald-Giemsa staining of K562shScr and K562shFHC cell
untreated or treated with hemin.
To rule out possible off-target effects of the shRNA, we investigated the expression of α-globin,
γ-globin, CD71 and CD235a in K562 cells where FHC expression was transiently silenced by using
a specific FHC-siRNA. Figure 2a shows a representative Western Blot of FHC protein levels at 24 h,
48 h and 72 h after the siRNA transfection while in Figure 2b H-ferritin mRNA levels are represented
as the mean of three independent experiments. Consistently with the findings obtained in the stably
FHC-silenced cells, the qRT-PCR analyses, shown in Figure 2c–f, highlighted a reduction of the
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erythroid-specific markers upon transient FHC silencing at each time point with a statistical significance
at 48 h and 72 h (p < 0.05). Also in these set of experiments CD235a showed the highest responsiveness
to FHC knockdown. CD235a and CD71 were further investigated, 72 h upon FHC transient silencing,
at the cell surface level: Figure 2g–h report representative FACS analyses that highlight markedly
reduced levels of both markers in K562siFHC cells compared to the control ones (CD235a, FL2-H mean:
46 vs. 67; % CD235a+: 22 vs. 86.7) (CD71, FL2-H mean: 53.3 vs. 121, CD71+: 83.4 vs. 87.2).
Figure 2. Transient FHC silencing down-regulates erythroid markers expression in K562 cells.
FHC amounts of K562 cells at 0, 24, 48 and 72 h after a transient transfection of a specific FHC
siRNA at protein (a) and mRNA (b) levels; Data represent mean ± SD (n = 3). * p < 0.05 compared
with 0 h, N.S.: not significant. The relative expression of α-globin (c); γ-globin (d); CD71 (e) and CD235a
(f) in K562siFHC cells at each time point was measured using qRT-PCR. Data represent mean ± SD
(n = 3). * p < 0.05 compared with K562cntr at 48 h; ◦ p < 0.05 as compared with K562cntr at 72 h;
N.S.: not significant. Flow cytometry analysis of CD235a- (g) and CD71- (h) positive cells in K562cntr
and K562siFHC cells at 72 h upon FHC siRNA transfection. Data are reported both as mean fluorescence
intensity of CD235a and CD71 (FL2-H) and as percentage (%) of CD235+ and CD71+ cells.
Taken together, these results indicate that ferritin heavy subunit knockdown is able to strongly
inhibit the erythroid transcriptional program in K562 cells, and to almost completely abrogate
the transcriptional induction of these genes in response to hemin treatment, thus suggesting that
appropriate intracellular amounts of FHC are needed for the correct expression of these key genes.
We recently found that FHC knockdown restrains K562 cell proliferation [24]. Because the
proliferation rate of a given cell population can be correlated to its differentiation state, here, by using
direct cell counting assays, we re-confirmed the decline of K562shFHC proliferative rate in comparison
with control cells at 24 h (37 × 104 vs. 48 × 104) and 48 h (51 × 104 vs. 64 × 104) (Figure 3a).
Using flow cytometry and Annexin V/7-AAD double staining, we assayed apoptosis of K562shScr and
K562shFHC cells and found that FHC silencing slightly increased late apoptosis (Annexin V+/7-AAD+,
6.2% vs. 13.7%, p < 0.05), but not early apoptosis (Annexin V+/7-AAD−, 2.8% vs. 3.8%) (Figure 3b).
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The analysis of cell cycle, using PI staining and flow cytometric detection, further confirmed the
presence of a higher percentage of K562shFHC cells in the G0/G1 phase as compared to control K562shScr
cells (33.6% vs. 19.9%, p < 0.05) (Figure 3c). The moderate extent of the FHC silencing-induced G0/G1
cell cycle arrest, in comparison with the strong interference with the erythroid commitment, makes it
difficult to correlate these two phenomena. Proliferation and differentiation can either be coupled
or inversely correlated in function on the differentiation stage [31], thus further studies are needed
to deeply investigate this point. Finally, through clonogenic assays we found that K562shFHC cells
displayed an approximately 2-fold decrease of clonogenic potential as compared to the control cells,
as shown by representative microscopy images and quantified in the histogram (p < 0.05) (Figure 3d).
Figure 3. FHC silencing suppresses the proliferative rate and the clonogenic potential of K562 cells.
(a) Direct cell counting of K562shScr and K562shFHC at 0, 24 and 48 h; (b)Apoptosis analysis in K562shScr
and K562shFHC using Annexin V/7-AAD double staining. The reported plots are representative of two
independent experiments; (c) Representative flow cytometry plots of cell cycle analysis in K562shScr and
K562shFHC with statistics on the right side. All data represent mean ± SD (n = 3). * p < 0.05 compared
with K562shScr cells; (d) Representative microscopy images and statistics of colony formation assay in
K562shScr and K562shFHC; colonies were observed and counted in each well of 12-well plate. Scale bar:
200μm. All data represent mean ± SD (n = 3). * p < 0.05 compared with K562shScr cells.
2.2. FHC Effects on K562 Erythroid Fate Are Mediated by miR-150
Transcription factors play a pivotal role in the cell differentiation fate since they are responsible
for the expression of lineage-specific genes and for the parallel repression of stemness-related
markers [7,32]. In erythropoiesis, the precise balance of GATAs transcription factors is one of
the best-known examples [7]. GATA-2 overexpression, in the presence of a reduction of GATA-1,
drives megakaryocytic differentiation at the expense of the erythroid one; on the contrary, terminal
erythroid differentiation is associated with GATA-1 increase, that in turn, down-regulates GATA-2
expression [6,7].
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However, transcription factors alone cannot account for every aspect of haematopoietic
differentiation. Post-transcriptional regulatory mechanisms, such as those played by microRNAs,
ensure a finer tuning and a more rapid response to stimuli [8,9]. Many recent studies have shown that a
number of miRNAs are involved in the fine regulation of the haematopoietic stem cells differentiation,
such as miR-15/16, miR-222, miR-150, miR-451, miR-210, and let-7d [8,9]. miR-150, in particular, has
been implicated in the control of lineage choice in MEPs fate decision: high levels of miR-150 drive
MEPs toward megakaryocytic maturation, whereas low levels lead to erythroid commitment [12,18].
Recently, we have demonstrated that FHC controls the expression of a set of miRNAs in a
variety of cancer cell types, including K562 cells [24] and that, in SKOV-3 ovarian carcinoma cells,
FHC promotes the expansion of a subset of cells with stem-like features through the modulation of
miR-150 [27].
In order to establish whether modulation of miR-150 expression in response to FHC knockdown
may contribute to the phenotypes observed in K562 and described above, we analyzed the steady
state amounts of GATA-1 and GATA-2 mRNAs and those of miR-150 in both transiently and stably
FHC-silenced cells. As shown in Figure 4a,b, FHC silencing down-regulates GATA-1 and, at the
same time, strongly induces GATA-2 expression. As highlighted in Figure 4c,d, this is accompanied
by a significant increase in miR-150 levels upon both transient and stable FHC silencing. Notably,
both GATAs switch and miR-150 up-regulation are consistent with the FHC-mediated arrest of K562
erythroid differentiation.
Figure 4. FHC silencing reduces GATA-1 and induces miR-150 up-regulation. (a) qRT-PCR analysis
of GATA-1 and GATA-2 genes in transiently FHC-silenced K562siFHC cells at 0 h, 24 h, 48 h, and 72 h,
compared to control K562cntr cells. All data represent mean ± SD (n = 3). * p < 0.05 compared with
K562cntr at 24 h; ◦ p < 0.05 compared with K562cntr at 48 h; § p < 0.05 as compared with K562cntr at
72 h. N.S. not significant; (b) qRT-PCR analysis of GATA-1 and GATA-2 genes in stably FHC-silenced
K562shFHC cells compared to control K562shScr cells. All data represent mean ± SD (n = 3). * p < 0.05
compared with K562shScr cells; (c) TaqMan analysis of miR-150 in transiently FHC-silenced K562siFHC
cells at 0 h, 24 h, 48 h, and 72 h, compared to control K562cntr cells. All data represent mean ± SD
(n = 3). * p < 0.05 compared with K562cntr at 24 h; ◦ p < 0.05 compared with K562cntr at 48 h; § p < 0.05
compared with K562cntr at 72 h; (d) TaqMan analysis of miR-150 in stably FHC-silenced K562shFHC
cells compared to control K562shScr cells. All data represent mean ± SD (n = 3). * p < 0.05 compared
with K562shScr cells.
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To shed further light on the role of miR-150 in the cascade of molecular events induced by FHC
silencing, we either reconstituted FHC or inhibited miR-150 inK562shFHC cells. FHC reconstitution,
whose efficiency is shown in Figure 5a, determined a significant reduction of miR-150, thus confirming
the existence of an inverse correlation between FHC and miR-150 steady state amounts (Figure 5b).
The results of a triplicate set of experiments, graphically represented in Figure 5c, indicate that both
FHC reconstitution and miR-150 inhibition were able to revert the GATAs switch. This is the first report
showing that GATAs transcription factors are potential downstream molecules of miR-150. Since the
bioinformatic online prediction tool FINDTAR3 did not underline any complementary regions between
GATAs and miR-150, we propose the existence of an indirect relationship between these two molecules,
mediated by an intermediate still to be determined. The down-modulation of α-globin, γ-globin and
CD-71 were efficiently counteracted by both FHC reconstitution and miR-150 inhibition (Figure 5d).
It has been already reported that the expression of both globins and CD71 is transcriptionally regulated
by GATA1 [33,34]. Taken all together our data suggest a model in which FHC amounts modulates,
through miR-150, GATA1 that in turn regulates globins and CD71. CD235a appears to be not included
in this pathways since its amounts strongly responded to the FHC reconstitution, increasing by
approximately 5-fold, but were unaffected by miR-150 inhibition.
Figure 5. miR-150 mediates the control exerted by FHC on GATAs, α-globin, γ-globin and CD71
expression. (a) pc3FHC expression vector almost completely restore FHC amounts in FHC-silenced
K562 cells (K562shFHC/pc3FHC). Data represent mean ± SD of 3 qRT-PCR analysis. * p < 0.05 compared
with K562shScr; ◦ p < 0.05 compared with K562shFHC; (b) TaqMan analysis of miR-150 levels after FHC
reconstitution and miR-150 inhibition highlight a significant down-regulation in K562shFHC/pc3FHC
and K562shFHC/miR−150 inhibitor compared to K562shFHC cells; (c) qRT-PCR analysis of GATA-1 and
GATA-2 genes in K562shFHC/pc3FHC and K562shFHC/miR−150 inhibitor as compared to K562shFHC cells.
Data represent mean ± SD (n = 3). * p < 0.05 compared with K562shScr at; ◦ p < 0.05 compared
with K562shFHC; § p < 0.05 compared with K562shFHC; (d) qRT-PCR analysis of α-globin, γ-globin,
CD71 and CD235a genes in K562shFHC/pc3FHC and K562shFHC/miR−150 inhibitor compared to K562shFHC
cells. Data represent mean ± SD (n = 3). * p < 0.05 compared with K562shScr at; ◦ p< 0.05 when
compared with K562shFHC; ◦◦ p < 0.001 compared with K562shFHC; § p < 0.05 compared with K562shFHC;
N.S. not significant.
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Notably, in FHC-silenced K562 cells, the up-regulation of miR-150 is unable to promote
megakaryocytic differentiation since the analysis of gene and surface expression of CD41,
CD61, and CD110 MK-specific markers did not highlight any modification in their steady state amount
(Figure S1). Megakaryocytic differentiation is driven not only by miR-150 but also by other microRNAs
such as miR-34a, miR-146a, miR-27a, and miR-28 [35]. The natural conclusion of our observations is
that, at least in FHC-silenced K562 cells, miR-150 is a central hub in the molecular phenomena resulting
in the arrest of the erythroid commitment while the megakaryocytic differentiation requires other so
far uncovered regulatory molecules.
The mechanisms by which FHC inhibits miR-150 expression require further and more targeted
analyses. To the best of our knowledge, in K562 cells, the nuclear form of H ferritin has been suggested
as specific repressor of the β-globin promoter [30] but no further evidences have emerged in this
direction. On the other hand, it has been recently shown that the transcript of FTH1P3, one intronless
member of the FHC multigene family, acts as molecular sponge of miR-224-5p in oral squamous cell
carcinoma cells [36]. Interestingly, as reported in Figure S2, the FINDTAR3 bioinformatic prediction
software highlights the existence of two regions of complementarity between FHC mRNA and miR-150
(FHC mRNA NM_002032 positions: 38–73; 165–188). This observation constitutes the molecular
ground for future studies aimed at analyzing a possible role of FHC mRNA as competitive endogenous
RNA (ceRNA).
In conclusion, we demonstrate that a costant expression of FHC is essential for K562 erythroid
differentiation since either its stable or its transient silencing is associated with an arrest toward this
commitment. Furthermore, our data delineate a new regulatory axis through which FHC controls
erythroid differentiation and lend strong support to the notion that, in addition to its role in iron
metabolism, FHC can act as a relevant regulator of gene expression through the modulation of miR-150.
3. Materials and Methods
3.1. Cell Culture
K562 cells were obtained from the American Type Culture Collection (ATCC, CCL-243; Manassas,
VA, USA). K562 cells were grown in RPMI 1640 media (Sigma Aldrich, St. Louis, MO, USA)
supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA) at 37 ◦C in 5% CO2.
Hemin (50 μM) (Sigma Aldrich) was used to induce erythroid differentiation of K562 cells.
3.2. K562 Cells Transfection and Transduction
FHC silencing of K562 cells was performed using two different methods: (i) stable transduction
of a lentiviral DNA containing an shRNA targeting the 196–210 region of the FHC mRNA
(sh29432) (K562shFHC) or a control shRNA without significant homology to known human mRNAs
(K562shScr) and (ii) transient transfection of a pre-cast siRNAspecific for FHC (K562siFHC) or a
negative control siRNA (K562cntr) (Thermo Fisher Scientific). Stable transduction was achieved,
as previously reported [19,23]. Transient transfections were performed using the Amaxa Nucleofactor
kit (Lonza, Basel, Switzerland) [37]. FHC stable knock-down was verified by Western Blot analysis
and RT-qPCR while FHC transient knockdown was checked at 24, 48 and 72 h by RT-qPCR analysis.
FHC-reconstitution in K562shFHC cells was performed using the expression vector containing the full
length of human FHC cDNA (pc3FHC) (K562shFHCpc3FHC).
K562shFHC cells were also transiently transfected with a final concentration of 100 nM of a specific
miR-150 inhibitor (K562shFHCmiR−150 inhibitor) obtained from Thermo Fisher Scientific, using the Amaxa
Nucleofactor kit (Lonza). 48 h after transfection, miR-150 levels were measured by TaqMan microRNA
Assay (Thermo Fisher Scientific).
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3.3. RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from K562 cells with the TRizol RNA isolation method (Thermo Fisher
Scientific), according to the manufacturer’s instructions. The purity and the integrity of each RNA
sample were checked, as previously reported [26]. Then, 1 μg of RNA from each sample was reverse
transcribed by using High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific).
Gene expression analysis was performed by using SYBR®Green qPCR Master Mix (Thermo Fisher
Scientific) [24]. Primers to detect FHC, CD235a, CD71, α-globin, γ-globin, GATA-1 and GATA-2 are
reported in Table 1. Relative quantification between samples and control transcript levels was
performed by using the comparative 2−ΔΔCt method [26]. Each sample was normalized to its
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) content.
Table 1. Primers used in qRT-PCR analysis.
Gene Forward Primer Reverse Primer
GAPDH 5′-TGA TGA CAT CAA GAA GGT GGT GAA G-3′ 5′-TCC TTG GAG GCC ATG TGG GCC AT-3′
FHC 5′-CAT CAA CCG CCA GAT CAA C-3′ 5′-GAT GGC TTT CAC CTG CTC AT-3′
α-globin 5′-GTG GAC GAC ATG CCC AAC-3′ 5′-TAT TTG GAG GTC AGC ACG GT-3′
γ-globin 5′-CAG AAA TAC ACA TAC ACA CTT CC-3′ 5′-GAG AGA TCA CAC ATG ATT TTC TT-3′
CD71 5′-ACT GGT CCA TGC TAA TTT TGG T-3′ 5′-AGT TCT GCG TTA ACA ATG GGA-3′
CD235a 5′-GAG AAA GGG TAC AAC TTG CC-3′ 5′-CAT TGA TCA CTT GTC TCT GG-3′
GATA-1 5′-GAT GAA TGG GCA GAA CAG GC-3′ 5′-TAG CTT GTA GTA GAG GCC GC-3′
GATA-2 5′-GAA CCG ACC ACT CAT CAA GC-3′ 5′-GCA GCT TGT AGT AGA GGC CA-3′
3.4. TaqMan miR-150 Analysis
Specific cDNA synthesis for miR-150, was performed using TaqMan® MicroRNA Reverse
Transcription Kit (Thermo Fisher Scientific) containing microRNA-specific RT primers and Taqman
miRNA assay. To measure miRNAs expression levels, 1.33 μL of each cDNA was added to the specific
TaqMan microRNA Assay (20×) and TaqMan 2× Universal PCR Master MiX (Thermo Fisher Scientific).
The amplification conditions for miRNA expression profile were the following: 10 min at 95 ◦C,
40 cycles at 95 ◦C for 15 s, and 60 ◦C for 60 s. The experiments were performed in duplicate and the
analysis was performed using the2−ΔΔCt formula using snRNA U6 as housekeeping microRNA [24].
3.5. Western Blot Analysis
Whole-cell lysis, protein extraction and Western Blot analyses of cultured K562shScr, K562shFHC,
K562cntr, and K562siFHC cells were performed, as previously reported [25,26]. For FHC protein
quantification, the incubation of the anti-rabbit polyclonal primary anti-FHC (H-53) (1:200; sc-25617,
Santa Cruz Biotechnology, Dallas, TX, USA) followed by the incubation with the HRP-conjugated
secondary antibody (1:3000 Cell Signaling) was carried out. The goat polyclonal anti-γ-Tubulin
antibody (C-20) (1:3000; sc-7396, Santa Cruz Biotechnology) was used as loading control.
The immunoreactive bands were visualized with the ECL Western blotting detection system
(Santa Cruz Biotechnology) and the bands intensity was quantified by using ImageJ (National
Institutes of Health, Bethesda, MD, USA).
3.6. Flow Cytometry Analyses
The expression of erythroid-specific cell-surface markers was determined by direct
immunofluorescence using the following conjugated antibodies: PE-CD235a and PE-CD71 (Miltenyi
Biotec, Bergisch Gladbach, Germany). Briefly, 2 × 105 cells were suspended in 100 μL PBS
supplemented and then stained with fluorochrome-conjugated antibodies for 30 min on ice. Cells were
washed twice with PBS before analysis. Flow cytometry analyses were carried out 1 h after staining.
The analysis was performed using FACScan flow cytometry (Becton Dickinson, Franklin Lakes,
NJ, USA) and the data files were analyzed by FlowJo software (FlowJo v8.8.6, Becton Dickinson,
Franklin Lakes, NJ, USA).
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For cell cycle analysis, 5 × 105 cells were washed in PBS twice, fixed by adding ethanol 100%, in a
drop wise manner, and then was stored at −20 ◦C overnight. Cells were then rinsed twice to remove
ethanol and incubated with PI solution for 1 h, in the dark, at room temperature prior to FACS analysis.
Apoptosis analysis was carried out using the Annexin V-PE Apoptosis Detection Kit (Becton
Dickinson, Franklin Lakes, NJ, USA). Cells were washed twice with cold PBS and then resuspended
in 1× Binding Buffer at a concentration of 1 × 106 cells/mL. Then, 5 μL of PE Annexin V and 5 μL
7-AAD were added to the cells incubated for 15 min at room temperature in the dark. Finally, 400 μL
of 1× Binding Buffer was added to each sample before flow cytometry analysis. The analysis was
performed in duplicate; here, a representative plot has been reported.
3.7. Direct Cell Counting
Briefly, 20 × 104 cells/well were seeded during the exponential phase of proliferating cells.
Cell pellets, obtained by centrifugation at 1000 rpm × 5 min, were washed with fresh PBS and then
resuspended in 5 mL by vigorously pipetting to disperse any clumps. The cell count was performed
by mixing 50 μL of sample with 50 μL of 0.4% trypan blue solution, afterwards the mixture was
loaded into the Bürker chamber. Each cell-count was performed in triplicate by using a 10× objective
according to the standard methods.
3.8. Haematopoietic Colony Formation Assay
For colony formation assays, K562 cells (5 × 102/mL) were plated in tissue culture 12 well plates
in MethoCult H4100 medium (StemCell Technologies, Vancouver, BC, Canada) consisting of RPMI
1640 supplemented with 1% methylcellulose and 10% FBS. After 14 days, plates were scored for colony
forming units (CFUs) using an inverted microscope (Leica, Wetzlar, Germany).
3.9. Cell Morphology Assay
For evaluating cell morphology, cells were cytocentrifuged onto glass slides, fixed in methanol
and stained with May Grunwald-Giemsa (Thermo Fisher Scientific) and photographed with
40× magnification with a digital camera Leica DFC420 C and Leica Application Suite Software
(v1.9.0, Leica).
3.10. Statistical Analysis
Statistical significance of data was assessed by Student’s t-test. p values < 0.05 were
considered significant.
3.11. Bioinformatic Analysis
We used the publicly available software programs FINDTAR3 to predict the existence of
complementary regions between miRNAs and mRNAs based on seed-pairing, free energy of
miRNA:mRNA duplex, and proper dynamic programming score.
Supplementary Materials: The following are available online at www.mdpi.com/1422-0067/18/10/2167/s1.
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Abstract: B-lymphocyte differentiation is one of the best understood developmental pathways in the
hematopoietic system. Our understanding of the developmental trajectories linking the multipotent
hematopoietic stem cell to the mature functional B-lymphocyte is extensive as a result of efforts to
identify and prospectively isolate progenitors at defined maturation stages. The identification of
defined progenitor compartments has been instrumental for the resolution of the molecular features
that defines given developmental stages as well as for our understanding of the mechanisms that
drive the progressive maturation process. Over the last years it has become increasingly clear that the
regulatory networks that control normal B-cell differentiation are targeted by mutations in human
B-lineage malignancies. This generates a most interesting link between development and disease that
can be explored to improve diagnosis and treatment protocols in lymphoid malignancies. The aim of
this review is to provide an overview of our current understanding of molecular regulation in normal
and malignant B-cell development.
Keywords: B-lymphocyte; development; transcription factors; lymphoid leukemia
1. Introduction
The generation of B-lymphocytes in the bone marrow (BM) is a highly complex process
guiding multipotent hematopoietic stem cells to become immunoglobulin-expressing B-cells.
The differentiation process depends on the orchestrated activities of transcription factor (TF) networks
and extracellular signals acting in conjunction to drive the expansion and maturation of progenitor
populations. The process is complicated by the fact that cells must undergo Immunoglobulin (Ig)
gene recombination and both positive and negative selection events to ensure proper functionality
(reviewed in [1]). Even though much of our understanding of this developmental pathway is based on
mouse models, there exist several similarities between mouse and human B-cell differentiation [2–4].
Furthermore, it is now evident that the same mechanisms that control normal B-lymphoid development
in mice and humans are targeted in B-lymphoid malignancies (reviewed in [5]). The aim of this review is
to provide an overview of our knowledge about developmental trajectories and regulatory networks in
normal early B-lymphocyte development and their potential involvement in malignant transformation.
2. Resolving Developmental Trajectories in B-Cell Development
In order to understand the process controlling the generation of highly specified blood cells,
it is of critical importance to identify and prospectively isolate cells at defined maturation stages.
B-lymphocyte development has been suggested to proceed from the hematopoietic stem cell, through
the lymphoid primed multipotent progenitor (LMPP) [6] stage, to generate a lymphoid-restricted
common lymphoid progenitor (CLP) [7]. CLPs have the capacity to generate B-lineage-restricted B220+
Fraction A compartment [8], proceeding in differentiation to generate CD19+ cells.
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While the progenitor cells within the classical CLP compartment retain lymphoid linage potentials
and display a reduced capacity to generate myeloid cells [7], the inclusion of additional surface markers
in the staining protocols has revealed a molecular and functional heterogeneity within this population.
Surface expression of Integrin α(2)β(7) (LPAM1) or CXCR6 identifies a subpopulation of cells with
reduced B but preserved NK/T lineage potential [9], and BST2 expression identifies a dendritic cell
population [10]. It is further possible to isolate a B220+ population with preserved combined B and
T-lineage potential within the classical CLP compartment [11,12]. Hence, it has become increasingly
clear that the CLP compartment is highly heterogeneous and likely harbors a variety of more or less
lineage-restricted progenitors.
One of the earliest markers associated with B-cell progenitors is B220, a heavily glycosylated splice
form of the CD45 protein (CD45R) (reviewed in [13]). Expression of B220 in combination with other
surface markers, such as CD43 (S7), CD24 (HSA), BP1, CD19, KIT (CD117), CD93 (AA4.1) [8,14–16],
and CD25 [17,18], can be used to identify specific subpopulations of B-cell progenitors. Combined
with functional and molecular analysis this has allowed for the establishment of a developmental
hierarchy instrumental for our understanding of B-cell development (Figure 1). However, while a
substantial fraction of the CD19− B-cell progenitors express B220, functional analysis fails to link B220
expression exclusively to B-lineage-committed progenitors. Rather, a fraction of the B220+ cells retain
T-cell [11,12,15], NK [19], and even myeloid potential [20,21].
These findings could be seen as evidence that early B-cell development does not follow one
distinct path but rather proceeds through multiple pathways whereby lineage potentials are lost in a
more or less stochastic manner (Figure 1). This model for lymphocyte development is supported by
the finding that early thymic progenitors display combined T-macrophage potential but most have a
limited ability to generate B-lineage cells [22]. Furthermore, the fetal liver contains cells with combined
B-macrophage or T-macrophage potential [23]. Additional complexity in developmental trajectories in
the fetal liver comes with the identification of B/T and B/NK bi-potent progenitors [9,24]. Hence, the
difficulty of identifying CD19− B-lineage committed progenitors could be a consequence of non-linear
developmental paths not subject to the restrictions predicted from a hematopoietic tree (Figure 1).
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Figure 1. Developmental trajectories in B-cell development. Schematic drawing displaying two models
for the developmental trajectories in B-cell development. Yellow indicates myeloid potential (M), gray
indicates potential to generate innate lymphoid cells (ILC), orange indicates T lineage potential (T),
and blue indicates B-cell potential. The arrows indicate potential developmental trajectories for the
defined lineages. The green square indicates B220+ populations.
While conventional surface marker expression did not allow for the prospective isolation of
committed CD19− B-cell progenitors, expression of a reporter gene under the control of the Igll1
(Lambda 5) promoter [25] allowed for the identification of B-lymphoid- restricted progenitors within
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the classical CLP compartment [26]. Despite the fact that the Igll1 gene, encoding one of the surrogate
light chains [27], is not crucial for the earliest stages of B-cell development [28,29], the gene is
transcribed in primitive progenitors serving as a marker for lineage commitment [30,31]. Continued
analysis of the cellular heterogeneity within the CLP compartment identified the surface marker Ly6D
as being expressed in a subpopulation of cells [32]. Transplantation experiments revealed that the
Ly6D+ “CLP” population was largely restricted to the production of B-lineage cells; subsequently, these
progenitors were denoted B-lymphocyte progenitors BLPs [32]. While the BLP population displayed a
minimal T-linage potential in vivo, in vitro differentiation analysis suggested that a fraction of the cells
retained the ability to generate T-lineage cells in response to a strong Notch signal [12]. This indicates
further heterogeneity within the BLP compartment. This heterogeneity is largely resolved using the
expression of the surface markers GNDF family receptor α2 (GFRA2) and bone marrow stroma cell
antigen 1 (BST1), to prospectively isolate BLP1, BLP2, and BLP3 cells displaying a progressive degree
of commitment to B-cell development [33] (Figure 1). Even though the progenitor populations defined
by GFRA2 and BST1 displayed variable levels of B220, their gene expression patterns as well as
functional analysis suggest that they represent highly similar or even identical developmental stages.
These findings would be in line with observations made using multiparameter molecular analysis of
human B-lineage development suggesting a hierarchical model based on progressive and ordered loss
of lineage potentials (Figure 1) [34].
While CD19 expression marks stably committed B-lineage progenitors, this population is complex
and can be further subdivided into defined developmental stages. The most immature cells express
KIT, CD127 (IL7Ra), CD49E, CD11A, CD54, and CD43 [17,18,35,36], while CD25 (IL2Rα) is restricted
to cells with a functional pre-BCR [17]. The expression of CD2 resembles that of CD25 because it is
restricted to cells with cytoplasmic immunoglobulin heavy (IgH) chains [37]. Despite that surface
antigens are most useful in the identification of progenitor stages in early B-cell development, a degree
of heterogeneity can be observed even within a defined developmental stage [18]. This argues for
the use of multiple markers for the identification of any given progenitor population. In all, the
development of protocols for the prospective isolation of defined progenitor compartments provides a
detailed map of the developmental trajectories in B-cell development generally compatible with the
hematopoietic tree.
3. Transcription Factor Networks Regulating Early B-Cell Development
With our increasing understanding of the developmental trajectories in early B-cell development, it
has been possible to explore molecular interplay at defined developmental stages. While lineage-specific
gene expression is often associated with functional lineage commitment, it has been reported that the
expression of lineage-associated genes can be detected already in multipotent progenitors [38,39]. These
early transcriptional programs are suggested to be associated with defined cell fates [40], indicating the
existence of functional lineage priming in non-committed progenitors (Figure 2). Lymphoid lineage
priming is mainly observed as activation of genes expressed in both B- and T-cells, including Rag1 and
Dntt [39,41]. The activation of these genes is dependent on the TFs TCF3 [42–44], IKZF1 (IKAROS) [45],
SPI1 (PU.1) [46,47], and MYB [48] acting in a concerted manner to promote the development of
lymphoid progenitors. While SPI1 and IKZF1 create a regulatory loop controlling lymphoid versus
myeloid cell fate [49], TCF3 initiates the B-lineage-restricted transcriptional program by activation of
the FoxO1 gene [50] (Figure 2). FOXO1 acts in a feed-forward loop with the TF EBF1 [51] to activate the
transcription of B-lineage genes during B-cell specification [52–54]. The ability of EBF1 to coordinate
the activation of transcriptionally inactive genes in epigenetically silenced chromatin [55,56] is likely a
consequence of EBF1 associating with chromatin remodeling complexes, thereby directly impacting
the structure and the epigenetic landscape [57,58]. Despite the LY6D+ “CLP” compartment being
intact or even increased in the absence of EBF1 [59,60], the GFRA2+ compartment is dramatically
decreased [33], the transcription of B-lineage-restricted genes is lost [51,52], and the cells are not
properly lineage-restricted [60]. This highlights the essential role of EBF1 in B-lineage specification.
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Figure 2. Schematic drawing of the transcription factor networks involved in priming (green arrows),
specification (yellow arrows), commitment (red arrows), and selection (blue arrows) in early B-cell
development. Red indicates B/T and NK cell potential, orange indicates B-cell potential, and yellow
indicates residual T-cell potential. Blue indicates IgM+ cells.
Even though EBF1 has the ability to repress genes associated with alternative cell fates [61,62]
and the loss of EBF1 in B-lineage cells results in plasticity [63], stable lineage commitment depends
on the TF PAX5. Despite a large portion of the B-lineage-restricted transcriptional program being
activated in the absence of PAX5 [64,65], the progenitor cells are not stably committed to B-lineage cell
fate [65–69]. In vitro differentiation or transplantation of PAX5-deficient pro-B cells, as well as deletion
of the Pax5 gene in B-lineage cells, results in the formation of both myeloid and T-lineage cells in vivo
and in vitro [65–71]. Lineage restriction is likely achieved through direct repression of target genes
such as Colony-stimulating factor receptor 1 (Csf1r or c-fms) gene [72] and Notch1 [73]. Even though this
suggests that lineage specification can be separated from commitment [65], the finding that PAX5 is a
direct EBF1 target [74] links these two processes in normal development. PAX5 and EBF1 target control
elements in the Ebf1 gene [75,76], creating a second regulatory loop and resulting in functional lineage
commitment (Figure 2). The importance of the reciprocal regulation and collaboration between EBF1
and PAX5 is highlighted by the finding that normal as well as malignant pro-B cells carrying trans
heterozygote mutations in the Ebf1 and Pax5 genes display lineage plasticity [77,78].
In addition to their function in stable lineage commitment, EBF1 and PAX5 are critical regulators of
genes encoding proteins forming the pre-B cell receptor (pre-BCR) [54,79–82]. This receptor is formed
as a newly generated IGH chain complex with surrogate light chains IGLL1 (λ5) and VPREB as well as
the signal transduction proteins CD79α and CD79β (reviewed in [1,83]). Combined signaling through
the pre-BCR and the IL7 receptor stimulates a proliferative burst [84] and causes a reduction in RAG
protein levels [85]. While the proliferative burst is of great importance for the expansion and overall
production of B-lineage cells, progressive development and Ig light chain rearrangement depend on the
cells exiting the cell cycle [86,87]. This maturation step is suggested to depend on a pre-BCR-mediated
activation of a regulatory network involving interferon regulatory factor (IRF4) and PAX5 [88]. PAX5
targets and activates the Ikzf3 gene [89], encoding a TF suggested to collaborate with IKZF1 to repress
genes encoding surrogate light chain components [90]. This results in a reduction of pre-BCR levels
on the surface of the pro-B cell, reducing the proliferative signal. IRF4 has a somewhat different role
in this process since it collaborates with the transcription factor FOXO1, stabilized by the pre-BCR
signal [88], to drive differentiation and reactivate Rag gene expression critical for recombination of the
Ig light chain genes [91–93]. Furthermore, IRF4 increases the expression of the CXCL12-responsive
chemokine receptor CXCR4 [87]. This has been suggested to stimulate migration of the pre-B cells to a
micromolecular niche with low levels of Il7 to further reduce the proliferative signal [87]. Hence, B-cell
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development is driven by an intricate interplay between stage-specific regulatory TF networks that
orchestrate the differentiation process.
4. Transcription Factor Networks Link Development to B-Lymphoid Malignancies
While these TF networks clearly play crucial roles in normal B-cell development, it is becoming
increasingly clear that they are closely connected to malignant transformation (reviewed in [5]). This is
because genetic alterations in the PAX5, EBF1, or IKZF1 genes are observed in a majority of B-ALL
patients [94–96]. Even though there are reports of translocations of TF coding genes resulting in
deregulated expression [97,98] or formation of fusion proteins [99–103], the most common genetic
alterations result in partial inactivation of one or several TFs [94–96]. Even though inherited point
mutations in PAX5 have been reported to result in increased leukemia incidence [104], the reduced
functional TF activity more commonly depends on the inactivation of the TF genes via somatic
heterozygote mutations and deletions [94–96]. The importance of TF dose for normal blood cell
development in mice is well established because heterozygote inactivation of the Myb [48], Spi1 [105],
Bcl11a [106], Ikzf1 [107], or Ebf1 [108] gene results in disturbances in B-cell differentiation. Despite
the fact that the heterozygote inactivation of the Pax5 gene in mice does not appear to result in any
dramatic developmental block [109,110], it has been suggested to result in alterations of cellular
metabolism that may promote transformation [111]. Furthermore, PAX5 deletions are often found in
combination with complex karyotypes and other genetic aberrations, including recurrent translocations
like t(12;21)(p13;q22) (ETV6-RUNX1) or t(1;19)(q23;p13) (TCF3-PBX1) [94,96]. PAX5 mutations are
also found in combination with genetic alterations in other TFs such as IKZF1 and EBF1 [94,96],
likely augmenting the effect of a reduced PAX5 dose. Interestingly, the phenotypic changes in
B-cell development in mice carrying heterozygote inactivation of a TF gene are often exacerbated
upon combined targeting of two TFs. Combined heterozygote inactivation of Ebf1/Tcf3 [108],
Ebf1/Runx1 [112], or Ebf1/Pax5 [113] results in more dramatic phenotypes than what is observed
in the single mutants. This highlights the importance of functional and correctly balanced TF networks
in B-cell development.
Even though leukemia is generally considered to be confined to one defined hematopoietic lineage,
about 7% of patients display a more complex disease [114,115]. These malignancies are denoted as
acute leukemia of ambiguous lineage (ALAL). ALAL can be manifested either as bi-lineal leukemia,
involving several lineages, or bi-phenotypic disease, with expansion of cells displaying combined
expression of normally lineage-restricted surface markers [114–116]. It has been reported that the
level of PAX5 regulates the formation of bi-phenotypic leukemia [117] and that B-ALL cells carrying
mutations in Pax5 can be converted into other lineages with preserved malignant features [78,118].
Furthermore, in MYC-induced lymphoma, oscillations in EBF1 and PAX5 levels result in lineage
plasticity [119]. Additionally, dramatic phenotypic changes with preserved cytogenetic features have
occasionally been reported from patients experiencing relapse of disease [120], further challenging the
idea that leukemia is restricted to a given lineage of cells. While this has been considered uncommon in
clinical practice [114,115], novel treatment protocols may reveal a higher degree of complexity in B-ALL.
Recently it was reported that 13 out of 20 patients relapsing after treatment of B-ALL with genetically
manipulated T-lymphocytes (chimeric antigen receptor (CAR-T) cells) targeting CD19 developed CD19
negative leukemia even at the clonal level [121,122]. This makes lineage plasticity a central mechanism
for resistance development upon targeted treatment of leukemia. Hence, disruptions in transcription
factor networks in leukemia may impact not only the transformation process per se but may also
underlie the development of resistance to lineage-targeted therapies.
5. Integration of External Signals and Transcription Factor Networks in Early B-Cell Development
Even though intrinsic cell events such as regulatory loops created by TF networks are of
critical importance for B-cell differentiation, the normal development and expansion of progenitors
depend on extracellular signals in the microenvironment. While some of these signals are shared
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with other hematopoietic progenitors, others are restricted to lymphoid progenitor compartments.
Among the former are Kit ligand (Steel factor, Stem Cell Factor SCF), acting via the receptor
tyrosine kinase cKIT [123]. This receptor is expressed in a variety of hematopoietic progenitor cells
including the multipotent hematopoietic stem cells [124], myeloid progenitors [125,126] as well as
the CLPs [7]. Subsequently, disruption of this signaling pathway results in defective formation of
multiple hematopoietic lineages [127–129]. The expression of cKIT is rather restricted in B-lymphoid
progenitors, but a substantial fraction of the pro-B cell compartment retains this surface receptor as
well as an ability to respond to the cytokine [130]. CXCL12 is another broadly acting cytokine involved
in the homing of cells to specific niches in the BM [131,132]. The protein acts via its surface receptor
CXCR4 and both the ligand and the receptor are crucial for normal homing of hematopoietic progenitor
cells [131,132], including B-cell progenitors [133]. The expression of CXCL12 is restricted to specific
subpopulations of stroma cells in the BM [131], contributing to the ability of this chemokine to act as
an organizer of the BM microenvironment.
B-cell development is also influenced by cytokines with more restricted activity. These include
FLT3 ligand (FL) acting through the FLT3 receptor expressed in the earliest lineage-restricted progenitor
cells. Both the LMPP [6] and the CLPs [134] express FLT3; however, upon progression of B-cell
development, the expression is downregulated as a consequence of the Flt3 gene being repressed by
PAX5 [135]. Ectopic expression of the FLT3 ligand causes alterations in blood cell development [136]
and disruption of this signaling pathway results in reductions in LMPPs and CLPs [137]. However, this
occurs without dramatic changes to the peripheral CD19+ B-cell compartments [137]. The phenotype
is exacerbated when combined with inactivation of Il7 signaling since this results in a complete block
in BM B-cell development [138]. In line with the idea that the Il7R is expressed on CLPs with all
lymphoid lineage potentials [7], lineage tracing analysis suggests that all B- and T-lymphoid cells as
well as a substantial portion of the NK cells in the adult mouse have a history of Il7 expression [139].
The IL7 receptor is expressed on B-cell progenitors and a deficiency in either the receptor [140] or the
ligand [141] results in a dramatic impairment in B-cell development already in the B-cell-restricted
CD19− compartments in the mouse BM [60,142]. The Il7 receptor α (IL7Rα) chain is also a component
of the receptor for thymic stromal lymphopoietin (TSLP), a cytokine acting via the Il7Rα and a specific
TSLP-receptor [143]. IL7 and TSLP appear to be functionally redundant since ectopic expression of the
latter largely rescues B-cell development in IL7-deficient mice [144].
Many cytokines would appear to be permissive, stimulating proliferation and reducing apoptosis
in the B-cell progenitors rather than driving development to a specific lineage in an instructive manner.
However, while T-cell development can be largely rescued by overexpression of BCL2 in mice deficient
in IL7 signaling, this does not fully rescue B-cell development [145,146]. This suggests partially distinct
functions for IL-7 signaling in the formation of different lymphoid lineages. One potential explanation
for this could be that STAT5 activation, resulting from IL7R signaling [147], induces Ebf1 transcription,
potentially driving the progenitor towards B-cell fate [148]. Furthermore, ectopic expression of EBF1
partially rescues B-cell development in mice lacking IL7 [148] or the BTB/POZ domain transcription
factor ZBTB17 (MIZ1), crucial for functional IL7 signaling [149]. While this would suggest that
IL7 has unique functions in the induction of the genetic program in early B-cell progenitors, the
finding that ectopic expression of FL can rescue B-cell development independently of IL7 argues for
a more permissive function [150]. Furthermore, the developmental block imposed by conditional
deletion of STAT5, a key mediator of Il7 signaling [147], can be partially rescued by ectopic expression
of anti-apoptotic proteins [151]. In all, it would appear that the IL7 signaling pathway has both
permissive and instructive components, as supported by the finding that deletion of the pro-apoptotic
protein BIM rescues survival but not differentiation of B-cell progenitors in Il7-deficient mice [152].
Despite the function of Il7 in human B-cell development being somewhat disputed [153],
inactivating mutations in the common gamma chain results in severe combined immunodeficiency
in humans [154] and activating mutations in the IL7 signaling pathway are commonly detected in
human malignancies [155]. Interestingly, heterozygote deletion of Pax5 or Ebf1, in combination with
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transgenic expression of a constitutive active STAT5, causes a synergistic increase in the formation
of B-lineage leukemia [156]. Hence, the interplay between TF networks and extracellular signals is
critical for normal B-cell development and disturbances may result in impaired immune response or
lymphoid malignancies.
6. Concluding Remarks
While the detailed understanding of maturation pathways is often considered a subject mainly
relevant to developmental biology, our increased understanding of molecular events involved in
malignant transformation highlights the relevance of cell differentiation in malignant transformation.
Understanding developmental trajectories can be important for diagnosis since, even though leukemia
is caused by expansion of progenitor B-cells, the heterogeneous expression of surface IG suggests
that leukemia can reside in both the pro- and pre-B cell compartments [114,115]. The use of more
advanced FACS staining protocols may resolve an even higher heterogeneity and possibly better
classify leukemia in both the CD19-positive and CD19-negative (ALAL) groups. Furthermore, it is
becoming increasingly clear that the regulatory networks that drive normal development are targeted
in the transformation process. This is knowledge that can be explored to identify novel diagnostic and
therapeutic approaches. Additionally, the understanding of the molecular regulation of lineage stability
can be used to predict the risk of relapse through lineage conversion in association with targeted
therapies. Hence, it can be predicted that basic developmental biology will become of increasing
importance for the improvement of modern cancer care in the near future.
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Abstract: After birth, the development of hematopoietic cells occurs in the bone marrow.
Hematopoietic differentiation is finely tuned by cell-intrinsic mechanisms and lineage-specific
transcription factors. However, it is now clear that the bone marrow microenvironment plays an
essential role in the maintenance of hematopoietic stem cells (HSC) and their differentiation into more
mature lineages. Mesenchymal and endothelial cells contribute to a protective microenvironment
called hematopoietic niches that secrete specific factors and establish a direct contact with developing
hematopoietic cells. A number of recent studies have addressed in mouse models the specific
molecular events that are involved in the cellular crosstalk between hematopoietic subsets and
their niches. This has led to the concept that hematopoietic differentiation and commitment towards
a given hematopoietic pathway is a dynamic process controlled at least partially by the bone marrow
microenvironment. In this review, we discuss the evolving view of murine hematopoietic–stromal
cell crosstalk that is involved in HSC maintenance and commitment towards B cell differentiation.
Keywords: early hematopoiesis; B lymphopoiesis; bone marrow niches; stromal cells
1. Introduction on Early Hematopoiesis and B Lymphopoiesis
In mammals, adult hematopoiesis occurs in the bone marrow (BM). Deciphering the different
stages of hematopoiesis and the developmental cues driving stem cell commitment towards a
particular lineage is essential in regenerative medicine and in the development of treatments for
hematopoietic diseases. Lymphoid development from hematopoietic stem cells (HSC) has been
extensively dissected in mouse models through genetic ablation of key genes and phenotypic
characterization of cell subsets at different maturation steps.
HSC have the lifelong capacity to self-renew and to give rise to all hematopoietic lineages.
The existence of HSC was first demonstrated by Till, McCulloch, and colleagues, who reported
that the bone marrow contains cells having the capacity to reconstitute lethally irradiated mice and
form myelo-erythroid colonies in the spleen (Colony-Forming Unite Spleen, CFU-S) [1,2]. Later,
Weissman and colleagues strongly contributed to the phenotypic identification of hematopoietic
cells enriched for HSC in mouse. The multipotent and self-renewal potentials were first shown to
be properties of a subset of cells lacking markers of committed hematopoietic lineages—so-called
lineage-negative (Lin−)—and expressing Sca1 and low levels of Thy1.1 [3]. It was then demonstrated
that the Lin−CD117+Sca1+ (LSK) fraction retained the multipotent potential and could be further
fractioned into long-term (LT) and short-term (ST) repopulating subsets [4,5]. The acquisition of CD34
expression by murine HSC marks the transition from LT- to ST-HSC [6]. Later on, the introduction
of differentially expressed markers such as CD135 (Flk2/Flt3) and signaling lymphocytic activation
molecule (SLAM) family proteins led to the identification of different multipotent progenitor (MPP)
subsets: the LSK CD150+CD48−CD34− subset LT-HSC on top of the hierarchy and more differentiated
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MPPs with a full spectrum of lineage reconstitution (ST-HSC/MPP1) or with a biased (but not
definitive) engagement towards particular lineages (MPP2 to MPP4; Figure 1) [6–12]. Finally, advances
in single-cell technology demonstrated that the phenotypic boundaries between subsets are not strict,
but rather represent a continuum of progenitor states acquiring lineage restrictions progressively.
This is usually illustrated as a landscape of hills and valleys branching from LT-HSC up to the different
committed lineages [13–18].
Figure 1. Murine early hematopoiesis from long-term hematopoietic stem cells towards the
different lineages. Plain and dashed arrows show the main and the alternative branch points,
respectively. Hematopoietic progenitors do not express markers of the different hematopoietic
lineages and are therefore said to be lineage-negative (Lin−). Markers used to characterize the
different hematopoietic progenitors are indicated. LT-HSC: long-term hematopoietic stem cell (HSC);
ST-HSC: short-term HSC; MPP: multipotent progenitor; LMPP: lymphoid-biased multipotent
progenitor; MEP: megakaryocyte-erythroid progenitor; GMP: granulocyte-monocyte progenitor; CLP:
common lymphoid progenitor; Mega: megakaryocyte; Erythro: erythrocyte; Granulo: granulocyte;
Mono: monocyte; Lympho: lymphocyte; Lin: lineage markers.
Progression from MPP4/LMPP to the common lymphoid progenitor (CLP) subset marks the entry
into the lymphoid lineage and is characterized by interleukin-7 receptor (IL7R) upregulation [9,19].
While CLPs (CD117loSca1+IL7R+) have the capacity to differentiate into all lymphoid subsets,
the upregulation of Ly6D marks the engagement into the B cell lineage [20]. The low natural killer
and T cell potentials retained by the Ly6D+ CLPs (called B lymphoid progenitors, BLP) are lost
upon entry in the earliest pre-pro-B cell stage, as indicated by B220 expression. The following B cell
differentiation steps have a specific and crucial role in the acquisition of a non-autoreactive B cell
receptor (BCR, or immunoglobulin, Ig) repertoire which is essential for efficient adaptive immune
responses. More than two decades ago, both Hardy and Rolink established independent combinations
of markers, known as the Philadelphia and Basel nomenclatures, respectively, which are still standards
for the phenotypic characterization of the different BM B cell subsets in mice (Figure 2A) [21,22].
Both nomenclatures use B220 and CD19 as lineage markers as well as the surface expression of BCR
as a marker of maturity. Hardy and colleagues established their classification based on CD43, CD24,
and BP1 expression, while Rolink and colleagues used CD43, CD117, and CD25 [23,24]. Importantly,
recent advances in multi-parameter flow cytometry now give the opportunity to consider both
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strategies together and improve the resolution of each subset (Figure 2B–D). These results clearly show
that both phenotypic strategies of B cell maturation intermediates are valid and overlapping.
Figure 2. Murine bone marrow (BM) B cell differentiation. (A) Schematic representation of the
different B cell differentiation stages with their denomination according to the Basel and Philadelphia
nomenclatures. The pattern of expression of the main markers used to characterize each subset is
shown with a line. The thickness of the line is representative of the level of expression. The dotted lines
indicate subsets where expression is progressively lost. VDJH and VJL rearrangements are indicated;
(B) BM B lymphopoiesis analysis by flow cytometry according to the Basel nomenclature; (C) BM B
lymphopoiesis analysis by flow cytometry according to the Philadelphia nomenclature. The gating
strategy and the main subsets are indicated in the panels; (D) BM B lymphopoiesis analysis by flow
cytometry taking into consideration both nomenclatures. This strategy improves the resolution of
the subsets, particularly of the pro-B, the pre-BI and the large pre-BII fractions (Fr. B to Fr. C’).
Indeed, while the separation between pro-B and pre-BI cells (Fr. B and C) is not possible with the
Basel nomenclature and the distinction between pre-BI and large pre-BII (Fr. C and C’) with CD24 is
dependent on mouse strains, the simultaneous use of BP1 and CD25 allows a clear definition of the
three subsets.
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B cell specification initiates at the pre-pro-B stage and is driven by the E2A transcription factor [25].
However, the definitive commitment to the B cell lineage occurs at the pro-B cell stage and is controlled
by Pax5. Indeed, loss of Pax5 results in B cell differentiation arrest at the pro-B cell stage, and Pax5−/−
pro-B cells acquire the capacity to differentiate into other lymphoid and myeloid lineages [26–28].
The rearrangements of genes encoding the Ig heavy chain (IgH) are initiated at the pro-B cell stage
between the DH and JH segments, while the complete VDJH recombination takes place at the pre-BI
stage. If a functional Igμ protein is generated from the recombination product, it is associated with
the surrogate light chain (SLC), composed of the invariant λ5 and VpreB proteins, and with the
Igα/Igβ signaling complex to form the pre-BCR [29–32]. Pre-BCR expression by large pre-BII cells
induces proliferation and differentiation towards the small pre-BII stage, where pre-BCR expression
is downmodulated, and Ig light chain (IgL) gene rearrangements are initiated. Upon expression
of a functional IgL chain, the BCR is formed by association with the Igμ chain at the immature B
cell stage. Finally, immature B cells expressing an autoreactive BCR receive a ‘no-go’ signal and have
the possibility of reinitiating rearrangements through receptor editing [33], while immature B cells
expressing a non-autoreactive BCR leave the BM to complete their maturation in the periphery.
Self-renewal, differentiation, and commitment events occurring during hematopoietic progenitor
development as well as B lymphopoiesis are driven by complex intrinsic regulatory networks described
in details elsewhere [25,34,35]. However, these networks are triggered and regulated by extrinsic
signals delivered by cells of the BM microenvironment through the secretion of growth factors and
direct cellular interactions. These supportive regions, called niches, are composed of mesenchymal,
endothelial, and hematopoietic cells. Advances in the analysis of stromal cell niches in vivo have been
possible thanks to the development of reporter and tissue-specific deletion systems in mouse models.
In this review, we will thus focus on the known molecular mechanisms by which murine mesenchymal
and endothelial cells control HSC behavior and B cell commitment.
2. The HSC Niche
2.1. Pioneer Views on the HSC Niche
The influence of cells from the BM microenvironment on the long-term growth of HSC was
first demonstrated using in vitro cultures in which adherent cells were present and composed of
macrophages, adipocytes, endothelial cells, and fibroblasts [36,37]. The analysis of the relationship
between hematopoietic cells and their microenvironment in vivo has long been limited to the
spatial localization of the different lineages in the BM conduit. The microscopic analysis of bone
transversal sections following injection of tritiated thymidine suggested a centripetal differentiation
of hematopoietic precursors from endosteal regions towards the center of the BM [38]. Furthermore,
by measuring the progenitor self-renewal property using CFU-S assays, it was shown that the number
of colonies formed was higher by transplanting cells from the sub-endosteal region rather than from
the central marrow (reviewed in [39]). These results suggested that cells of the microenvironment
located close to the bone border were involved in HSC maintenance.
The development of mouse models allowing tissue-specific deletion of genes or expression of
fluorescent proteins as well as the technological progress in confocal microscopy have been crucial for
the dissection of BM organization. The existence of an osteoblastic niche for HSC was first proposed.
In a first model, the number of HSC could be significantly increased by manipulating osteoblast (OB)
number through the injection of parathyroid hormone (PTH) or by specifically over-expressing the
PTH receptor using the OB-specific Col1a1 promoter [40]. Similarly, increasing spindle-shaped OB
numbers through conditional deletion of the Bmpr1a gene in Mx-Cre/Bmpr1alox/lox mice induced a
parallel increase in HSC [41]. Altogether, these results suggested the importance of an osteoblastic
niche in the maintenance of HSC.
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2.2. The Peri-Sinusoidal HSC Niche
The existence of an osteoblastic niche was then challenged by the development of a mouse
model in which green fluorescent protein (GFP) was knocked-in downstream of the C–X–C
Motif Chemokine Ligand 12 (CXCL12) promoter that allowed visualization of CXCL12-producing
cells [42,43]. CXCL12 was first described as a growth factor for early B cells, but deletion of CXCR4,
its receptor, also induced major hematopoietic defects [44,45]. Deletion of Cxcr4 in adult HSC using
Mx-Cre/Cxcr4lox/− mice injected with poly(I:C) induced a strong decrease in HSC number, suggesting
a crucial role of CXCL12 in HSC maintenance [43]. However, expansion of the HSC population
was observed when ROSA-Cre ERT2 and Tamoxifen were used to delete Cxcr4, suggesting that HSC
maintenance and expansion are tightly dependent on the chemokine context of the bone marrow [46].
CXCL12 was further shown to be a chemoattractant for human and mouse hematopoietic progenitors
and to allow their retention in the BM [47–49]. In vivo tracing of CXCL12-expressing cells using
Cxcl12-GFP or Cxcl12-dsRed knock-in mice showed that GFP was strongly expressed by reticular cells
(called CAR cells for CXCL12-abundant reticular cells), which were scattered throughout the BM and
in contact with the vasculature. In contrast, the expression of Cxcl12 by BM endothelial cells (BMEC)
and OB was 100 and 1000 times lower, respectively [42,43,50]. Accordingly, CD150+CD48− HSC were
essentially localized in peri-sinusoidal regions and in contact with CAR cells [7,43]. Specific deletion
of Cxcl12 in peri-sinusoidal stromal (PSS) cells, but not in OBs, led to an increase in circulating HSC
(Figure 3). Furthermore, specific deletion in BMEC induced a decrease in HSC frequency but no loss of
retention, indicating that CXCL12 plays a differential role in BMEC and PSS cells by allowing HSC
maintenance and retention, respectively [50–52]. Stem cell factor (SCF), the ligand of the receptor
tyrosine kinase c-kit, was also shown to be implicated in stem cell maintenance [53]. The use of
SCF-GFP knock-in and SCF-GFP/CXCL12-dsRed double knock-in mice showed that SCF is expressed
by BMEC and co-expressed with CXCL12 by PSS cells [50,54]. Specific deletion of Kitl encoding SCF in
PSS cells decreased HSC maintenance and retention. In contrast, deletion in BMEC or OB resulted,
respectively, in decreased HSC maintenance or in an absence of phenotype (Figure 3 [54]). Altogether,
these results cast doubt over the existence of an osteoblastic niche and demonstrate the importance of
perivascular niches, and more particularly of PSS cells, for HSC maintenance and retention.
In light of the recent knowledge accumulated on mesenchymal cell niches and development,
it seems likely that the parallel increase in OB and HSC numbers is only correlative and that HSC are
instead regulated by an osteoblastic progenitor. Indeed, in vitro differentiation assays have shown that
CAR and PSS cells have the capacity to differentiate into osteoblasts or adipocytes [55,56]. Furthermore,
PTH/PTHR signaling, which was shown to increase OB number, is able to directly stimulate PSS
cell number and to favor differentiation into OB [40,56]. Finally, inducible and non-inducible
lineage-tracing mouse models confirmed that PSS cells contain progenitors of osteoblasts in adult
BM [57,58].
2.3. The Endosteal/Peri-Arteriolar Niche
Despite the clear involvement of peri-sinusoidal niches in HSC maintenance, some results still
argue in favor of a function for the endosteal niche. Indeed, because of bone remodeling activity,
the local concentration of calcium at the endosteal surface is high. Interestingly, HSC, which express
the calcium-sensing receptor (CaSR), were found to be strongly decreased in Casr−/− mice. In addition,
transplanted Casr−/− HSC, unlike wild-type (WT) HSC, failed to localize close to the endothelium [59].
The adhesion to extra-cellular matrix proteins as well as the migration towards CXCL12 of HSC treated
in vitro with a CaSR agonist were increased. Homing and engraftment into the BM of in vitro treated
HSC were also improved [60]. Finally, the frequency of quiescent HSC was reported to be higher close
to the bone surface in endosteal and trabecular regions [61], indicating that these regions may indeed
play a role in HSC maintenance.
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Figure 3. Bone marrow niches for hematopoietic stem cells and B cells. HSC are located in both
endosteal/arteriolar and in peri-sinusoidal regions which express high levels of CXCL12 and stem cell
factor (SCF). Quiescent HSC are enriched in the endosteal/arteriolar niche. Differentiation of MPP
up to the pro-B cell stage takes place in the peri-sinusoidal niche, where the level of CXCL12 and
IL7 are high. Pre-B cell then relocalize close to GAL1-expressing stromal cells located away from the
sinusoids. At the next immature B cell stage, cells expressing an auto-reactive B cell receptor (BCR)
are retained in the BM in order to initiate receptor editing, while non-autoreactive cells leave the
BM to finish their maturation in the periphery. Mature/recirculating B cells and plasma cells follow
CXCL12 gradients to home to the BM. Recirculating B cell survival relies on dendritic cells. PC survival
relies on the secretion of IL6 and A proliferation-inducing ligand (APRIL) by monocytes, eosinophil,
and megakaryocytes. The colored triangle represents the gradient of IL7 expression from high (red)
to low (green). The table in the bottom right summarizes the influence of CXCL12 and SCF specific
deletion in PSS cells, pericytes, or BMEC on HSC retention (R) and maintenance (M). MPP; multipotent
progenitor; CLP: common lymphoid progenitor; BLP: B lymphoid progenitor; Imm. B: immature
B cell; Recirc. B: recirculating B cell; PC: plasma cell; Mono: monocyte; Eosino: eosinophil; Mega:
megakaryocyte; DC: dendritic cell; aBMEC: arteriolar bone marrow endothelial cell; sBMEC: sinusoidal
BMEC; PSS cell: peri-sinusoidal stromal cell.
Importantly, endosteal and trabecular regions are enriched in arteries, while sinusoidal venous
structures are more central [62,63]. By taking into consideration the large extent of the sinusoidal
network in the BM compared to arteriolar structures, Frenette and colleagues showed that the
proportion of HSC in the vicinity of arterioles was highly significant [62]. Furthermore, quiescent
HSC identified by their capacity to retain EdU (5-ethynyl-2′-deoxyuridine) labelling in the long term,
by their low levels of reactive oxygen species (ROS) or by their high expression of hypoxia-inducible
transcription factor 1 (HIF-1α) [6,64,65], were found to be frequently located close to arteriolar
cells [62,66,67]. Finally, low vessel permeability ensures HSC quiescence and retention in the BM [67].
Indeed, sinusoidal BMEC (sBMEC), but not arteriolar BMEC (aBMEC), were shown to be permeable
and to be the site of trans-endothelial trafficking of HSPC. Notably, when the integrity of aBMEC was
affected, HSC and HSPC numbers were decreased, while HSPC trafficking was increased, confirming
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the importance of arteriolar niches for HSC quiescence. Also, NG2+Nestin+ pericytes associated with
arterioles were shown to express HSC niche genes, including CXCL12 [51,62]. These cells were mainly
located at the metaphysis and adjacent to cortical bone at the diaphysis [67]. When pericytes were
specifically depleted upon injection of tamoxifen and diphtheria toxin in NG2-CreERT/ROSA26iDTR
mice (iDTR: inducible Diphteria Toxin Receptor), HSC were decreased and less quiescent and
relocalized away from arteries [62]. A similar effect was observed upon the specific deletion of
CXCL12, but not of SCF, from pericytes [51].
Altogether, these results suggest that cells of the endosteal/peri-arteriolar region control HSC
maintenance and quiescence, while cells present in the peri-sinusoidal region control HSC maintenance
and retention (Figure 3). CXCL12 expressed by PSS cells, pericytes, and BMEC as well as SCF expressed
by PSS cells and BMEC play a crucial role in these functions, but other factors have also been identified.
Furthermore, the complexity of the HSC niche is not limited to mesenchymal cells and BMEC, as the
involvement of hematopoietic cells (megakaryocytes and macrophages) and Schwann cells have also
been demonstrated. The function of these cells in the maintenance of HSC homeostasis has been
extensively discussed elsewhere [68,69].
3. Niches for Lymphoid Progenitors
The localization of HSPCs was first performed by tracking injected stained cells using bi-photon
live imaging [70]. While HSC were found close to the bone surface, MPPs and more differentiated
progenitors were found further away, but their association to particular regions was not studied.
Because of the strong influence of CXCL12 on HSC maintenance, it has been difficult to assess its
specific role on the development of more committed progenitors. In contrast, the function of IL7
in the differentiation of BLPs, but not of CLPs, has been clearly established using Il7−/− mice [71].
Contradictory results have been obtained when Cxcl12 and Il7 were specifically deleted in OBs. Indeed,
CLP number decreased upon Cxcl12 deletion using the Col2.3-Cre but not the Bglap-Cre systems,
although both promoters were supposed to be expressed in OBs [50,52]. Conversely, CLPs were
decreased upon Il7 deletion using the Bglap-Cre, but not the Col2.3-Cre, system [72,73]. Of note,
both promoters drive partial Cre expression in perivascular stromal cells of the BM [54,74]. Therefore,
it can be speculated that CLPs are controlled by stromal cells located away from the endosteum.
We previously demonstrated using the Il7-Cre/Rosa-eYFP mouse model and by qPCR on sorted
cells, that PSS cells expressing CXCL12 were the main source of IL7 [75]. A more recent study confirmed
our results by suggesting the existence of IL7− and IL7+ PSS cells [73]. Importantly, BMEC, but not OBs,
express low levels of IL7, confirming that the phenotype observed upon Il7 deletion using Bglap-Cre
or Col2.3-Cre could be attributed to Cre expression in perivascular stromal cells. Specific deletion of
Cxcr4 in MPPs or CLPs showed the crucial role played by CXCL12 on MPP development and on the
BLP fraction of CLP [73]. Furthermore, CXCL12 was shown to position BLPs close to IL7+ PSS cells
in order to get an efficient stimulation through the IL7R signaling pathway. Specific deletion of Il7 in
PSS cells using the LepR-Cre system induced a specific decrease in BLPs, confirming the phenotype
observed in Il7−/− mice [71,73]. Finally, HSC and MPPs were found indifferently in contact with both
IL7− and IL7+ PSS cells [73]. However, it cannot be excluded that these subsets may have differential
functions. Indeed, while Cxcl12 specific deletion in all PSS cells using the LepR-Cre system induced a
loss of retention of HSC, specific deletion in IL7+ PSS cells using Il7-Cre mice had only a marginal effect
on HSC and MPP numbers and no effect on HSC retention [50,51,73]. Furthermore, specific deletion of
Kitl (SCF) in all PSS cells induced a decrease in HSC maintenance and retention, but only a decrease in
HSC maintenance when deleted in IL7+ PSS cells. Therefore, the specific function of the different PSS
subsets remains to be addressed.
Taking into consideration the most recent advances in niche biology, HSC, MPP, and CLP subsets
are most likely preferentially located in peri-sinusoidal regions (Figure 3). These different data are
in agreement with the hemosphere model proposed by Adams and colleagues, in which clonal
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hematopoiesis was observed in micro-anatomical structures composed of stromal and endothelial
cells [76].
4. B Cell Niches
4.1. Pioneer Views on B Cell Niches
Early on, Whitlock and Witte demonstrated that adherent BM cells sustain long-term B cell
cultures [77]. By removing glucocorticoids, known to impair lymphocyte development, from Dexter
type cultures, differentiation of B cells, including IgM+ immature B cells, could be observed for more
than 10 weeks, and the recovered cells could be clonally expanded. Stromal cell lines were then
derived from these cultures, leading to the identification of the main factors involved in early B cell
development, namely, CXCL12 and IL7 [44,78,79]. The generation of cell lines with distinct phenotypic
characteristics and supportive functions suggested the existence of heterogeneity between stromal
cells. However, this heterogeneity may have been related to stromal cell instability, as modifications
in surface marker expression could be observed upon cloning [80]. These in vitro co-culture systems
were further developed by Rolink and Melchers to decipher B cell differentiation mechanisms and
the influence of extrinsic cues [81,82]. They demonstrated that stromal cells and IL7 were able to
maintain long-term proliferation of pro-B/pre-BI, while removal of IL7 induced their differentiation
into immature B cells [81,83]. Importantly, IL7-dependent pro-B/pre-BI cell growth was inhibited by
a blocking anti c-kit/CD117 antibody, indicating that c-kit, the receptor for SCF, was an important
co-factor for IL7-dependent early B cell proliferation [84].
Contacts between B cells and stromal reticular cells were first observed in situ by electron
microscopy on BM histological sections [85]. In this study, B cell development was proposed to be
centripetal, with early B cells being mainly located close to the endosteum and in intermediate zones,
while IgM+ B cells were positioned in the vicinity of the central sinus. Furthermore, lymphoid cells,
unlike myeloid cells, were closely associated to β1 integrin-expressing reticular cells [86]. Finally,
β1 integrin expression revealed heterogeneity between stromal cells, with β1-integrin+ cells mainly
localized in the peripheral region of the BM.
4.2. Early B Cell Niches
The evidence for the existence of stromal cell niches for early B cell development became clear with
the identification of CXCL12 and IL7 as crucial growth factors produced by the BM microenvironment.
B lymphopoiesis is strongly affected in the fetal liver and in the BM of Cxcl12- and Cxcr4-deficient
mice [45,87,88]. Nevertheless, because of the crucial role played by the CXCL12/CXCR4 axis in
HSC and BLP [43,73,89], it is difficult to evaluate their influence on early B cell development in
non-conditional KO mice. An increase in pro-B cells was however observed in the fetal blood of
Cxcr4−/− mice as well as in the blood of adult WT mice reconstituted with Cxcr4−/− fetal liver cells,
indicating a role for the CXCR4/CXCL12 axis in early B cell retention [48]. This effect was further
confirmed in B cell-specific CD19-Cre/CXCR4lox/lox knock-out mice [90]. Although CXCR4-deficient
IgM− B cells retain the capacity to proliferate in the presence of IL7 in in vitro co-cultures and to
differentiate into IgM+ B cells in the absence of IL7, a role for CXCL12 on early B cell development
cannot be excluded, since differentiation towards the immature B cell stage is impaired in the absence
of CXCR4 in vivo [48,90]. Furthermore, CXCL12, together with IL7 or SCF, stimulates the proliferation
of pre-B cell clones and the survival of B cell progenitors in vitro, suggesting that CXCL12 may
act synergistically with other factors in the earliest steps of B cell differentiation [44,89]. Finally,
CXCL12 has been shown to induce α4β1 integrin-dependent adhesion of pro-B and pre-B cells to
VCAM-1 through the activation of focal adhesion kinase (FAK) [91]. Accordingly, B cell development is
affected in the BM of α4 integrin- and FAK-deficient mice [92,93], and pro-B cell egress in the periphery
of FAK−/− mice.
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As said earlier, IL7 plays an important role in pre-pro-B and pro-B cell proliferation [78,81].
Interestingly, pro-B cells need high concentrations of IL7 to proliferate, while a decrease in IL7
concentration favors differentiation toward the pre-BI stage, in which recombination between V
and DJ gene segments and then intracellular expression of the Igμ chain are induced [94]. IL7 has
also been implicated in B cell differentiation and survival [95,96]. As a consequence, deletion of the
Il7 and Il7r genes leads to a severe block at the earliest stages of B cell development [97,98]. Finally,
IL7 was further shown to control B cell potential already from CLPs by regulating EBF1 and Pax5
expression [71].
The identification of the niches for early B cells is still controversial. Pre-pro-B and pro-B
cells were first proposed to be associated with distinct niches, expressing, respectively, CXCL12
or IL7 [42]. However, we and others have shown that both factors are co-expressed by PSS cells [73,75].
The discrepancies between the studies may be due to the low level of IL7 expression in vivo and thus to
the difficulty to detect positive cells using reporter systems or antibodies [99,100]. Therefore, one could
not exclude that IL7 expression in CXCL12-expressing cells was missed in the early study by Tokoyoda
and collaborators because of the lack of antibody staining sensitivity.
Other studies have proposed that OBs may play a role in early B cell development. Acute
depletion of osteoblastic cells using mice expressing the herpes virus thymidine kinase under the
control of the Col1a1 promoter (Col2.3Δ-TK Tg mice) induced a decrease in both pre-pro-B and pro-B
cells. Alternatively, depletion of the G protein α subunit, using the Osx-Cre system, impaired pro-B
cell development. Although the promoters used in these mouse models were first thought to be
specifically activated in OBs, recent results show that they are already activated in osteo-progenitors,
including PSS cells [57,58,73]. Accordingly, Bglap-Cre/Cxcl12lox/− mice that lack CXCL12 expression
in OBs did not show any B cell phenotype, while pre-pro-B cells were impaired in Osx-Cre/Cxcl12lox/−
mice. This demonstrates the importance of CXCL12 expression in osteo-progenitors for pre-pro-B cell
development [52].
IL7 is essentially expressed by a subset of PSS cells and at very low levels by BMECs [73,75].
Specific depletion of IL7 from PSS cells using LepR-Cre/Il7lox/− mice induced a strong decrease of B
cell progenitors from the BLP stage, while depletion in BMEC using Tie2-Cre/Il7lox/− mice induced
a low but significant decrease only from the pro-B cell stage [73]. These results indicate that pro-B
cells are more affected by low IL7 fluctuations than BLP and are consistent with the fact that pro-B cell
proliferation requires high levels of IL7 [94].
Altogether, these results suggest that the niche sustaining pre-pro-B and pro-B cell homeostasis is
located in the peri-sinusoidal region, where both CXCL12 and IL7 levels are high (Figure 3). However,
its precise location and the nature of the stromal cells involved in the control of their development
remain to be defined.
4.3. The Pre-B Cell Niche
The expression of the pre-BCR at the large pre-BII stage is a crucial checkpoint allowing the
selection of functional Igμ chains, the amplification of cells expressing such chains—ensuring higher Ig
diversity—, and the induction of IgL recombination. The SLC plays a crucial role in pre-BCR signaling.
Indeed, deletion of either λ5 or VpreB leads to a severe block at the pre-BI/large pre-BII transition,
and deletion of both results in a complete block of differentiation [101–103]. Pre-BCR signaling relies
on ligand-independent and ligand-dependent mechanisms, which both implicate the extra loop (EL)
of λ5. Interactions between adjacent λ5-EL and VpreB-EL or between λ5-EL and a glycosylated
chain linked to the Igμ constant region at position N46 were proposed to induce self-aggregation
of the pre-BCR, resulting in tonic signaling [104,105]. This tonic signal is, however, increased by
inducing pre-BCR cross-linking with an anti IgM antibody, suggesting the existence of a ligand for the
pre-BCR [104]. Heparan sulfate proteoglycans present at the surface of stromal cells have the capacity
to bind λ5-EL [106]. Interestingly, pretreatment of pre-B cells with heparan sulfate improves pre-BCR
signaling induced by anti IgM cross-linking [107]. Galectin-1 (GAL1), an S-type lectin which binds
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β-galactoside glycoconjugates through its carbohydrate recognition domain (CRD), is a ligand for
the pre-BCR and binds λ5-EL through direct protein–protein contacts [108,109]. GAL1 is secreted by
stromal cells and acts as a docking protein by interacting with both the pre-BCR and glycosylated chains
of integrins at the surface of pre-B cells to form a complex lattice [110,111]. Clustering of the pre-BCR is
further increased by the interaction of the pre-B cell integrins with their ligands expressed by stromal
cells, resulting in pre-BCR signaling. Accordingly, the inactivation of GAL1 expression by stromal cells
in vitro and in vivo impairs large pre-BII cell proliferation and differentiation [111]. More recently,
we identified GAL1-expressing stromal cells in the BM. Such cells are different from IL7-expressing
cells and are not localized in peri-sinusoidal regions [75]. Most importantly, large pre-BII cells are in
close contact with these GAL1+ cells. While pro-B cells need high levels of IL7 for their proliferation,
large pre-BII cells are sensitive to low levels of IL7 [94], suggesting that the transition from the IL7+ to
the GAL1+ stromal cell niche plays an important role in B cell development.
4.4. Immature B Cell Niches
The main features at the immature B cell stage are the negative selection of auto-reactive BCR
and their egress to the periphery where they complete their maturation. As compared to pro-B and
pre-B cells, immature B cells express low levels of CXCR4 and have a decreased capacity to adhere
to VCAM1 in a CXCL12-induced manner [91,112]. Moreover, when mice transgenic for a hen egg
lysosome (HEL)-specific BCR were treated with HEL to simulate self-antigen engagement, immature B
cells upregulated CXCR4, resulting in reduced egress to the periphery. This suggests that immature B
cells are retained in the BM if their BCR is auto-reactive. In line with this result, cannabinoid receptor
2 was shown to be involved in the retention of immature B cells in sinusoids and to favor receptor
editing [113]. Furthermore, immature B cells are protected from BCR-mediated apoptosis and have the
capacity to reinitiate the recombination-activating genes RAG1 and RAG2 when incubated with cells of
the BM microenvironment expressing DX5 and low levels of Thy1 [114,115]. Altogether, these results
show that endothelial and/or stromal cells play an important role in the retention of auto-reactive
immature B cells in the BM and in receptor editing.
4.5. Recirculating B Cell and Plasma Cell Niches
BM also represents a privileged homing site for plasma cells (PC) and mature B cells. In particular,
the BM represents a reservoir for long-lived PC recently requalified as “memory plasma cells” [116].
In addition, the capacity of mature B cells and plasma blasts to home to the BM is likely critical
to ensure protection of the hematopoietic system and of maturing immune cells against pathogens.
The CXCR4/CXCL12 axis plays a crucial role in the homing of mature B cells (called recirculating B cells
in the BM) and plasma blasts, as demonstrated using CXCR4-deficient cells [48,90,117]. Both subsets
localize in peri-sinusoidal regions and even in direct contact with CXCLC12-expressing PSS cells in the
case of PC [42,118] (Figure 3). Cells of hematopoietic origin are part of the supportive niche and deliver
survival cues to PC and recirculating B cells. Dendritic cells (DC) forming clusters in peri-vascular
regions are located in close proximity to recirculating B cells [119]. Upon specific depletion of these
DC using CD11c-DTR transgenic mice, wild-type but not Bcl2 transgenic recirculating B cells are lost,
demonstrating a role for the DC in their survival. Monocytes, eosinophils, and megakaryocytes are
also involved in the survival of long-lived PC through the secretion of A proliferation-inducing ligand
(APRIL) and IL6 [120–122]. Interestingly, monocytes and eosinophils express CXCR4 and the α4β1
integrin, which participate in the positioning of B cells, including PC close to CXCL12-expressing
cells [42,91,122]. The complexity of long-lived PC niches, in which hematopoietic cells provide survival
signals, while stromal cells represent an anchoring site, is intriguing. Indeed, long-lived PC are sessile
and scattered throughout the BM in contact with stromal cells [123]. PC anchoring to stromal cells is
likely to occur via the α4β1 and αLβ2 integrins, since treatment with a combination of monoclonal
antibodies (mAbs) against these integrins (clone PS/2 and M17/4, respectively) depletes PC from
the BM [124]. Whether a unique BM stromal cell subset expresses the different ligands for α4β1 and
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αLβ2 (fibronectin and VCAM-1 for the former and ICAM-1 for the latter) remains to be demonstrated.
However, these results argue for a model in which plasma blasts use CXCL12-driven migration
to reach a limited number of niches made of stromal cells and IL6/APRIL-secreting eosinophils,
before switching off migration and anchoring to stromal cells. This would be in agreement with
studies showing that eosinophil depletion reduces by 70% the number of PC and that generation of
new plasma blasts is accompanied by long-lived PC mobilization from the BM [121,125]. Therefore,
BM stromal cells not only are able to give direct signals to differentiating hematopoietic cells, but also
act as regulators of long-lived PC.
5. Concluding Remarks
At the time of stochastic versus instructive models of lymphocyte commitment and differentiation
in the early nineties, pioneer studies by Rolink and others clearly established that BM stromal cells
play a key role in the generation and regeneration of the B-lymphocyte lineage [126]. On one hand,
this prompted many teams to work with co-culture conditions in order to generate large quantities
of mature cells starting from few progenitors. On the other hand, this paved the way toward the
search for stromal cells supporting long-term hematopoiesis [127]. More recently, and thanks to the
use of reporter mice, the progress made in understanding BM organization and BM stromal cell
heterogeneity has been tremendous. The influence of the BM microenvironment on pathologies
affecting hematopoietic progenitors has benefited from the important advances in normal HSC
niche characterization [128,129]. Resistance and relapse in the case of B cell acute lymphoblastic
leukemia, the pathological equivalent of differentiating B cells, also concerns a great proportion of
patients, most particularly adults. It is now clear that part of the resistance to treatment is related to
protective cues transmitted by stromal cells [130]. Therefore, it is now crucial to translate our current
understanding of mouse BM organization to human physiological and pathological situations.
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Abstract: Interleukin-7 (IL-7) is essential for lymphocyte development. To identify the functional
subdomains in the cytoplasmic tail of the IL-7 receptor (IL-7R) α chain, here, we constructed a
series of IL-7Rα deletion mutants. We found that IL-7Rα-deficient hematopoietic progenitor cells
(HPCs) gave rise to B cells both in vitro and in vivo when a wild-type (WT) IL-7Rα chain was
introduced; however, no B cells were observed under the same conditions from IL-7Rα-deficient
HPCs with introduction of the exogenous IL-7Rα subunit, which lacked the amino acid region at
positions 414–441 (d414–441 mutant). Signal transducer and activator of transcription 5 (STAT5)
was phosphorylated in cells with the d414–441 mutant, similar to that in WT cells, in response
to IL-7 stimulation. In contrast, more truncated STAT5 (tSTAT5) was generated in cells with the
d414–441 mutant than in WT cells. Additionally, the introduction of exogenous tSTAT5 blocked B
lymphopoiesis but not myeloid cell development from WT HPCs in vivo. These results suggested that
amino acids 414–441 in the IL-7Rα chain formed a critical subdomain necessary for the supportive
roles of IL-7 in B-cell development.
Keywords: interleukin-7; interleukin-7 receptor; B-cell development; signal transducer and activator
of transcription 5
1. Introduction
Interleukin-7 (IL-7) provides signals via the IL-7 receptor (IL-7R), which are required during many
stages of lymphocyte development [1,2]. IL-7R is composed of two different receptor subunits, IL-7Rα
and common γ (γc) chains [3,4]. IL-7Rα is also a component of the thymic stromal lymphopoietin
receptor complex, whereas γc is common to functional receptor complexes for IL-2, IL-4, IL-7, IL-9,
IL-15, and IL-21 [5]. The developmental processes governed by IL-7R signaling include initiation
of cell proliferation, protection from apoptotic cell death, and induction of lineage-specific events
(i.e., gene rearrangement in antigen receptor loci) [6]. Mutations that interfere with IL-7R signaling
cause profound immunodeficiency in both humans and mice [7–9], highlighting the central role IL-7
plays in lymphopoiesis.
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Activation of signal transduction pathways via IL-7R begins with IL-7 binding to IL-7R complexes,
followed by heterodimerization and conformational changes in IL-7Rα and γc chains [10]. Next, Janus
kinase 1 (JAK1) and JAK3 interphosphorylate, inducing kinase activity in both molecules. Activated
JAK1 and JAK3 phosphorylate tyrosine residues on their substrates, including other kinases, adaptor
molecules, and receptor subunits [11]. Phosphorylated tyrosine residues in the cytoplasmic domains
of cytokine receptors can be docking sites for downstream signaling molecules with SH2 domains,
such as phosphatidylinositol 3-kinase (PI3K) and signal transducer and activator of transcription 5
(STAT5) [11].
Four tyrosine residues are present in the cytoplasmic domain of mouse IL-7Rα. Among these
four tyrosine residues, the third, Y449, is necessary for STAT5 binding to IL-7Rα [12,13]. Because the
introduction of a constitutively active form of STAT5 in IL-7Rα−/− hematopoietic stem cells (HSCs)
rescues impaired B-cell development [14], STAT5 is considered a critical signaling molecule for IL-7R
signaling [12]. Indeed, B-cell development is completely shut down in 7RαYYFY knock-in mice, in
which Y449 of IL-7Rα is substituted with phenylalanine (F449). In contrast, the number of early T-cell
progenitors in 7RαYYFY knock-in mice is reduced, but the number of mature T cells in the periphery
is close to normal. Therefore, other functional subdomains that play a role in the regulation of signal
transduction via IL-7R should exist in the cytoplasmic tail of IL-7Rα.
In addition to the tyrosine residues, two motifs, namely Box1 and Box2, which are conserved
in a number of cytokine receptors, are also recognized in the IL-7Rα chain [10,15,16]. These two
subdomains are known to form binding sites of JAK family kinases. Therefore, if Box1 or Box2 is
removed, the mutated cytokine receptors lack the ability to trigger signals upon binding of a cognate
cytokine [10,15,16]. The acidic region, which was first identified in IL-2Rβ chain and forms a binding
site for Src tyrosine kinases, such as Lck and Fyn, is also found in the IL-7Rα chain [17]. However, no
other functional subdomains have been identified in the cytoplasmic tail of the IL-7Rα chain.
Therefore, in the present study, we constructed a series of IL-7Rα-deletion mutants to uncover
hidden functional subdomains in the cytoplasmic tail of IL-7Rα chain. Our results provide important
insights into B-cell development and IL-7R signal transduction.
2. Results
2.1. Identification of the IL-7Rα Cytoplasmic Regions that Are Necessary for IL-7-Mediated Cell Proliferation
We constructed a series of IL-7Rα deletion mutants to study the roles of different cytoplasmic
regions in IL-7R signaling (Figure 1a). We divided the IL-7Rα cytoplasmic domain into nine segments
and made deletion mutants lacking each segment. We also generated one mutant lacking all nine
segments (dCyt). Two of the segments were chosen such that we could delete conserved motifs,
such as Box1 (d280–307) and Box2 (d308–322) [18]. The d280–307 mutant lacked all amino acid
residues between Box1 and Box2. Segments 379–396 and 397–413 were chosen so that only the first
(Y390) or second (Y401) tyrosine residue was deleted (d379–396 and d397–413 mutants, respectively).
The d414–441 mutant conserved all four tyrosine residues but lacked most of the amino acid residues
between the second and third residues. Finally, we deleted the C terminal region of IL-7Rα, which
contained the third (Y449) and fourth (Y456) tyrosine residues.
We screened each mutant using two different criteria. The first was the ability to transduce
growth signals in an IL-2-dependent mouse T-cell line (CTLL-2 cells). The other was the potential to
support B-cell development from hematopoietic progenitor cells (HPCs). In this case, we purified c-Kit+
lineage− Sca-1+ (KLS) HPCs from the bone marrow of IL-7Rα−/− mice and introduced wild-type (WT)
and mutant IL-7Rα chains using a retroviral system. We used the nonfunctional IL-7Rα YYFY mutant
as a negative control and the WT IL-7Rα chain as a positive control. After mutant IL-7Rα chains were
introduced into IL-7Rα−/− HPCs, we cultured the IL-7Rα−/− HPCs with exogenous WT or mutant
IL-7Rα subunits on OP9 cells in the presence of stem cell factor (SCF), Flt3 ligand, and IL-7 for 6 days.
Then, we examined the presence of CD19+ cells after culture.
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As was the case with other cytokine receptor subunits, Box1 and Box2 were indispensable for
IL-7Rα function based on the IL-7-mediated proliferation of CTLL-2 cells (see d272–279 and d308–322
mutants in Figure 1b). In addition, the d280–307 mutant, which lacked the region between Box1
and Box2, was not functional. Thus, dBox1, d280–307, and dBox2 mutants were not functional,
perhaps due to the lack of association with JAK1 [19,20]. The d442–459 mutant was nonfunctional
as well, presumably because of the lack of STAT5 binding in the absence of Y449. Although the
d323–356 mutant showed lower functionality than the wild-type (WT) IL-7Rα chain, other mutants
(i.e., d357–378, d379–396, d397–413, and d414–441) induced cell proliferation at a level comparable to
that of the WT IL-7Rα chain (Figure 1b).
Figure 1. Identification of functional subdomains in the cytoplasmic tail of the IL-7Rα subunit.
(a) Schematic structure of IL-7Rα deletion mutants. The positions of four tyrosine residues and Box1/2
in the intracytoplasmic domain of IL-7Rα are also indicated. The functionality of each mutant was
tested by analysis of IL-7-mediated cell proliferation with CTLL-2 cells (b) and by appearance of CD19+
cells from IL-7Rα−/− c-Kit+ lineage− Sca-1+ (KLS) cells after the in vitro cultures (c). The data shown
in (b) are representative of three independent experiments and normalized to the proliferation rate of
each line in the presence of IL-2 to minimize variations in input cell numbers. Then, the proliferation
rate of CTLL-2 cells with each mutant was compared to the rate of the cells with wild-type (WT) IL-7Rα
chain (* p < 0.05).
2.2. The Amino Acids Region from Positions 414 to 441 of the IL-7Rα Subunit Was Necessary for B-Cell
Development
There was no discrepancy between the ability to transduce growth signals and the potential
to support B-cell development except for with the d414–441 mutant (Figures 1 and 2). Stagnation
of B-cell development in IL-7Rα−/− HPCs with the d414–441 mutant occurred at the transition
stage from pre-proB (B220+CD19−) to proB (B220+CD19+) cells (Figure 2), where IL-7 stimulation
was indispensable for the stage transition [14]. We also examined B-cell differentiation potential in
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KLS cells with the d414–441 mutant in vivo by injecting the cells into 400 rad-irradiated recombinant
activating gene 2 (RAG2)−/− mice. We found that no B cells were derived from IL-7Rα−/− HPCs with
the d414–441 mutant, as was the case for IL-7Rα−/− HPCs with the nonfunctional IL-7Rα YYFY mutant
at 5 weeks after injection (Figure 3). These results indicated that the amino acid region from positions
414 to 441 of IL-7Rα played a critical role in IL-7-dependent B-lymphocyte development.
Figure 2. The d414–441 mutant did not support IL-7-mediated stage transition from the pre-proB
(B220+CD19−) to proB stage (B220+CD19+) during B-cell development. KLS cells from IL-7Rα−/−
bone marrow were infected with retroviruses expressing the YYFY mutant (negative control), d414–441
mutant, or WT IL-7Rα (positive control). Two days after infection, green fluorescent protein
(GFP)-positive cells were purified by fluorescence-assisted cell sorting (FACS) and cultured on OP9
stromal cell layers in the presence of stem cell factor (SCF), Flt3 ligand, and IL-7 for 6 days. Cells were
then stained with anti-B220 and anti-CD19 antibodies and analyzed by FACS.
Figure 3. The d414–441 mutant did not support B-cell development in vivo. We infected IL-7Rα−/−
KLS cells (CD45.2) with recombinant viruses, as indicated in the figure. GFP-positive cells were purified
and injected into 400 rad-irradiated RAG2−/− (CD45.1) mice intravenously. Four weeks after injection,
splenocytes from host mice were stained with anti-CD45.2, anti-CD19, anti-B220, and IgM antibodies
and analyzed by FACS.
2.3. The Truncated Form of STAT5 (tSTAT5) Was Upregulated in CTLL-2 Cells with the d414–441 Mutant
Compared with that in WT Cells after IL-7 Stimulation
The d414–441 mutant could transduce growth signals in CTLL-2 cells as efficiently as WT IL-7Rα
(Figure 1) but did not support B-lymphocyte development (Figures 2 and 3). Because STAT5 plays a
critical role in IL-7R signaling, we examined the phosphorylation status of STAT5 in CTLL-2 cells with
the d414–441 mutant after IL-7 stimulation. As shown in Figure 4, the level of STAT5 phosphorylation in
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the d414–441 mutant was comparable to that in WT cells. Moreover, tSTAT5 was obviously upregulated
in CTLL-2 cells with the d414–441 mutant than in cells expressing WT IL-7Rα (Figure 4).
Figure 4. Signal transducer and activator of transcription 5 (STAT5) phosphorylation in response to
IL-7 treatment in CTLL-2 cells expressing WT IL-7Rα and d414–441 mutant. Cells were starved of IL-2
for 8 h and stimulated with 100 ng/mL IL-7 for the indicated times. Whole cell lysates were subjected
to sodium dodecyl sulfate polyacrylamide gel electrophoresis, and STAT5 activation was analyzed
with immunoblotting using anti-phospho-STAT5 antibodies. Expression of β-actin was also examined
with anti-β-actin antibodies as a loading control.
tSTAT5 can be generated by partial proteolysis after stimulation with cytokines, including IL-2 and
IL-3. We previously demonstrated that tSTAT5 is a dominant-negative form of STAT5 [21]. Therefore,
we examined whether B-cell development from HPCs was blocked in the presence of tSTAT5. For this
purpose, we purified KLS cells as HPCs from WT mouse bone marrow. After the introduction of
tSTAT5 (or control) in WT HPCs using a retroviral system, we injected these cells into RAG2−/−
mice. We then examined spleen cells in RAG2−/− mice with HPCs with or without tSTAT5 at 5 weeks
after injection. We found that B-cell development was severely impaired in the presence of tSTAT5,
although the number of Mac-1+ myeloid cells was not changed (Figure 5). These results suggested that
the amino acid region from positions 414 to 441 of the IL-7Rα chain may form a docking site for the
molecule, which inhibits the generation of tSTAT5 in cells after IL-7 stimulation.
Figure 5. Truncated STAT5 (tSTAT5) had inhibitory functions in B-cell development. KLS cells from WT
mice were infected with control or tSTAT5 retroviruses. These cells were injected into 400 rad-irradiated
RAG2−/− mice. Recipient-derived cells in the spleens of host mice were analyzed at 5 weeks after
injection. The numbers in the plots were the means of B and myeloid cell numbers from three mice.
3. Discussion
Activation of cytokine receptor signals is triggered by JAKs, resulting in phosphorylation of
tyrosine residues of various signal molecules and the cytoplasmic tail of receptor subunits [22].
Therefore, among various protein modifications, phosphorylation is a main driver of signal cascades via
cytokine receptors upon cognate ligand binding. However, other protein modifications are necessary
for proper cytokine receptor signal transduction. For example, a number of molecules are acetylated in
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the cytoplasm, playing a role in positive regulation of interferon receptor signals [23]. Acetylated STAT1
and STAT2 exhibit enhanced transcriptional activity upon activation by tyrosine phosphorylation.
Recently, we demonstrated that acetylation of JAK1, JAK3, and STAT5 occurs immediately in T cells
in an IL-2-dependent manner [21]. This acetylation occurs via CREB binding protein (CBP), which
relocates from the nucleus to the cytoplasm upon IL-2 stimulation. Acetylated STAT5 is a target
of STAT5 protease, resulting in limited proteolysis and generation of tSTAT5. In this study, we
demonstrated that tSTAT5 generation was increased after IL-7 stimulation if the 414–441 region in
the IL-7Rα subunit was deleted. Therefore, we propose that the 414–441 region in the IL-7Rα subunit
may form a binding site for inhibitors of CBP function. As shown in Figure 6, the 414–441 region
contains multiple proline residues, which may serve as a docking site for the SH3 domain, although a
conventional PxxP motif is absent. Accordingly, it is difficult to hypothesize which molecules may
associate with the 414–441 region just based on the amino acid sequence.
Figure 6. Comparison of the 414–441 region with the corresponding sites of IL-7Rα in various species.
The 414-441 region contains proline residues (in red). These amino acids may provide docking site for
the SH3 domain.
Various deletion mutants and point mutants of cytokine receptor subunits have been generated to
identify the functional subdomains in the cytoplasmic tails of receptor subunits [24–26]. As a result,
multiple signal pathways have been shown to be activated by different regions of the cytoplasmic
tails of cytokine receptors. These studies have also shown that proliferation and differentiation signals
are independent of one another. Accordingly, the d414–441 IL-7Rα mutant retained the potential to
stimulate cell proliferation but lacked the ability to support B-cell development from HPCs. However,
it is unclear why there was such a discrepancy despite the observation that STAT5 plays roles in both
cell proliferation and support of B-cell development. In B-cell development, the first checkpoint at
which IL-7 stimulation is required is the transition from the pre-proB cell population to the proB cell
population. Expression of the transcription factor early B-cell factor (EBF) is indispensable for this
stage transition [27]. We previously demonstrated that IL-7 stimulation is necessary for upregulation
of EBF before entry to the proB cell stage [14]. Moreover, there was a threshold for EBF expression
that was sufficient for the transition to the proB cell population from more immature cells. In addition,
B-cell progenitors need to be stimulated with IL-7 before the pre-proB cell stage to enable sufficient
EBF expression in response to IL-7 for the transition to the proB stage [28]. Therefore, one possible
explanation for the discrepancy between proliferation and support of B-cell development by the
d414–441 mutant may be related to the sensitivity of the mutant to the strength of STAT5 activity.
Transcription levels of EBF could be more sensitive to STAT5 activity than proliferation. Furthermore,
IL-7-induced EBF expression is mediated directly by STAT5, whereas cell proliferation is regulated
by not only STAT5 but also other signaling components, such as PI3K, which associates with IL-7Rα
at the region containing Y449 [29]. Since lack of a hypothetical molecule associated with the 414–441
region of the IL-7Rα chain may diminish IL-7R function in B-cell development, it is possible that the
associated molecule plays a role in the regulation of B-cell number in vivo. Further investigations are
necessary to determine why IL-7-stimulated cell proliferation and B-cell development have different
requirements for the 414–441 region of IL-7Rα.
Notably, tSTAT5 inhibited IL-2-mediated proliferation of CTLL-2 cells, in contrast to IL-7-mediated
cell growth. In all of our experiments, IL-2 was found to stimulate cell proliferation more strongly
115
Int. J. Mol. Sci. 2018, 19, 2522
than IL-7; IL-7-driven cell proliferation levels which were only approximately 40% of that induced by
IL-2. Therefore, cell proliferation in response to IL-2 may be more sensitive to negative effects, such
as the presence of tSTAT5, than IL-7-mediated stimulation. Additionally, the effects of deletion of
amino acids 414–441 from IL-7Rα may be different between T-cell development and B lymphopoiesis,
as was the case in 7RαYYFY knock-in mice. Further studies using d414–441 mutant knock-in mice
are needed to obtain insights into possible differential roles of the 414–441 region of IL-7Rα in T- and
B-cell development. These future studies are expected to highlight the importance of acetylation in the
regulation of signal transduction via cytokine receptors.
4. Materials and Methods
4.1. Mice
IL-7Rα−/− and RAG2−/− (CD45.1) mice on a C57Bl/6 background were bred, maintained under
a specific pathogen-free environment at the Duke University Medical Center Animal Care Facility and
the animal facility at Toho University School of Medicine, and used at 8–12 weeks of age. All studies
and procedures were approved by the Duke University Animal Care and Use Committee (A246-07-09,
24 September 2009) and Toho University Administrative Panel for Animal Care (18-54-311, 1 April 2018)
and Recombinant DNA (18-54-303, 1 April 2018).
4.2. Construction of Mutant IL-7Rα Subunits and Retrovirus Production
IL-7Rα deletion mutants shown in Figure 1 were generated by polymerase chain reaction
(PCR) using full-length mouse IL-7Rα cDNA as a template and the following primers: 5′-tcaaggagg
atgggatcc-3′ (common forward primer) and 5′-tacatagttgttccagagttttcttgacaggtttattcttttttttccat-3′
(272-279, reverse primer), 5′-cttcaacgcctttcacctcatgagtatgatcggggagactaggccatacg-3′ (280-307, reverse
primer), 5′-gtgcaggaagatcattgggcagaaactggcagtccaggaaactttcggga-3′ (308-322, reverse primer),
5′-ctcttctaactgtttctggtgggctactttccacctcgtccctggcttca-3′ (323-356, reverse primer), 5′-tagaggaaaggagt
ggaggggcattgctgactgaagtctcaggcgagcggttt-3′ (367-378, reverse primer), 5′-agtcttgatacacagg aggcttatta
ttgcaggtactcagatttctagcc-3′ (379-396, reverse primer), 5′-atggttgagggacagggacagggaccctatttctgtcaccat
ctctgtagtca-3′ (397-413, reverse primer), 5′-catacgcttcttcttgattcagtacgacatttgtgtttccagagtttggc-3′ (414-441,
reverse primer), and 5′-tgaggaagtggagatgggctg-3′ (442-459, reverse primer). The IL-7Rα YYFY mutant,
in which Y449 was substituted with F, was generated by site-directed mutagenesis. Mutants were
confirmed by sequencing. All cDNAs were subcloned between the 5′-long terminal repeat and internal
ribosome entry site (IRES) in the Murine Stem Cell Virus (MSCV)-IRES-green fluorescent protein (GFP)
vector. IL-7Rα and tSTAT5 in the MSCV-IRES-GFP vector were described previously [14,21,30,31].
Retroviruses were prepared as described in [14].
4.3. Establishment of CTLL-2 Transfectants
CTLL-2 IL-2-dependent mouse T cells were cultured in complete medium (RPMI 1640 with 10%
fetal calf serum [FCS] and 50 μM 2-mercaptoethanol) supplemented with 2 ng/mL hIL-2. CTLL-2
transfectants stably expressing WT or mutant IL-7Rα subunits were established with retroviral systems,
followed by purification of GFP+ cells by fluorescence-assisted cell sorting (FACS) as described
previously [32]. All GFP+ cells expressed exogenously introduced genes, as shown by staining for cell
surface IL-7Rα.
4.4. Proliferation Assays
CTLL-2 transfectants were maintained in complete medium supplemented with hIL-2.
After washing three times with phosphate-buffered saline, 5 × 104 cells in complete medium were
cultured in each well of a 96-well plate in the presence of IL-7 (10 ng/mL) at 37 ◦C for 48 h.
[3H]-thymidine (1 μCi) was added to the culture 4 h before harvesting. Cells were harvested with an
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automatic cell harvester on a glass filter (Harvester 96; TOMTEC, Hamden, CT, USA). Radioactivity
was determined USA).
4.5. Cell Sorting and FACS Analysis
Antibodies used in FACS sorting and analyses were as follows: phycoerythrin (PE)- or
biotin-conjugated anti-IL-7Rα (A7R34); PE/Cy5- or allophycocyanin (APC)-conjugated anti-B220
(RA3-6B2); PE-anti-CD19 (6D5); fluorescein isothiocyanate (FITC)-, PE-, or PE-/Cy5-conjugated
anti-Mac-1 (M1/70); PE/Cy5-conjugated anti-CD3 (145-2C11); anti-CD4 (RM4-5); anti-CD8 (53-6.7);
anti-Gr-1 (RB6-8C5); anti-TER119 antibodies; and APC-conjugated anti-c-Kit (2B8); all antibodies were
purchased from eBioscience (San Diego, CA, USA), Tombo (San Diego, CA, USA), or BD Bioscience
(Mountan View, CA, USA). Alexa Fluor 594-anti-Sca-1 antibodies were prepared in our laboratory using
standard procedures. Biotin-conjugated antibodies were visualized with PE-streptavidin (eBioscience).
The HPCs used in this paper were KLS cells, in which HSCs were highly enriched [33,34]. For cell
surface phenotyping, cells were incubated with normal rat IgG (Sigma, St. Louis, MO, USA) and
then fluorescence- or biotin-conjugated antibodies on ice for 20 min. If necessary, cells were further
incubated with PE-streptavidin after washing with staining medium (Hanks’ Balanced Salt solution
(HBSS) with 2% FCS and 0.02% NaN3). FACS analysis was performed using a FACSVantage with the
DiVa option equipped with 488-nm argon, 599-nm dye, and 408-nm krypton lasers (BD Bioscience
Flow Cytometry Systems) at the FACS facility of Duke University Comprehensive Cancer Center.
A FACSAriaIII at the FACS facility of Toho University School of Medicine was also used for cell sorting.
In addition, an LSRFortessa X-20 (BD Bioscience) was used for analyses. Data were analyzed with
FlowJo software (BD Bioscience). Dead cells were excluded from analyses and sorting as cells showing
positive staining with propidium iodide or 7-AAD.
4.6. Immunoblotting
CTLL-2 and its derivatives were cultured in complete medium without IL-2 for 6 h. These
factor-starved cells were stimulated with a saturating amount of IL-7 (100 ng/mL) for the indicated
times (Figure 4) at 37 ◦C. Cells were centrifuged and solubilized with lysis buffer (1% Triton X-100,
50 mM Tris-Cl, 300 mM NaCl, and 5 mM ethylenediaminetetraacetic acid) with protease inhibitor
cocktail and phosphatase inhibitor cocktail (Sigma). After centrifugation, cell lysates were subjected
to sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrophoretically transferred to
Immobilon-FL membranes (Millipore, Burlington, MA, USA). After blocking with 3% bovine serum
albumin (BSA) in TBS-T (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH = 7.5), membranes
were incubated with anti-phospho-STAT5 (Tyr694) antibodies (Cell Signaling Technology, Danvers,
MA, USA) in 1% BSA in TBS-T. After washing, membranes were further incubated with Alexa Fluor
680-conjugated anti-rabbit immunoglobulin (Molecular Probes, Eugene, OR, USA). Membranes were
analyzed using an Odyssey infrared imaging system (LI-COR, Lincoln, NE, USA).
4.7. In Vitro and In Vivo Differentiation Assays
In vitro culture of HPCs was performed as described previously [28]. In brief, after retroviral
infection, HPCs were cultured on OP9 cells in the presence of IL-7, Flt3 ligand, and SCF for 6 days.
In vivo injections were performed as described in Reference [28] as well. In the experiment shown in
Figure 3, HPCs were purified from IL-7Rα−/− mice (CD45.2) and were intravenously injected into
400 rad-irradiated RAG2−/− (CD45.1) mice. For the investigation shown in Figure 5, HPCs were
purified from C57Bl/6 mice (CD45.2) and intravenously injected into 400 rad-irradiated RAG2−/−
mice (CD45.1).
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Abstract: Antibody Secreting Cells (ASCs) are a fundamental component of humoral immunity,
however, deregulated or excessive antibody production contributes to the pathology of autoimmune
diseases, while transformation of ASCs results in the malignancy Multiple Myeloma (MM).
Despite substantial recent improvements in treating these conditions, there is as yet no widely
used ASC-specific therapeutic approach, highlighting a critical need to identify novel methods of
targeting normal and malignant ASCs. Surface molecules specifically expressed by the target cell
population represent ideal candidates for a monoclonal antibody-based therapy. By interrogating the
ASC gene signature that we previously defined we identified three surface proteins, Plpp5, Clptm1l
and Itm2c, which represent potential targets for novel MM treatments. Plpp5, Clptm1l and Itm2c are
highly and selectively expressed by mouse and human ASCs as well as MM cells. To investigate
the function of these proteins within the humoral immune system we have generated three novel
mouse strains, each carrying a loss-of-function mutation in either Plpp5, Clptm1l or Itm2c. Through
analysis of these novel strains, we have shown that Plpp5, Clptm1l and Itm2c are dispensable for the
development, maturation and differentiation of B-lymphocytes, and for the production of antibodies
by ASCs. As adult mice lacking either protein showed no apparent disease phenotypes, it is likely
that targeting these molecules on ASCs will have minimal on-target adverse effects.
Keywords: plasma cell; antibody; CLPTM1L; ITM2C; PLPP5; membrane protein
1. Introduction
The differentiation of mature B cells into Antibody Secreting Cells (ASCs) is an essential part of the
adaptive immune response and underlies virtually all current vaccination strategies. The antibodies
that these cells produce are important for the elimination of infecting pathogens and the persistent
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secretion of these antibodies after pathogen clearance provides long-term protection against re-infection.
However, the generation of self-reactive antibodies is the driver of many autoimmune diseases,
including Systemic Lupus Erythematosus and Sjörgrens Syndrome and we currently lack effective
methods of targeting the long-lived ASC population [1]. Furthermore, Multiple Myeloma (MM)
is an ASC malignancy that constitutes approximately 10% of all hematological malignancies [2].
MM derives from the clonal expansion of a transformed post germinal center plasma cell, leading
to bone marrow plasmacytosis and production of a monoclonal immunoglobulin. In addition to
the consequences of effacement of normal bone marrow hematopoiesis resulting in anemia and
other cytopenias, patients with MM develop specific end-organ sequale including renal failure,
hypercalcemia and bone lesions [3]. Despite recent advances in treatment for this disease, through the
use of proteasome inhibitors and immunomodulatory drugs, MM remains incurable and the median
survival from diagnosis is only 5–6 years [2]. Recently, monoclonal antibody (mAb)-based therapies
have been at the forefront of novel treatments for MM.
mAb-based immunotherapies are a highly specific and effective method of targeting a given
cell type for depletion. The power of this therapy in the treatment of hematological cancers was
first demonstrated by Rituximab, directed against CD20, a cell surface protein that is expressed on
mature B cells, however, Rituximab is ineffective against MM and ASCs, as they no longer express
CD20 [4,5]. There are several mAb therapies targeting MM cells that are currently in clinical use
including Elotuzumab, and Daratumumab, which target Signaling lymphocytic activation molecule F7
(SLAMF7) [6,7] and CD38 [8], respectively. Unfortunately, the development of clones resistant to these
therapies ultimately means that cancer regrowth is inevitable. Developing new targeted therapies for
MM to use in combination with existing ones increases the likelihood that all clones could be targeted
during treatment and would allow for more complete clearance of the cancer.
To increase our understanding of ASC biology and to enable us to identify novel therapeutic
strategies to target pathogenic ASC, including MM, we have previously examined the transcriptional
changes that occur during B cell differentiation in the mouse [9]. This study allowed us to define
a robust ASC gene signature, a collection of genes consistently upregulated during the process of
terminal differentiation. It is highly likely that this signature contains surface molecules, which are
selectively expressed on ASCs and will consequently be suitable targets for an ASC directed
immunotherapy. In agreement with this conclusion, all the current targets of mAb therapy for MM are
found within the ASC gene signature, however, there is also a large collection of genes whose function
remains either undetermined or that had not previously been associated with ASCs. We believe that
some of these genes will present potential novel ways of targeting ASCs and MM.
We have identified three genes within the ASC gene signature, phospholipid phosphatase 5
(Plpp5), cleft-lip and palate transmembrane protein 1-like (Clptm1l) and integral membrane protein
type 2 C (Itm2c), that are candidates for a mAb-based therapy to target pathogenic plasma cells.
All three proteins display surface expression, and their highly conserved human homologues are
expressed in both healthy ASCs and in MM cells. To identify possible side-effects of targeting these
three proteins, we generated three novel stains of mice, each carrying a loss-of-function mutation in
one of the three candidate genes. This work details the first analysis of Plpp5, Clptm1l or Itm2c function
within immune cells.
2. Results
2.1. Identification of Candidate Cell Surface Proteins in Anibody Secreting Cells
We have previously generated gene expression profiles for mature B cells and ASC populations
and identified a subset of genes, termed the ASC gene signature, which are upregulated during the
process of B cell terminal differentiation [9]. From this signature, we searched the current literature
for proteins with evidence of surface localization, resulting in a shortened list of 39 genes encoding
membrane spanning proteins for which there is some evidence for cell surface localization (Figure 1A).
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In addition to the established markers of plasma cells, including Sdc1 (Cd138) and Slamf7, there were
many genes with no known association with ASC biology, thus representing potential novel targets
for an ASC specific therapy. From this shortened list we selected three genes for further investigation,
Plpp5, Clptm1l and Itm2c. All three of these genes are poorly characterized and currently have no
published association with any immune cell type. We next interrogated the Immgen Consortium
database (www.immgen.org) to examine the expression of these three genes across a range of immune
cell populations (Figure 1B) [10]. Plpp5 and Clptm1l displayed high expression almost exclusively in
ASC populations, while Itm2c was also highly expressed in dendritic cells. The selective expression of
these genes suggests that they are candidates for a possible ASC-specific therapy.
Figure 1. Identification of genes encoding novel surface proteins in mouse ASCs. (A) Expression profiles
of genes within the ASC gene signature that encode transmembrane proteins that are either known or
predicted to be expressed on the plasma membrane. The expression of five additional genes encoding cell
surface proteins expressed in B cells, but not plasma cells is shown for comparison. The positions of Plpp5,
Clptm1l and Itm2c are highlighted in red. Expression is represented as a Z-score as defined by the legend;
(B) expression of Plpp5, Clptm1l and Itm2c in selected mouse immune cell populations. Data obtained
from the Immgen Consortium. Expression value normalized by DEseq2. Immgen nomenclature: BM,
bone marrow; Sp, splenic; PC, peritoneal cavity; Lu, lung; LTHSC.34+, CD34+ long-term hematopoietic
stem cell; proB.CLP, common lymphoid progenitor; proB.FrA, pre-pro-B cell; proB.FrBC, pro-B cell;
B.Fo, Follicular B cell; B.MZ, MZ B cell; B.mem, memory B cell; B.GC.CC, GC centrocyte; B.GC.CB, GC
centroblast; B.PB., Plasmablast; B.PC, Plasma cell; T.4.Nve, naïve CD4+ T cell; T.8.Nve, naïve CD8+ T cell;
Treg.4.25hi, CD25hi Treg; NK.27+11b−, CD27+ Cd11b− NK cell; DC.8+, CD8+ Dendritic Cell (DC); DC.4+,
CD4+ DC; DC.pDC, plasmacytoid DC; GN, neutrophil; MF.Alv, alveolar macrophage.
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2.2. Plpp5, Clptm1l and Itm2c Are Highly Conserved between Mice and Humans
Having identified Plpp5, Clptm1l and Itm2c as candidate ASC markers in the mouse, we next
examined whether their sequences and expression patterns were conserved in humans. We performed
pairwise sequence analysis of the mouse and human amino acid sequences for each of PLPP5,
CLPTM1L and ITM2C, and found that they have sequence identity of 87.9%, 92.8%, and 92.9%
respectively (Figure 2A–C). To determine whether PLPP5, CLPTM1L and ITM2C have similar
expression patterns in mice and humans, we examined the expression of each gene in human B cell and
ASC populations (Figure 2D). The pattern of expression of CLPTM1L and ITM2C during the terminal
differentiation of both mouse and human B cells was very similar; low expression in B cell subsets,
which increased markedly in ASC populations. CLPTM1L and ITM2C displayed the same pattern of
expression as SLC3A2, SDC1 and SLAMF7, which are current targets of ASC-directed immunotherapies.
The expression of PLPP5 differed between mice and humans, with expression in both naïve B cells
and ASCs in humans while expression in mice was exclusive to ASCs. To determine whether the
expression of these genes within human immune cell populations mirrored expression in the mouse
we interrogated the BLUEPRINT consortium RNAseq database (http://www.blueprint-epigenome.eu)
and observed that PLPP5, CLPTM1L and ITM2C expression was similarly restricted to B cells and
ASCs (Figure 2E) [11]. The high degree of sequence identity and similar expression patterns suggests
that it is likely that these genes serve a similar function in both mice and humans ASCs.
Figure 2. Cont.
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Figure 2. Expression of the human homologues in ASCs. Alignment of mouse and human amino acid
sequences for (A) PLPP5, (B) ITM2C, and (C) CLPTM1L. Symbols indicate conserved (I), highly similar
(:), and similar (.) residues. (D) RNAseq showing the expression of PLPP5, CLPTM1L, ITM2C and
three established clinical candidates SLC3A2, SDC1 and SLAMF7 in purified human B cell and ASC
populations. Data are the mean reads per kilobase per million reads (RPKM) ± SD from 3–5 donors
each. Cord naïve B cell (CD19+ CD20+ HLA-DR+ IgG−), blood naïve B cell (CD19+ IgD+ CD27−), tonsil
naïve B cell (CD19+ CD38− CD27−), tonsil germinal center (GCB) B cell (CD19+ CD38+ CD27+), blood
memory B cell (CD19+ IgD− CD27+ CD38−/low), tonsil plasma cell/plasmablast (PC, CD19+ CD27++
CD38++), bone marrow plasma cell (BM PC, CD138++ CD38+). (E) RNAseq showing the expression of
PLPP5, CLPTM1L and ITM2C in human immune cell populations. Data obtained from the BLUEPRINT
consortium (www.blueprint-epigenome.eu). Data are the mean fragments per kilobase per million
reads (FPKM) ± SD. Blood naïve B cell (n = 5, CD19+ CD20+ CD23+ CD38low), tonsil GCB cell (n = 3,
CD19+ CD20+ CD38medium), tonsil PC (n = 21, CD20medium CD38++), blood eosinophil (n = 2, CD66+
CD16−), blood erythroblast (n = 8, CD36+ CD71+ CD235a+), blood neutrophil (n = 16, CD66b+ CD16+),
cultured macrophages (n = 18) and conventional dendritic cell cDC (n = 3), blood CD4+ T cell (n = 10,
CD3+ CD4+ CD45RA+), blood CD8+ T cell (n = 2, CD3+ CD8+ CD45RA+), blood natural killer (NK)
cell (n = 4, CD3− CD56+ CD16dim).
2.3. Confirmation of Plpp5, Clptm1l and Itm2c Surface Expression and Prediction of Membrane Topology
Since there has been only limited analysis of the protein products of PLPP5, CLPTM1L and
ITM2C we conducted an in silico analysis with several tools (Phobius, Spoctopus, TMHMM2 and
TMMOD [12–15] to predict putative signal peptides, trans-membrane (TM) domains and membrane
topology. The majority of the tools predicted murine and human CLPTM1L and PLPP5 being type
IIIb membrane proteins, lacking signal peptides with six putative TM domains. Murine and human
ITM2C was predicted to be a type II transmembrane protein without a signal peptide and one
putative TM domain. To confirm surface expression and orientation we generated amino- and/or
carboxy-terminal tagged expression constructs for each protein. Flow cytometric analysis of transiently
expressed CLPTM1L and PLPP5, using tag-specific antibodies showed only surface staining of the
N-terminal FLAG tag of PLPP5 (Figure 3A). However, both tags were detected in an intra-cellular stain
(Figure 3B). Using anti-CLPTM1L or PLPP5 specific polyclonal antibodies that were raised against
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peptides localized within the central to N-terminal region, we detected surface expression of both
transmembrane proteins (Figure 3C).
Carboxy-terminal-tagged ITM2C was detected on the cell surface of transiently transfected
FS-293F cells by surface staining with a tag-specific antibody and an ITM2C specific antibody
(Figure 3D). However, we observed about 30% of tag-positive cells in the tag-specific surface stain,
but almost 60% of ITM2C positive cells using the specific antibody. This discrepancy is likely due to
protein cleavage of the carboxy-terminal end of ITM2C [16]. The surface staining of human CLPTM1L
and ITM2C fits well with the predicted topology (Figure 3E,F) and a previous study [17], demonstrating
that these proteins are expressed on the cell surface. The cell surface detection of the N-terminal tag of
PLPP5 suggests that the predicted trans-membrane domain at the N-terminal end is not utilized and
that a 57 amino acid N-terminal region that contains the polyclonal antibody-binding site is exposed at
the cell surface (Figure 3G).
Figure 3. Cell surface expression of human PLPP5, CLPTM1L and ITM2C. FS-293F cells were transiently
transfected with human CLPTM1L or PLPP5 expression constructs with N-terminal FLAG tags and
C-terminal HA tags. (A) Cell surface or (B) Intra-cellular flow cytometric staining with anti-FLAG
and anti-HA antibodies; (C) cell surface staining of transduced FS-293F cells with Rabbit (Rb) IgG
control, Rb anti-CLPTM1L polyclonal (p)Ab and Rb anti-PLPP5 pAb (grey histograms: un-transfected
cells, black lines: FLAG-Human-CLPTM1L-HA cells, dashed line: FLAG-Human-PLPP5-HA cells);
(D) FS-293F cells were transiently transfected with a human ITM2C expression constructs with or
without C-terminal FLAG tags. Flow cytometric analysis of surface anti-FLAG and Rb anti-ITM2C
pAb staining (grey histograms: un-transfected cells, black lines: Human-ITM2C transfected cells);
(E–G) predicted domain structure and cell surface localization of (E) CLPTM1L, (F) ITM2C and
(G) PLPP5. (dark-grey boxes: putative TM-domains, hatched boxes: peptides used for pAb generation,
black triangle Furin cleavage site).
2.4. PLPP5, CLPTM1L and ITM2C Are Highly Expressed in Multiple Myeloma
To determine whether PLPP5, CLPTM1L and ITM2C were potential targets in MM cells, we first
analyzed the expression of each gene in a range of MM cells lines using qPCR (Figure 4A). The expression
of PLPP5, CLPTM1L and ITM2C varied between different established human myeloma cell lines,
however, all cell lines examined had detectable expression of at least one of these genes of interest.
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We next determined the expression of PLPP5, CLPTM1L, ITM2C and SLAMF7 (as a positive control) in
primary MM and plasma cell (PC) samples (Figure 4B). All four genes showed significantly increased
expression in MM samples compared to PCs. To confirm that there was a corresponding increase in
protein expression we examined the expression of PLPP5 in a selection of MM cell lines (Figure 4C).
In agreement with our qPCR data, all examined cell lines showed cell surface expression of PLPP5.
 
Figure 4. PLPP5, CLPTM1L and ITM2C are expressed in human Multiple Myeloma. (A) Expression
of PLPP5, CLPTM1L, and ITM2C in human myeloma cell lines and primary human CD19+ B cells as
determined by qPCR. Expression data was normalized by the house-keeping genes GAPDH, GPBP1
and TPT1. Bars show median normalized expression of experimental replicates (n = 3 myeloma cell
lines, n = 4 for CD19+ primary peripheral B cells); (B) expression of PLPP5, CLPTM1L, ITM2C and
SLAMF7 in primary bone marrow MM samples (n = 83), sorted plasma cells (n = 12), peripheral blood B
cells (n = 4) and T cells (n = 4). Expression data was normalized as in (A). Bars show median expression
and interquartile range. One-way ANOVA with Tukey’s multiple comparison test on log transformed
data from MM, plasma cells and B cells; * (p < 0.05), *** (p < 0.001), **** (p < 0.0001). (C) cell surface
expression of PLPP5 in human myeloma cell lines was determined by flow cytometry. Grey histograms:
unstained cells, black lines: anti-rabbit (Rb) IgG control, red lines: Rb anti-PLPP5; (D) expression
of CLPTM1L in human tonsil, spleen and bone marrow trephine from patients with non-Hodgkin’s
Lymphoma (labeled, Bone marrow) or multiple myeloma. Spleen image was obtained from the Human
Protein Atlas v18 (www.proteinatlas.org/ENSG00000049656-CLPTM1L/tissue/spleen#img). Images
were captured at 100× magnification.
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Finally, we used a commercially available anti-CLPTM1L antibody to perform immunohistochemistry
on human tonsil and on bone marrow from patients with either non-Hodgkin’s lymphoma (non-involved
bone marrow) or MM (Figure 4D). Staining revealed that there were a small number of CLPTM1L-
positive cells in the bone marrow and in the tonsil surrounding a follicle, which was the expected
location and prevalence for ASCs. Our staining was in agreement with images obtained from the
Human Protein Atlas [18], which showed a small number of anti-CLPTM1L-labeled cells in human
spleen. Staining of bone marrow from a patient with MM revealed widespread CLPTM1L-positive
cells, further supporting our qRNA analysis showing high CLPTM1L expression in MM. Together,
these results confirm that PLPP5, CLPTM1L and ITM2C are expressed in human ASCs and MM, and are
therefore candidates for ASC-directed immunotherapy.
2.5. Generation of Plpp5, Clptm1l and Itm2c Knock-Out Mouse Models
As noted above PLPP5, CLPTM1L and ITM2C are poorly characterized proteins, whose functions
are unknown, although mutation in CLPTM1L has been associated with several human cancers
(see Discussion). To interrogate the roles of these proteins within ASCs we generated knock-out mouse
strains, each carrying loss-of-function mutations in either Plpp5, Clptm1l or Itm2c.
The Plpp5 deficient mice were generated using embryonic stem (ES) cells obtained from the KOMP
Repository (Figure 5A). The ES cells carried an IRES-LacZ cassette replacing exons 2–6 of the Plpp5
gene. The ES cells were injected into day 3.5 blastocysts to generate chimeric mice, which were then
bred to generate heterozygous and ultimately homozygous progeny. PCR amplification using primer
pairs that spanned the insertion site confirmed the targeting vector was inserted correctly (Figure 5B).
To demonstrate that the insertion of the targeting vector disrupted the Plpp5 locus, we measured
the abundance of Plpp5 mRNA transcripts in lipopolysaccharide (LPS) stimulated wild type (WT),
Plpp5+/− and Plpp5−/− B cell cultures (Figure 5C). This analysis confirmed that there was no detectable
Plpp5 mRNA in the culture from Plpp5−/− mice.
We generated Clptm1l mutant mice using ES cells obtained from the EUCOMM Consortium
(Figure 5D). The construction of the targeting vector meant that the inactivation of Clptm1l could
be performed conditionally (“flox” allele) or constitutively (“del” allele). As before, the ES cells
were used to generate chimeric mice. These mice were crossed to Flp recombinase-expressing mice
to excise the Neo-LacZ selection cassette and produce the functional Clptm1lflox allele. Clptm1lflox/+
mice were crossed to a strain expressing Cre recombinase in the germline to generate the Clptm1ldel
allele. The excision of exon three creates a frame shift mutation with a stop codon immediately
downstream. The correct structure of each allele was confirmed by PCR (Figure 5E). WT, Clptm1ldel/+
and Clptm1ldel/del B cells were stimulated with LPS and the abundance of Clptm1l mRNA in each
culture was measured to confirm the absence of Clptm1l expression in del/del mice (Figure 5F).
Curiously, we observed the abundance of Clptm1l mRNA was greater in the Clptm1ldel/+ cells than in
the WT cell (Figure 5F). To investigate a potential consequence of this finding, our subsequent studies
also included Clptm1ldel/+ mice.
We generated an Itm2c null mouse de novo using CRISPR/Cas9-mediated gene deletion. Guide
RNAs were designed to target intronic sequences flanking exons 2 and 5, resulting in the deletion
of the intervening exons (Figure 5G). This region was amplified by PCR to confirm that the desired
resection event had occurred (Figure 5H). As before, we stimulated naïve B cells from WT, Itm2c+/−
and Itm2c−/− mice with LPS and measured the abundance of Itm2c mRNA in each culture (Figure 5I).
Itm2c transcripts were not detectable in the cultures produced from Itm2c−/− cells.
Plpp5−/−, and Itm2c−/− mice were viable and showed no overt physical defects or disease
phenotype. Plpp5−/− and Itm2c−/− pups were born at the expected frequencies from +/− × +/−
matings, suggesting that the loss of either gene did not have a detrimental impact on viability. In contrast,
Clptm1ldel/del mice were born at a significantly lower than expected frequency from heterozygous
mating pairs (Table 1). Additionally, fewer than 15% of the Clptm1ldel/del pups that were born, survived
past day 2 (Table 2). Curiously, those Clptm1ldel/del pups that survived the neo-natal period appeared
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healthy and indistinguishable from their littermates. Together, this suggests that Clptm1l has a function
that is important for the survival of embryonic and neonatal mice, which warrants further investigation
in the future. Both male and female Plpp5−/−, Clptm1ldel/del and Itm2c−/− mice were able to produce
viable pups, suggesting that none of these genes play an important role in fertility.
Figure 5. Generation of Plpp5, Clptm1l and Itm2c deficient mouse models. (A) Strategy for the generation
of the non-functional (−) Plpp5 allele; (B) gel electrophoresis of PCR products amplified from WT,
Plpp5+/− and Plpp5−/− pups. –ve, negative control water only; (C) mRNA expression of Plpp5 in
WT, Plpp5+/− and Plpp5−/− B cell cultures following 4 days of LPS stimulation; (D) strategy for the
generation of the conditional (flox) and non-functional (del) Clptm1l alleles; (E) gel electrophoresis of
PCR products amplified from WT, Clptm1lflox/+, Clptm1ldel/+, Clptm1lflox/del and Clptm1ldel/del pups;
(F) mRNA expression of Clptm1l in WT, Clptm1ldel/+ and Clptm1ldel/del B cell cultures following 4 days
of LPS stimulation; (G) strategy for the generation of the non-functional (−) Itm2c allele using CRISPR.
The location of the small guide RNAs are indicated; (H) gel electrophoresis of PCR products amplified
from WT, Itm2c+/− and Itm2c−/− pups; (I) mRNA expression of Itm2c in WT, Itm2c+/− and Itm2c−/−
B cell cultures following 4 days of LPS stimulation. All mRNA expression was determined using
qRT-PCR and normalized to Hprt expression. Data are the mean ± SD of technical triplicates. Genomic
structures in (A,D,G) indicate the numbered exons of each gene (gray boxes) and the mutant alleles
generated. The targeting constructs for Plpp5 and Clptm1l are shown below the WT genes. The positions
of genotyping primers, LoxP and Frt sites are indicated.
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Table 1. Genotypes of offspring from Clptm1ldel/+ with Clptm1ldel/+ mating.
Genotype: Clptm1l+/+ Clptm1ldel/+ Clptm1ldel/del
Expected 13.25 26.5 13.25
Observed 21 29 3 *
* p = 0.00175.
Table 2. Survival of Clptm1ldel/del pups.
Total Number Born Number Survived Past Day 2
37 5
2.6. Characterization of Plpp5, Clptm1l and Itm2c Deficient Mice
RNA-seq data from the Immgen consortium showed that Plpp5, Clptm1l and Itm2c were not highly
expressed in hematopoietic stem cells, lymphoid progenitors or developing B cell populations (Figure 1B),
making it unlikely that the loss of either protein would impact B cell development and maturation.
To ensure that B cell development was normal we analyzed B cell maturation stages in the spleen and
bone marrow of each mutant strain. As expected, we did not observe differences in the frequency or
number of precursor (B220+IgM−), immature (B220loIgM+), or recirculating mature (B220hiIgM+) B cells in
the bone marrow of WT mice compared with Plpp5−/−, Clptm1ldel/del or Itm2c−/− mice (Supplementary
Figure S1A,B). Furthermore, we did not detect any changes in the frequency or total number or naïve
mature (B220+IgDhiIgM+) or immature (B220+IgDloIgMhi) B cell in the spleens of Plpp5, Clptm1l or Itm2c
deficient mice compared to WT mice (Supplementary Figure S1C,D).
To determine whether the loss of Plpp5, Clptm1l or Itm2c influenced the generation of ASCs
in vivo, we analyzed the steady state ASC populations in both the BM and spleen in each of the mutant
mouse strains. We crossed each strain to Blimp-1-GFP mice [19], which allowed us to differentiate
between the PC and the plasmablast (PB) populations in the spleen. We did not observe any marked
difference in the frequency of BM PCs (CD138+Blimp-1-GFP+), Spl PCs (CD138+Blimp-1-GFPhi) or Spl
PBs (CD138+Blimp-1-GFPint) between WT and the Plpp5−/−, Clptm1ldel/+, Clptm1ldel/del or Itm2c−/−
mice. (Figure 6A,B). We also did not detect a significant difference in the serum concentrations of IgM,
IgG1, IgG2b, IgG2c, IgG3 or IgA in the mice deficient in Plpp5, Clptm1l or Itm2c when compared with
WT controls (Figure 6C).
To determine whether the loss of Plpp5, Clptm1l or Itm2c would alter the response to
stimulation, we isolated naïve B cells from mice of each genotype and cultured them under multiple
T cell-dependent (CD40 Ligand (CD40L) + Interleukin (IL)-4 ± IL-5), T cell-independent (LPS) or
mixed (LPS + IL-4) stimulation conditions. We did not observe any difference in the differentiation
of B cells to ASCs from any of the mutant mice under any of the conditions tested (Supplementary
Figure S2A). Additionally, there was no observable defect in the ability of Plpp5, Clptm1l or Itm2c
deficient B cells to undergo immunoglobulin class-switch recombination under any of the tested
stimulation conditions (Supplementary Figure S2B). Interestingly, we observed a significant increase
in the proportion of Clptm1ldel/+ B cells that had undergone class-switch recombination following
T cell-dependent stimulation when compared to WT cells. We next used retroviral transduction to
ectopically express each gene in activated B cells and found that this premature expression did not
impact on the efficiency of ASC differentiation or class-switch recombination in LPS stimulated B cells
(Supplementary Figure S2C,D).
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Figure 6. Characterization of ASC populations in Plpp5−/−, Clptm1ldel/+, Clptm1ldel/del and Itm2c−/−
mice. (A) Frequency and; (B) total cell number of bone marrow plasma cells (BMPC), splenic plasma
cells (Spl PC) and splenic plasmablasts (Spl PB) in Plpp5−/−, Clptm1ldel/+, Clptm1ldel/del, Itm2c−/− and
age-matched WT mice. Results are combined from two (Clptm1l) or three (Plpp5, Itm2c) independent
experiments. Each dot represents a single mouse, horizontal lines show the means ± SEM; (C) serum
concentration of immunoglobulin isotypes in Plpp5−/−, Clptm1ldel/+, Clptm1ldel/del, Itm2c−/− and
age- and sex-matched WT mice as determined by ELISA. Data are the mean of six samples from two
independent experiments ± SEM. Statistical significance was analyzed using unpaired t-test, correcting
for multiple comparisons. n.s., not significant (p > 0.05).
Finally, we examined the ability of Plpp5, Clptm1l and Itm2c deficient mice to form an antigen
specific response following immunization. We immunized Plpp5−/−, Clptm1ldel/del, Itm2c−/−
and age-matched WT controls with 4(hydroxy-3-nitrophenyl) acetyl coupled to Keyhole Limpet
Hemocyanin (NP-KLH) and determined the frequency of antigen-specific ASCs at multiple timepoints
post-immunization (Figure 7). No significant difference was observed in the number of NP-specific
ASCs in Plpp5−/− and Itm2c−/− mice when compared to WT controls at any examined timepoint.
Unfortunately, due to the survival disadvantage in the Clptm1ldel/del mice we were unable to obtain
enough age-matched Clptm1ldel/del mice to do multiple immunization timepoints. However, NP-specific
ASCs were detectable in Clptm1ldel/del mice 3 months post-immunization, indicating that Clptm1l
deficient mice are capable of mounting a long-lived response to immunization. Together, these data
demonstrate that Plpp5, Clptm1l and Itm2c are dispensable for the differentiation of B cells into ASCs,
both in vivo and in vitro.
131
Int. J. Mol. Sci. 2018, 19, 2161
 
Figure 7. Characterization of the antigen-specific antibody response of Plpp5−/− Clptm1ldel/del and
Itm2c−/− mice. Mice were immunized intraperitoneally with NP-KLH in alum and, at the indicated
time post-immunization, the number of NP20-specific IgG1+ ASCs in the (A) spleen and (B) BM
was determined by ELISpot. Plpp5 data are combined from three independent experiments at each
time point where n = 3–6. Itm2c data are combined from 1 (day (d) 7) or 2 (d14, d28, 3 months (m))
independent experiments where n = 3–4. Clptm1l data are from 1 experiment where n = 4. Data are
the mean ±SEM. Statistical significance was analyzed using unpaired t-test, correcting for multiple
comparisons. n.s., not significant (p > 0.05).
3. Discussion
Despite recent improvements in the treatment of MM, it remains an incurable disease. The use of
mAb therapies in the treatment of MM has been promising, with recent approvals for anti-SLAMF7 and
anti-CD38 mAbs [20,21]. However, the presence of resistant MM cells means that patients often relapse.
This highlights the continuing need for novel methods to target MM cells as combination therapies
that kill MM cells through multiple approaches increases the likelihood that complete clearance of
the cancer can be achieved. Surface molecules present exciting candidates for immunotherapies as
they allow for the selective targeting of a cell population either through mAbs or, more recently,
through chimeric antigen receptor T cells, which combine the specificity of mAbs with the cytotoxic
capabilities of conventional CD8+ T cells [20]. Therefore, we chose to focus on surface proteins that
are expressed in ASCs and consequently MM. In this study we have examined three proteins, PLPP5,
CLPTM1L and ITM2C, which are ASC surface proteins that we believe present promising candidates
for an ASC-directed immunotherapy, but whose biological functions were largely unknown.
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PLPP5 (also known as PPAPDC1B and HTPAP) encodes a lipid phosphatase that has been shown
to be present on the plasma membrane and within the cytoplasm of PLPP5 overexpressing human
hepatocellular carcinoma cell lines [22,23]. Although the function of PLPP5 has not been determined,
it has been proposed to have an oncogenic role in breast cancer. PLPP5 is estimated to be amplified in
10–15% of ductal breast carcinomas, and its knock-down in breast cancer cell lines causes an increase
in apoptosis [24,25]. Similar observations have also been reported in pancreatic adenocarcinoma and
small-cell lung cancer cell lines [25]. Within the mouse immune system we found that Plpp5 expression
was highly restricted to ASCs. Although its expression in ASCs and MM cell was conserved in human
samples, we also observed considerable PLPP5 expression in naïve, but not germinal center or memory
B cells, suggesting that any mAb therapy based on PLPP5-binding and depletion would also target
naïve B cells. As B cell depletion using Rituximab has been successfully used for many years in
lymphoma [26] and some autoimmune contexts [27], the expression of PLPP5 in B cells is not likely to
be an insurmountable obstacle for an anti-PLPP5-based therapy for MM or Ab mediated autoimmunity.
CLPTM1L is a close homologue of Cleft lip and palate transmembrane protein 1 (CLPTM1)
and is predicted to contain six transmembrane domains [17]. There is conflicting data regarding
the subcellular localization of CLPTM1L, with previous studies observing it exclusively in the
mitochondria [28] or endoplasmic reticulum [29], while the data presented here and another recent
study [17], have found evidence for localization to the plasma membrane. It is possible that the location
of CLPTM1L is dependent on cell context or that aberrant localization is a result of the high levels
of expression seen in the examined cancer cell lines. Mutations in CLPTM1L have been identified as
risk factors in a range of cancers, including lung [30,31], pancreatic [32], colorectal [33], glioma [34]
and testicular germ cell cancer [35], and the expression of CLPTM1L is significantly increased in
cancerous cells when compared to healthy adjacent tissues [29,30,36]. This increase in expression in
malignant cells was also evident in our analysis of primary MM samples compared with plasma cells.
The knock-down of CLPTM1L with siRNA or targeting with an anti-CLPTM1L antibody increased
the sensitivity of CLPTM1L overexpressing cancer cells to killing through genotoxic stress inducing
agents [17,30]. Together, these observations suggest that targeting CLPTM1L in MM could potentially
increase sensitivity to other treatments, however, this remains to be tested.
Curiously, we observed that Clptm1ldel/del pups appeared to not only be born at lower than
anticipated frequencies, but to have an initial survival disadvantage compared to their Clptm1l+/+
and Clptm1ldel/+ littermates. Clptm1ldel/del mice that survived past two days old showed no sign of
physical defect or fitness disadvantage, suggesting that Clptm1l plays an important role in early life
but is dispensable later on. Future investigation into the role of Clptm1l in adult mice should utilize
the conditional strain that we have generated to avoid the complication of the poor neonatal survival
that we have observed.
ITM2C is a member of the type 2 integral transmembrane family that has previously been reported
to be localized to the plasma membrane [37], Golgi apparatus [38] and within lysosomes [39]. Previous
work has focused on its role within the brain, as it is highly expressed in both the embryonic and adult
mouse brain, as well as in adult human brain tissue [40,41]. Within the immune system, we observed
strong expression of ITM2C in mouse and human ASCs, but also expression in dendritic cells and
some macrophage populations. Whether these non-ASC expression domains will impact on the utility
of any anti-ITM2C mAb therapy remains to be determined, but it is noteworthy that the two clinically
approved mAb for MM, Daratumumab (CD38) and Elotuzumab (SLAMF7) target antigens expressed
on ASC and multiple other cell types.
ITM2C is thought to have a role in the inhibition of the β-amyloid protein processing pathway
based on the observations that it is capable of directly binding the β-amyloid precursor protein and
Itm2c expression is inversely correlated with β-amyloid peptide production [38,42]. Due to the high
expression of Itm2c within the embryonic mouse brain we were surprised to find that Itm2c−/−
pups were viable and showed no evidence of a fitness disadvantage when compared to littermates.
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Additionally, Itm2c is expressed in the testis during sexual maturation [43], however, Itm2c−/− male
mice were able to produce pups indicating that the loss of Itm2c does not influence fertility.
Despite the increase in expression of Plpp5, Clptm1l and Itm2c during B cell differentiation, we did
not identify any of these genes as being essential for either the generation of ASCs in steady state,
either in vitro or in vivo, or for the ability of ASCs to secrete antibody. The presence of long-lived
plasma cells in the spleen and bone marrow of all three KO mice suggests that these genes are also
not required for the long-term survival of ASCs, or for homing to and retention within the bone
marrow. This conclusion is supported by the presence of normal numbers of antigen-specific ASC
after a T-dependent immunization. Whether this is due to functional redundancy with related proteins
is at present unclear. However, it is noteworthy that the ITM2 family consists of three members
(a, b, c) that show around 40% amino acid identity [40] and similar expression domains in late B cells
(www.immgen.org) raising the possibility of redundancy between ITM2 family members.
This work describes the first investigation into the roles of PLPP5, CLPTM1L and ITM2C within
the immune system. Furthermore, this work details the first time mutant mouse strains of each gene
have been described and presents them as valuable tools for the investigation into the roles of these
genes within other cell populations of interest, particularly in the context of cancer. With their surface
localization and their high expression within both ASCs and MM samples, PLPP5. CLPTM1L and
ITM2C represent enticing candidates for novel immunotherapies to target these cell populations.
Adult mutant mice showed no apparent fitness defect or disease phenotype, which suggests that
targeting these molecules will have minimal on target side effects. The next stage in the investigation
of these proteins will be the generation of mAbs, first to allow for further investigation into the biology
of PLPP5. CLPTM1L and ITM2C and then to determine their potential for therapeutic use.
4. Materials and Methods
4.1. Mice
Mice were bred and maintained on a C57BL/6 background and housed in a specific pathogen
free facility. Plpp5 mutant mice were generated using Plpp5tm1(KOMP)Mbp embryonic stem (ES) cells
obtained from the KOMP Repository. Clptm1l mice were made using Clptm1ltm1a (EUCOMM)Hmgu ES
cells obtained from the EUCOMM Consortium. In the case of Itm2c, we originally obtained targeted
ES cells from EUCOMM (ID:69805, clones EDP0351_4_B07 and _F05). No germline transmission
occurred with the B07 ES cells, while the F05 ES cells contained a gene duplication at the Itm2c locus
and were thus not useful for to generate a loss-of-function allele. As an alternative, Itm2c mice were
generated in house using CRISPR/Cas9. Guide sequences were AACTGCTAAAGAGGGTGGTC
and GGTCGACATTCACTATAGTC. In the first generation, mice were generated that bore Itm2c
deletions with micro heterogeneities around the deletion endpoints. As founders, we chose to
mate a male and female that carried identical mutated sequences. Primers for genotyping were as
follows: Plpp5WT-F (GTCTTAGTGTTGGCAAGTAGCTATGGG), Plpp5WT-R (CCATCTGCTTGG
AGAAGAGTAAGCC), Plpp5KO-F (GCCTGTCAATCTTCCCCGTTTCCTCCCC), Plpp5KO-R
(GGTGAGAGGAGAATTCTGGAATCCATCC), ClptWT-F (TCCTATTCATCACCCTGTGCCAGG),
ClptWT-R (CCCACCTCTGTTAGAGCCTCAGACTAC), ClptDel-F (TCCTATTCATCACCCTGTGC
CAGG), ClptDel-R (CTGATGGCGAGCTCAGACCATAACTTCG), Itm2cWT-F (AAATTCGGGCTG
ATTGTTTG), Itm2cWT-R (CCTAAGAGCTCCTGGTGACG), Itm2cKO-F (TTCCCATGAACTCCTT
GGTC), Itm2cKO-R (GCGAGGCAAGTGAGGTAGAC). Blimp-1-GFP [19], Flp [44] and Cre [45]
recombinase expressing mice have been described previously. All animal experiments were conducted
in accordance with protocols approved by the Walter and Eliza Hall Institute Animal Ethics Committee
(2016.002, approved 31 March 2016).
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4.2. Bioinformatic Analysis
RNAseq data for mouse immune cells derives from (GSE60927) [9] and the Immunological
Genome Consortium database (www.immgen.org). RNA-seq from human hematopoietic cell
populations derives from the BLUEPRINT consortium (www.blueprint-epigenome.eu) and Fedele et al.
(unpublished). Pairwise sequence alignments between the mouse and human protein sequences were
performed using EMBOSS Needle [46]. In silico analysis of the protein structures used the Phobius [13],
Spoctopus [15], TMHMM2 [14] and TMMOD [12] tools.
4.3. Generation, Expression and Detection of Tagged Proteins
The coding sequence of the predominant isoform of human CLPTM1L (NP_110409) and PLPP5
(NP_001096029) were synthesized at GeneArt (Thermo Fisher, Waltham, MA, USA) inframe with a 5′
FLAG-tag coding sequence (DYKDDDDK) and 3′ a HA-tag coding-sequence (YPYDVPDYA). ITM2C
(NP_071862) coding sequence was synthesized with a 3′ FLAG-tag coding sequence. The coding
sequences were cloned into a pCDNA 3.1-based expression vector and transiently transfected into
FreeStyle 293-F (FS-293F) using 293fectin (Gibco, Thermo Fisher, Waltham, MA, USA) according to
manufacturer’s protocol. Expression was enhanced by adding Lucratone Lupin (Millipore-Sigma,
Burlington, MA, USA) at 0.5% v/v final concentration 18 h post-transfection. FS293-S cells were
cultured in Freestyle 293 Expression Media (Gibco). Cells were analyzed 48 h post-transfection.
For intra-cellular staining, cells were fixed and permeabilized using BDCytofix/Cytoperm system
according to the manufacturer’s guidelines (BD Biosciences, Franklin Lakes, NJ, USA). Cells were blocked
with FcR Blocking reagent (130-059-901, Miltenyi Biotec, Bergisch Gladbach, Germany) and stained
using the following antibodies: Mouse anti-HA-Alexa Fluro-488 mAb (2350, Cell Signaling Technology,
Danvers, MA, USA), Rabbit anti-FLAG polyclonal (p)Ab (2368, Cell Signaling Technology), Rabbit
anti-Human-CLPTM1L pAb (GTX116893, Genetex, Irvine, CA, USA), Rabbit anti Human-ITM2C pAb
(GTX116904, Genetex) and Rabbit anti-Human-PLPP5 (LS-B4624, LifeSpan BioSciences, Seattle, WA, USA).
Rabbit IgG isotype control (GTX35035, Genetex) was used in some experiments. Unconjugated rabbit pAb
were detected with secondary antibody anti-Rabbit IgG Alexa Flour 647 (4414, Cell Signaling Technology).
Cells were analyzed on FACSCanto (BD Biosciences).
4.4. Patient Samples
BM from MM patients (newly diagnosed, relapsed/refractory) or healthy donors was obtained
following written informed consent as per Alfred Hospital Human Ethics Committee-approved
protocol. Isolation of bone marrow mononuclear cells (BMMNC), determination of MM cell proportion
and isolation of CD138+ cells from MM cells and plasma cells from healthy donors was performed as
previously described [47]. Briefly, Ficoll Plaque Plus (GE Healthcare, Chicago, IL, USA) was utilized to
isolate BMMNC as per manufacturer’s guidelines. Red blood cells were removed using red blood cell
lysis buffer (10 mmol/L KHCO3, 150 mmol/L NH4Cl and 0.1 mmol/L EDTA, pH 8.0) for 5 min at 37 ◦C
followed by washing with sterile phosphate buffered saline (PBS). The proportion of MM or normal
plasma cells (CD38+CD45−CD138+) in BMMNC isolated from each patient was determined through
flow cytometric enumeration on a FACSCalibur Flow Cytometer (BD Biosciences). To isolate MM cells,
anti-CD138 MACS beads were employed using manufacturer’s guidelines (Miltenyi Biotec). CD138+
cells were selected through magnetic isolation using an MS-column (Miltenyi Biotec). For normal
BM, flow cytometry was performed to ensure that proportion of plasma cells fell within the normal
range (<3%). Normal plasma cells were isolated through the utilization of plasma cell isolation kit II
(Miltenyi Biotec). Purified cells were stored in TRIzol (Life Technologies, Thermo Fisher, Waltham,
MA, USA). Human B cells and T cell controls were purified from peripheral blood mononuclear
cells (PBMCs) derived from buffy coats using anti-CD19-MACS beads or anti-CD3-MACS beads
respectively. All samples were de-identified for this study.
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Protocols were approved by the Alfred Hospital Human Ethics Committee, Monash Health and
the Walter and Eliza Hall Institute Human Research Ethics Committees.
4.5. Flow Cytometry
4.5.1. Mouse
Single cell suspensions were labeled with the following mAbs: anti-CD138 (281-2), anti-B220
(RA3-6B2), anti-IgG1 (X56), all from BD Biosciences; anti-IgD (11–26c.2a) and anti-IgM (II/41),
both from eBioScience (Affymetrix, Santa Clara, CA, USA). Cells were analyzed on FACSCanto
Flow Cytometer (BD Biosciences).
4.5.2. Human
Human multiple myeloma cell lines were labeled with Rabbit anti-Human-PLPP5 pAb (LS-B4624,
LifeSpan BioSciences) or Rabbit IgG isotype control (GTX35035, Genetex). Unconjugated pAb was
detected with secondary antibody anti-Rabbit IgG Alexa Flour 647 (4414, Cell Signaling Technology).
Cells were analyzed on FACSCanto (BD Biosciences).
4.6. Multiple Myeloma Cell Lines
Human multiple myeloma cell lines were grown in RPMI supplemented with 10% FCS,
1% L-Glutamine, 1% HEPES, 1% non-essential amino acids, 1% Sodium pyruvate, 50 μM
β-mercaptoethanol. Recombinant Human IL-6 (R&D Systems, Minneapolis, MN, USA) was supplied
when necessary. 1 × 106 cells were harvested in experimental triplicates or duplicates over subsequent
passages for RNA purification.
4.7. Immunohistochemistry
Paraffin-embedded (de-identified) archival samples were de-waxed, and antigen retrieval was
performed (120 C under 20 psi pressure, 3 min, 1 mM EDTA, pH 9.0). Blocking was with 5% FCS in
PBS, 15 min. Primary rabbit anti-CLPTM1L antibody (HPA014791, Sigma-Aldrich, St. Louis, MO, USA)
was added at 1:100, incubated at RT for 15 min, washed with 5% FCS in PBS, then the secondary
antibody (goat anti-rabbit Ig-HRP, sc-2004, 1:500; Santa Cruz Biotechnology, Dallas, TX, USA) was
added and incubated for 40 min, washed and developed using standard protocols.
4.8. B Cell Isolation and Cell Culture
Naïve splenic B cells were isolated using a B Cell Isolation Kit (Miltenyi Biotech,) and cultured
in RPMI (supplemented with 10% FCS, 1% L-Glutamine, 1% HEPES, 1% non-essential amino acids,
1% Sodium pyruvate, 50 μM β-mercaptoethanol) with combinations of 20 μg/mL lipopolysaccharide
(LPS, Sigma-Aldrich) and 100 ng/mL CD40 ligand (CD40L), 10 ng/mL Interleukin-4 (IL-4) and
5 ng/mL Interleukin-5 (IL-5) (all from R&D Systems).
4.9. RNA Isolation and qRT-PCR
4.9.1. Mouse
Naïve B cells were culture for 4 days in the presence of LPS before being resuspended in RLT
lysis buffer (QIAGEN, Venlo, Netherlands) and transferred to a QIA shredder column (QIAGEN) for
lysis and homogenization. RNA extraction was performed using an RNeasy Plus Mini Kit (QIAGEN).
cDNA was generated using iScript reverse transcription supermix (BioRad, Hercules, CA, USA).
qPCR was performed using Taqman probes (Hprt: Mm00446968_m1, Clptm1l: Mm00524746_m1, Plpp5:
Mm01210970_m1, Itm2c: 00499081_m1) and TaqMan Universal Mastermix all from Applied Biosystems.
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4.9.2. Human
Primary cells and myeloma cell lines were homogenized in RLT lysis buffer using the QIA
shredder columns (QIAGEN). RNA extraction for myeloma cell lines and PBMC derived control B
and T cells was performed using the RNeasy mini kit (QIAGEN) including a genomic DNA digestion
step. RNA extraction from primary human plasma cells and MM cells was performed using a RNeasy
micro kit (QIAGEN). cDNA was generated using SSIII First-Strand cDNA synthesis kit (Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA). qPCR used Taqman probes (Applied Biosystems,
Foster City, CA, USA): CLPTM1L: Hs00363947_m1, ITM2C: Hs00985194_g1, PLPP5: Hs00998335_g1,
SLAMF7: HS00221793_m1, GPBP1: Hs00607556_m1, GAPDH: Hs02758991_g1, TPT1: Hs01044518_g1.
Raw qPCR data was imported into LinReg [48] software to determine Cq and reaction specificities.
Final analysis was conducted in qBASEplus (Biogazelle, Zwijnaarde, Belgium).
4.10. ELISA
Blood for serum antibody analysis was collected from all mice at 49 days of age. Plates were coated
with anti-mouse IgM, IgG1, IgG2b, IgG2c, IgG3 or IgA (Southern Biotech, Birmingham, AL, USA) for
24 h before the addition of diluted serum. IgM, IgG1, IgG2b, IgG3 standards were obtained from
Sigma-Aldrich, IgG2c standard was from Southern Biotech, and IgA standard was from Organon
Tekcika–Cappel (Durham, NC, USA). Serum Ig was detected with anti-IgM-HRP, anti-IgG1-HRP,
anti-IgG2b-HRP, anti-IgG2c-HRP, anti-IgG3-HRP, anti-IgA-biotin and streptavidin-HRP (Southern
Biotech) and visualised using ABTS substrate (2,2′-Azinobis (3-ethylbenzthiazoline Sulfonic Acid);
Sigma-Aldrich). All samples and standards were measured in duplicate.
4.11. Retroviral Transduction of B Cells
Plasmids containing pMD1-gag-pol, pCAG-Eco, and pMIG (expressing either GFP alone
(empty vector) or murine Plpp5, Itm2c or Clptm1l and GFP) were transfected into 293T cells using the
Calcium phosphate method. Retroviral supernatant was collected after 48 h and transferred to B cells
that had been pre-stimulated with LPS for 24 h. Transduction was performed using a spin infection in
the presence of polybrene (4 μg/mL). Transduced cells were then cultured in LPS for a further 3 days
before analysis.
4.12. Immunization
4(hydroxy-3-nitrophenyl) acetyl coupled to Keyhole Limpet Hemocyanin (NP-KLH) (Biosearch
Technologies, Petaluma, CA, USA) at concentration of 1 mg/mL was added to Imject Alum (Thermo
Scientific) at a ratio of 1:1. 200 μL was injected into mice intraperitoneally. All mice were at least
7 weeks old at the time of immunization.
4.13. ELISpot
Multiscreen HA plates (Millipore-Sigma) were coated with 10 μg/mL NP20-BSA for 4 h before
the addition of cells. Plates were then incubated for 14–18 h at 37 ◦C 10% CO2. NP-specific antibody
was detected with anti-IgG1-HRP and visualized using 3-amino-9-ethylCarbazole (Sigma-Aldrich).
4.14. Statistical Analysis
Gene expression in human MM, plasma cells and B cells were analyzed using one-way ANOVA
with Tukey’s multiple comparison test on log transformed data. Data from Plpp5−/− Itm2c−/− and
Clptm1ldel/del experiments were analyzed using unpaired t-tests using the Holm–Sidak method to
correct for multiple comparisons.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2161/s1.
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Abstract: The most important feature of humoral immunity is the adaptation of the diversity
of newly generated B cell receptors, that is, the antigen receptor repertoire, to the body’s own
and foreign structures. This includes the transient propagation of B progenitor cells and B cells,
which possess receptors that are positively selected via anabolic signalling pathways under highly
competitive conditions. The metabolic regulation of early B-cell development thus has important
consequences for the expansion of normal or malignant pre-B cell clones. In addition, cellular
senescence programs based on the expression of B cell identity factors, such as Pax5, act to prevent
excessive proliferation and cellular deviation. Here, we review the basic mechanisms underlying
the regulation of glycolysis and oxidative phosphorylation during early B cell development in bone
marrow. We focus on the regulation of glycolysis and mitochondrial oxidative phosphorylation
at the transition from non-transformed pro- to pre-B cells and discuss some ongoing issues.
We introduce Swiprosin-2/EFhd1 as a potential regulator of glycolysis in pro-B cells that has also
been linked to Ca2+-mediated mitoflashes. Mitoflashes are bioenergetic mitochondrial events that
control mitochondrial metabolism and signalling in both healthy and disease states. We discuss how
Ca2+ fluctuations in pro- and pre-B cells may translate into mitoflashes in early B cells and speculate
about the consequences of these changes.
Keywords: B lymphocyte development; metabolism; EFhd1; pre-BCR; mitochondria; mitoflash;
oxidative phosphorylation; glycolysis
1. B Lymphocyte Development
B lymphocytes develop in adult vertebrates in the bone marrow (BM). They are derived from
pluripotent stem cells and develop through the following stages: hematopoietic stem cells (HSCs);
common lymphoid progenitors (CLPs); B cell-biased lymphoid progenitors (BLPs); and pre-pro-, pro-
and pre-B cells. B cell precursors require cell contact and specific niches in the BM for their survival and
growth [1]. Proliferative HSC and pre-pro-B cells, the earliest committed B lymphocyte progenitors,
develop in the vicinity of sinusoids [2–4]. Pre-pro-B cells localize next to CXCL12 (also: SDF-1,
stromal cell derived factor)-abundant reticular (CAR) cells, whereas pro-B cells are found adjacent
to IL-7-expressing stromal cells, the majority of which are in close contact with the vasculature [5].
Pre-B cells localize near Galectin-1-expressing cells [1]. Each of these different niches possesses
Int. J. Mol. Sci. 2018, 19, 2192; doi:10.3390/ijms19082192 www.mdpi.com/journal/ijms141
Int. J. Mol. Sci. 2018, 19, 2192
different oxygen tensions, indicating that there is a need to adapt mitochondrial respiration during
different B cell developmental stages [6]. The specific characteristics of the niches required for early B
lymphocyte development need further exploration and are at least partially and indirectly dependent
on osteoblasts [2,4]. The active migration of cells towards their respective niches is induced by
chemokines such as CXCL12 [3,5]. CXCL12 and CXCR4, the only receptor for CXCL12, are required for
HSC and B cell development in a non-redundant manner [1,7–9], with CXCL12 eliciting an intracellular
Ca2+ signal [7]. The first step of B lymphocyte development is controlled by the transcription factors
(TFs) PU.1 and Ikaros (IKZF1), both of which are expressed in CLPs. Progenitors then commit to
the B cell lineage by expressing E2A, EBF-1 and Pax-5 (reviewed in [10]). Pre-pro-B cells develop
into pro-B cells (Figure 1), in which proliferation is supported by numerous factors, especially the
cytokine interleukin 7 (IL-7) as well as CXCL12 and stem cell factor (SCF) [1]. Another important
factor supporting early B cell development is Fms-like tyrosine kinase (Flt) 3 ligand [1]. B lymphocyte
development follows defined stages that can be distinguished by the expression of cell surface markers,
genetic rearrangements of Immunoglobulin (Ig) heavy and light chain loci and cell size and mitotic
activity [11] (Figure 1; for detailed reviews see [1,12–14]).
In pro-B cells, binding of IL-7 to the IL-7 receptor drives the expression of the anti-apoptotic
molecules Bcl-2 and myeloid-cell leukaemia sequence 1 (MCL1), enhancing survival and
proliferation [3,15]. In vitro IL-7 induces proliferation in pro-B cells (Hardy fraction B and C) but
not in further differentiated B cells [11]. This IL-7 dependency appears to be stronger in mice than
in humans [16]. During development from pro-B cells to immature B cells, IL-7R is downregulated
and responsiveness to IL-7 decreases [17,18]. A much smaller proportion of pre-B cells and immature
B cells is found with higher concentrations of IL-7 but this is not due to the active suppression
of differentiation. In fact, pro-B cells can also differentiate into pre-B cells and sIgM+ cells in the
presence of higher IL-7 concentrations but these cells are outnumbered by proliferating pro-B cells [18].
The expression of Rag1 and 2 by pro-B cells allows diverse to joining (D-J) and variable D-J (VDJ)
recombination of the gene segments that encode the μ heavy chain (μHC) of the B cell receptor (BCR)
in pre-pro-B cells (Fraction A; Hardy et al. [11]) and pro-B cells (Hardy fraction B/C), respectively
(Figure 1; reviewed in detail in [12–14]). After productive VDJ recombination, the newly formed μHC
can pair with the surrogate light chain complex consisting of VpreB and λ5, resulting in pre-BCR
expression and the appearance of large pre-B cells (Hardy fraction C/C’) (Figure 1). Mice deficient in
either of these Rag genes show a developmental B lymphocyte block and accumulate pro-B cells in the
BM because rearrangement of μHC D-J and then VDJ elements cannot take place [19,20].
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Figure 1. Relationship between oxidative phosphorylation and glycolysis during early murine B cell
development. Summary of experimental determinations of the mitochondrial membrane potential
Δψm, glucose uptake, ROS production, Oxphos and glycolysis during B cell development from pro- to
large and from small pre-B to immature B cells [21,22]. Extracellular flux analysis of pro- and small
pre-B cells (mainly small) obtained from rag2−/− or rag2−/−; μHC knock-in mice or from sorted
wildtype pro- and pre-B cells (mainly small) obtained from IL-7 cultures revealed a decline in both
glycolysis and OxPhos, with the decline in glycolysis being more pronounced [21]. Consequently,
small pre-B cells show a higher OxPhos to glycolysis ratio in both systems, with a lower ratio observed
in the IL-7 cultures. Immature B cells reveal an even lower rate of OxPhos [22]. Missing data are
indicated by question marks. The increase in glycolysis and OxPhos in large pre-B cells is speculative
(see boxed question marks in matching colours) and based on literature reviews.
Ectopic expression of the μHC on a Rag2−/− background in mice led to the development of
phenotypic pre-B cells, while the introduction of μHC and lambda (λ)-LC led to the production of
peripheral, monoclonal and immunoglobulin-secreting B cells [20]. The Pre-BCR elicits an increase in the
cytosolic Ca2+ concentration [23–26] and acts as an inducible proliferative signal in pre-B cells with an
expansion factor of 20–100 (approximately 4–6 cell divisions) [27]. Hence, B cell clones with an optimal
pre-BCR signalling strength, based on μHC idiotype, will expand (pre-BCR signal 1) [28]. This defines the
basis for the (mostly autoreactive) pre-immune BCR repertoire, which represents a direct link between
metabolism, growth control and autoreactivity [29,30]. The mechanisms by which the pre-BCR induces
this expansion signal at the structural level have been reviewed elsewhere [5,31,32]. Expression of the
pre-BCR also inhibits further rearrangements of the V to DJ loci in the not yet re-arranged μHC allele (allelic
exclusion) [28]. After the first round of clonal expansion, pre-B cells become quiescent again and decrease
in size (pre-BCR signal 2). In these resting, small pre-B cells (Hardy fraction D), gene rearrangements occur
in the V and J segments encoding the BCR light chain [14]. Successful VJ rearrangement gives rise to light
chain protein, BCR expression and naïve, immature B cells (Hardy fraction E) (Figure 1). Immature B cells
then complete development into resting mature follicular and marginal zone B cells in the spleen [33].
As outlined above, pro-B cells proliferate in response to IL-7, expand transiently into large pre-B cells upon
early pre-BCR expression and then become quiescent as small pre-B cells again to allow VJ recombination
to occur (reviewed in Clark et al. [14]) (Figure 1). The proximal signalling pathways that control these
transitions have been reviewed in detail elsewhere [14,32,34] but several questions remain incompletely
answered. For example, how is pro-B cell proliferation maintained homeostatically? How does IL-7 affect
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early B cell metabolism? How do pre-BCRs, IL-7 and nutrients control the transient expansion of large
pre-B cells and the subsequent quiescence of small pre-B cells? The purpose of this review is to summarize
what is currently known about metabolism during early B cell development.
2. Oxidative Phosphorylation and Glycolysis in Pro- and Pre-B Cells
The ultimate downstream biochemical events that supply cells with adenosine triphosphate
(ATP) are glycolysis and mitochondrial oxidative phosphorylation (OxPhos) (reviewed in detail in
the context of lymphocytes [35]). The oxidation of fatty acids (FAs), carbohydrates and amino acids
is coupled to ATP synthesis in mitochondria by the proton gradient across the inner mitochondrial
membrane (IMM). The proton gradient (ΔpHm) across the IMM is established by the electron transport
chain (ETC) by mitochondrial respiratory chain complexes I, III and IV, which pump protons from
the matrix into the mitochondrial intermembrane space [35]. ΔpH and the mitochondrial membrane
potential (Δψm) contribute independently to the proton motive force (Δp) that drives the synthesis of
ATP via the ATP synthase complex (complex V) (Δp = ΔpHm + Δψm) [36]. The concentration of ATP
relative to that of ADP and AMP is an indicator of the cellular energy status and is sensed by a kinase
complex called adenosine monophosphate – activated protein kinase (AMPK). When the AMP/ATP
ratio reaches a certain threshold, AMPK becomes activated to support catabolic pathways and ensure
an ongoing energy supply. AMPK activity promotes mitochondrial biogenesis and autophagy and
represses the mammalian target of Rapamycin (mTOR) pathway [37–39].
Inhibition experiments performed with 2-deoxyglucose (2-DG), a non-hydrolysable glucose analogue
that blocks glycolysis, have shown that pro-/early/pre-B cells depend on the glycolytic pathway, whereas
late (small) pre-B cells do not [40]. In contrast, a lack of glucose did not prevent the development of
IgM-positive cells in vitro in total BM cultures [41]. It should be noted that 2-DG has off-target effects,
including endoplasmic reticulum (ER) stress, autophagy induction, interference with mannose and
reduced protein N-glycosylation (reviewed in detail in [42]). Hence, these findings need to be reconciled.
However, the experiments performed by Kojima et al. revealed the existence of a metabolic checkpoint in
early B cell development. This finding was corroborated by a genetic screen that revealed the existence
of a metabolic checkpoint controlled by folliculin interacting protein 1 (Fnip1). Fnip1 forms a complex
with AMPK [39] and in Fnip1−/− mice, B cell development is blocked at the large pre-B cell stage due
to an imbalance in metabolism [41]. In WT BM B cell cultures derived from total BM cells grown in the
presence of IL-7, SCF and Flt 3 ligand for 48 h, depleting the cells of glucose, glutamine or essential amino
acids did not affect the number of developing IgM-positive B cells. However, Fnip1−/− B cell progenitors
were sensitive to these depletions, indicating a state of energy exhaustion. Under the same experimental
conditions, oligomycin (an inhibitor of ATP synthase activity in mitochondrial respiratory chain complex
V) at 10 or 50 nM did not affect the appearance of-IgM positive WT B cells, while 10 nM oligomycin did
alter the appearance of these cells in Fnip1−/− cultures. Extracellular flux analyses performed with a
Seahorse analyser showed that pro-/pre-B cells responded to IL-7 by increasing their oxygen consumption
rate (OCR; an indicator of oxidative phosphorylation/OxPhos) (We would like to add, as a technical
note not related specifically to the cited publication [41], that measuring OCR in a Seahorse analyser
does not provide information about the substrates fuelling the TCA cycle. Information about these
substrates can be obtained by using labelled substrates or inhibitors. For instance, FA importation into
mitochondria can be inhibited by Etomoxir but at high concentrations, Etomoxir exerts off-target effects,
including inhibiting complex I of the electron transport chain [43]) and extracellular acidification rate
(ECAR; an indicator of glycolysis) (ECAR measured in a Seahorse analyser represents a pH measurement.
To ensure that an observed decrease in extracellular pH is due to an increase in lactate secretion that
occurs as a consequence of glycolysis, it is recommended that lactate should be measured or 13C-labeled
glucose be tracked) [41]. However, Fnip1−/− pro/pre-B cells responded better. To determine which
substrates fuel the observed increase in OCR, sorted pro-/pre-B cells were treated with 2-DG and Etomoxir.
Both treatments reduced the OCR in WT cells but it was reduced even more in Fnip1−/− pro-/pre-B cells.
These data suggested that pro-/pre-B cells utilize glucose and FA for OxPhos and that Fnip1 renders
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pro-/pre-B cells resilient to inhibition of glycolysis and of FA oxidation. Further experiments connected
this metabolic checkpoint to the Fnip1:AMPK complex and the pro-/pre-B cell transition (Figure 2A).
The anabolic ATP exhaustion observed in Fnip1−/− pro-/pre-B cells is likely mediated by an increase
in rps6ka1 expression [41]. A similar mechanism has been observed in transformed haploinsufficient
Phosphatase and Tensin homologue (PTEN)-/+ and PTEN−/− pre-B acute lymphoblastic leukaemia
(ALL) cells [41,44]. While the experiments performed by Kojima et al. and Park et al. were seminal,
measurements of OxPhos and glycolysis in discrete pro- and pre-B cell populations have not yet been
performed under more defined conditions (e.g., medium with IL-7 only). Thus, we analysed metabolism
in discrete pro- and pre-B cells (Figure 1) [21]. Mitochondrial mass relative to cell size is decreased in large
pre-B cells but remains constant during later B cell development [21]. Pro-B cells exhibited the highest Δψμ;
Δψμ is then significantly lower in small pre-B cells and declines further during development. Reactive
oxygen species (ROS) production, as measured by 2′-7′-dichlorodihydrofluorescein diacetate (DCDFA, a
dye that does not specifically quantify mitochondrial ROS) and glucose uptake are highest in large pre-B
cells but reduced in small pre-B cells, supporting the data described by Kojima and colleagues [40]. To
measure glycolysis and OxPhos directly in pro- and pre-B cells, we established a μHC knock-in (ki) mouse
model (33.C9μHCki) and crossed these mice to Rag1−/− mice [19] (Rag1−/−;33.C9μHCki) [21]. Pre-B cells
obtained from Rag1−/−;33.C9μHCki mice are mainly small. Extracellular flux analyses performed with
sorted primary pro- and pre-B cells obtained from this system revealed that in general, under normoxic
conditions, OCR and ECAR were lower in Rag1−/−;33.C9μHCki pre-B cells than pro-B cells. These data
were confirmed by Zeng et al., who also analysed immature B cells, which have an OCR similar to
that of small pre-B cells [22]. In contrast to Zeng et al. we also assessed glycolysis. In our experiments,
glycolysis (evaluated by ECAR) was significantly reduced relative to OCR in small pre- versus pro-B
cells, resulting in a higher OCR/ECAR ratio (Figure 1). However, the contributing mechanisms and
consequences of the alterations in OCR/ECAR ratios and mitochondrial spare capacity observed in this
system require more study. Nevertheless, we noted that the OCR/ECAR ratio was in general lower in
IL-7 cultures, suggesting that IL-7 promotes glycolysis (Figure 1). In fact, IL-7 promotes glycolysis by
activating Akt [13,45,46] and this might be important in IL-7-rich niches in BM [1,6]. IL-7 also appears to
elevate mitochondrial spare capacity, perhaps via the pyruvate that is generated by glycolysis and directed
towards the tricarbon (TCA) cycle (Figure 2A). The data described in Park et al. [41] do indeed imply that
mixed pro-/pre-B cell cultures use pyruvate derived from glycolysis to fuel and maintain OxPhos but
more experiments are needed to define the TCA substrates used in pro- and pre-B cells. In summary,
pre-BCR expression ultimately promotes metabolic quiescence (pre-BCR signal 2) by reducing glycolysis
(as defined by ECAR using a Seahorse analyser), resulting in an increased OCR/ECAR ratio. The decrease
in glycolysis observed in small pre-B cells compared to pro-B cells is in agreement with the proposal that
Akt is inactivated [32,47] (pre-BCR signal 2) and that glucose up-take [21] and responsiveness to IL-7
are reduced.
It appears that the reduction of metabolism observed in small pre-B cells is maintained in
immature B cells [22]. Additionally, resting splenic B cells exhibit low metabolic activity [48] and
consume FA to produce ATP via OxPhos, as shown by metabolic tracking of FA [48]. Upon BCR
activation or by lipopolysaccharide (LPS) mediated TLR4 activation, normal but not anergic splenic
murine B cells again upregulated both OxPhos and glycolysis in a Myc-dependent manner in a
balanced ratio [48–50], concomitant with an increase in the glucose transporter glut1. The newly
activated B cells then oxidize glutamine and pyruvate [48]. Interestingly, murine peritoneal B1 B cells
are metabolically more active than follicular B cells and depend on glycolysis [51]. Glycolysis (analysed
in inhibition experiments performed with dichloroacetate, an inhibitor of pyruvate dehydrogenase)
also supported the secretion of antibodies from murine and human B cells both in vitro and in vivo [48].
Glucose taken up by plasma cells is mainly used for antibody glycosylation [52]. No information is
available regarding differences between follicular and marginal zone B cells or whether small pre-B
cells or immature B cells rely on FA. In addition, extracellular flux analyses of primary pro-and small
pre-B cells failed to identify large pre-B cells for technical reasons. Large pre-B cells could, in the future,
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potentially be enriched from Irf4/8 double [53] or BLNK/SLP-65 knock-out mice [54], which fail
to downregulate pre-BCR, show hyperproliferation of large pre-B cells and are prone to malignant
transformation. It is likely that glycolysis is increased in large pre-B cells and this would provide
more energy and more anaplerotic reactions for macromolecules and intermediate products, thereby
protecting cells from ROS [55], in addition to more pyruvate to support mitochondrial ATP production
(Figure 1). A genetic in vivo system that allows the mitochondrial respiratory chain to be manipulated
could address this question. For instance, experiments performed in mice with an inducible deletion
of the mitochondrial pyruvate importer Mcp2 (in Mcp2fl/fl;ROSA26 CreER mice) revealed that plasma
cells in the BM rely on this mechanism [52].
A caveat of all the studies mentioned so far is that ex vivo experiments are generally performed
under normoxic conditions, while many parts of the BM and several of its niches are hypoxic [6].
Immune cells adapt to hypoxia by stabilizing HIF at the protein level [56]. Indeed, HIF1α deficiency
impaired early B cell development in Rag2−/− blastocyst complementation chimeras by reducing
the number of proliferating CD43-HSA+B220+ cells [57]. On the other hand, B cell development
in the BM of HIF1αfl/fl or HIF2αfl/fl mice crossed to Mb1-Cre mice is normal [58]. Although the
CD43-HSA+B220+ cells affected by HIF1α deficiency are likely proliferating pre B cells, there is the
possibility that HIF1α mediated metabolic adaptations influence B cell development already before
the mb-1 promotor is active. HIF-1α controls glycolysis in BM precursor B cells in a developmental
stage-specific manner by regulating the genes that encode glucose transporters and the key glycolytic
enzyme 6-phosphofructo-2-kinase/fructose-2,6-bishosphatase 3 [40]. Interestingly, HIF1α-deficient
B cell progenitors compensated for defects in glycolytic enzymes by increasing the expression of
respiratory chain-related genes and TCA-related genes, enabling more efficient pyruvate usage [40].
These data reveal that B cell progenitors are metabolically flexible and show a propensity to adapt
to different oxygen tensions in the BM, thus ensuring survival and correct development. A very
interesting point is that these adaptations in the BM due to loss of HIF1α appear to impact on B1 B
cells and autoimmunity [57]. In accordance, recent elegant experiments have revealed that HIF1α is
important for expansion of CD1dhighCD5+ B cells via glycolysis and production of anti-inflammatory
IL-10 by those B cells [58]. Further studies performed under hypoxic conditions are required to
fully explore the physiological role of glycolysis and OxPhos in pro-B and pre-B cells. Another
important experimental step was to establish a system that physiologically represents human early
B-cell development [59]. Studying metabolic changes during early human B cell development in vitro
could provide crucial evidence about the development of autoreactivity, malignant transformation and
B cell repopulation following eradication of the bone marrow (e.g., by radiation or chemotherapy) [59].
3. Signalling Pathways Linking Membrane Receptor Signals to Glycolysis and Oxidative
Phosphorylation in Pro- and Early Pre-B Cells
The genes that control mitochondria and glycolysis are targets of both pre-BCR and BCR [48,60].
This indicates that the metabolic machinery of B cells integrates signals down-stream of (pre-) BCRs and
growth factors [47,48], thereby, connecting the μHC idiotype with metabolism. The IL-7 and pre-BCR
signalling network in pro- and pre-B cells has been reviewed in detail elsewhere [13,34]. Briefly, pro-B
cells receive signals related to survival and proliferation via IL-7, Janus kinase (JAK) and signal transducer
of activation and transcription (STAT) factors that enforce B cell identity via the expression of Pax5 and
Ebf1. Interestingly, the B cell identity-related TFs Pax5 and IKZF1 limit glucose uptake in normal B cells
and thereby support a metabolic program that leads to metabolic exhaustion when an oncogene, such as
Bcr-Abl, is activated [61]. IL-7 activates the phosphatidyl-inositol-3-kinase (PI3K) pathway, leading to
the activation of extracellular regulated kinase (Erk) [62] and Akt and the inactivation of Foxo1 [15,63,64].
The early pre-BCR signal also engages the PI3K cascade via Syk. In particular, the PI3K and Erk pathways
control proliferation during pre-B cell development [46,47,62]. It appears, however, that PI3K activity
needs to be limited by PTEN, which controls IL-7R expression, to allow pro-B cell development [22].
In mammals, mTOR is downstream of PI3K signalling in B cells (reviewed in [39]). mTOR is a kinase
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complex that supports IL-7-induced anabolism via glycolysis and Myc [22] (Figure 2A). The mTORC1
complex is positively regulated by Raptor, whereas the mTORC2 complex is controlled by Rictor. Anabolic
mTORC1 activity is counterbalanced by AMPK (reviewed in [39]). Because Fnip1 forms a complex with
AMPK and a lack of Fnip1 leads to the hyperactivation of mTOR, Fnip1 mediates the inhibitory effects of
AMPK on mTOR [41,65] (Figure 2A). The conditional deletion of Raptor in B cells in mb1-Cre mice [66]
led to the B cell-specific inactivation of the mTORC1 complex [67].
 
Figure 2. Relationship between oxidative phosphorylation and glycolysis during early murine B cell
development. In pro- and large pre-B cells, growth is controlled by IL-7 and the pre-BCR, which lead
to the activation of the PI3K/Akt/mTOR pathway. mTORC1 activates glycolysis and OxPhos and is
required for the protein expression of μHC, which controls pre-BCR expression and signalling. Whether
control of μHC protein expression occurs via glycolysis and/or OxPhos is not clear. Surface expression
of the pre-BCR leads to the downregulation of EFhd1, a Ca2+-binding protein localized on the inner
mitochondrial membrane. EFhd1 suppresses glycolysis in transformed pro-B cells and is induced by
PTEN. In primary pre-B cells, overexpression of EFhd1 induces PGC1α, which is also controlled by
AMPK1, a negative regulator of anabolic pathways and a positive regulator of catabolic pathways.
AMPK activity is controlled by ADP/AMP and ATP/ADP ratios and fructose 1,6 bisphosphate and is
an indicator of glycolytic flux. AMPK activity is also modified by FNIP1. Loss of FNIP1 by genetic
ablation leads to anabolic exhaustion in pro-/pre-B cells. IL-7 increases the mitochondrial spare capacity
in pre-B cells. (A) The network in pro- and large pre-B cells with an activated PI3K pathway and
inactivated Foxo1; and (B) the network in small pre-B cells, in which the PI3K and mTORC1 pathways
are inactivated but Foxo1 is activated. It is unclear whether large pre-B cells depend solely on glycolysis
or whether glycolytic pathways are mutually linked to OxPhos.
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mTORC1-deficient pro- and perhaps early pre-B cells (Hardy fractions C and C’) developed in
these mice, small pre-B cells (fraction D) were strongly reduced and later stages were absent. Although
VDJ and VJ recombination were normal in the remaining C/C’ and D fraction cells, the expression of
the IgM (μ) heavy chain was severely impaired, even when expressed as anti-hen egg lysozyme (HEL)
transgenic BCR. Hence, B cell development was not rescued by the expression of anti-HEL BCR. It is
unclear why mTORC1 activity is required for IgM expression. It is possible that mTORC1 controls IgM
stability downstream of glycolysis and OxPhos, or it may support glycosylation via the hexosamine
biosynthetic pathway and thereby stabilize the membrane expression of μHC within the pre-BCR
complex (Figure 2A).
4. Swiprosin-2/EFhd1 as a Regulator of Glycolysis in Pro-B Cells
Swiprosin-2/EFhd1 (EFhd1) is a Ca2+-binding protein that localizes to the IMM and consists of
an N-terminal disordered region, two central Ca2+-binding EF-hands and a C-terminal coiled-coil
domain [68–71] (Figure 3). EFhd1 is a target gene of the TFs involved in B cell identity and
controlling early B cell development. These TFs include Foxo1, Brg1 and Ebf1 in pro-B cells [72,73].
PTEN also promotes efhd1 expression [44] (Figure 2A). EFhd1 becomes upregulated together with
PGC-1α, uncoupling protein (UCP) 2 and other proteins involved in mitochondrial functions in the
distal convoluted tubule cells of the kidney by inducing the deletion of the cytosolic Ca2+ buffer
parvalbumin [74]. We showed that EFhd1 is expressed in primary mouse pro-B cells at the RNA and
protein levels [21]. Surface expression of the pre-BCR resulted in the downregulation of EFhd1 in
pro-B cells. Hence, IgM-positive B cells no longer express EFhd1 [21]. These data indicate that very
early pre-B cells still express EFhd1 protein, although the half-life of EFhd1 is unknown (Figure 2A).
The mechanism underlying the surface pre-BCR-mediated repression of EFhd1 is also unknown but it
may involve tonic pre-BCR/BCR signals. Pro-B cells only tolerate a moderate amount of EFhd1 and
pre-B cells need to downregulate EFhd1, probably to maintain mitochondrial ATP production during
the pro- to pre-B cell transition [21].
As optimal pre-BCR signalling strength depends on efficient pairing of the newly generated
μHC with VpreB and λ5, the downregulation of EFhd1 by the pre-BCR might link μHC
signalling competence (the μHC repertoire) to metabolic fitness in pre-B cells. Along these lines,
the Crispr-Cas9-mediated knock-out of EFhd1 as well as the its shRNA-mediated knock-down in
the transformed pro-B cell line 38B9 resulted in increased glycolysis and a higher glycolytic rate and
glycolytic spare capacity [21] (Figure 2A,B). We propose that the downregulation of EFhd1 in pro-B
cells by pre-BCR signals is one of the mechanisms that drives pre-B cell expansion via glycolysis.
We further speculate that the pre-BCR-mediated repression of EFhd1 represents a cellular readout for
optimal pre-BCR signalling strength. The upregulation of PGC-1α by EFhd1 and its negative effect on
glycolysis indicate that EFhd1 is a potential catabolic factor. It is thus of interest that the efhd1 promotor
is frequently methylated in tumour biopsies in colorectal cancer patients [75].
5. Signalling Pathways Linking Membrane Receptor Signals to Glycolysis and Oxidative
Phosphorylation in Late Pre-B Cells
In parallel with decreasing IL-7 responsiveness, the pre-BCR initiates the expression of
SLP-65/BLNK, allowing large pre-B cells to differentiate into small pre-B cells, by inhibiting the
PI3K/Akt pathway and inducing a concomitant increase in FOXO1 activity [47,76,77] (Figure 2B).
In small pre-B cells, PI3K and mTORC1 activity are strongly inhibited, enabling Foxo1 to suppress cell
growth and facilitate LC rearrangement. EFhd1 is downregulated and its putative catabolic, that is,
limiting effect on glycolysis may be overcome by a reduction in mTORC1 activity and an increase in
Foxo1 activity (speculative model shown in Figure 2B). Together with Pax5, FOXO1 transactivates
Rag1/2, IRF4 and p27, thereby inducing cell cycle arrest, while LC rearrangement takes place in
small pre-B cells [13,73,78]. FOXO1 is also activated by ROS and upregulates superoxide dismutase
2 (sod2) [15]. The increase in the FOXO1 target gene, sod2, observed in pre-B cells [21] is compatible
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with the dephosphorylation and activation of FOXO1, which occurs as a consequence of reduced
Akt activity [15] and might limit ROS. Interestingly, EFhd1 has been shown to be downregulated by
SOD2 [79] (Figure 2B).
6. Putative Existence of Mitoflashes in Early B Cells—Regulated by EFhd1?
Careful measurement of mitochondrial pH (pHmito) has revealed that pHmito is in dynamic
equilibrium with cytosolic pH (reviewed in [36]). Similarly, the cytosolic Ca2+ concentration is
connected to the mitochondrial Ca2+ concentration via connections between the ER and mitochondria
(reviewed in [80]) and Ca2+-binding proteins in mitochondria, likely including EFhd1 (reviewed in [69]).
The spontaneous pHmito elevations that coincide with drops in Δψm can occur in single mitochondria
or discrete regions of the mitochondrial network and have been termed “mitoflashes” [81,82].
Mitoflashes are modulated by, for example, metabolic state, oxidative stress, developmental stage,
aging and Ca2+ [82]. It is currently a matter of debate as to whether mitoflashes do or do not represent
superoxide bursts [83] but there appears to be some consensus that they are related to pHmito [81,82].
It thus has been proposed that the term “MitopHlash” [81,84] should be used and we will not
address superoxide here. In general, during a mitoflash, spontaneous drops in Δψm are coupled
to mitochondrial matrix alkalinization, thereby preserving an intact Δp and enabling ongoing ATP
production [36]. Experiments performed in 293 cells have shown that EFhd1 is a mitochondrial
Ca2+ sensor of Ca2+-dependent mitoflashes induced by ionomycin [85]. This function of EFhd1
depends on its EF-hands, as shown in experiments with point mutations (i.e., E116A and E152A) at
critical residues [86] in each of its two EF-hands. Furthermore, EFhd1 does not induce alterations in
mitochondrial Ca2+ handling [85]. These data raise the possibility that EFhd1 is a Ca2+ sensor that
monitors Ca2+ flux from the ER to mitochondria [69] and that EFhd1 may be coupled to complex I,
III or IV of the respiratory chain or H+ coupled Ca2+ transporters located in mitochondria. In fact,
pHmito and mitochondrial Ca2+ are coupled [87]. There is room for speculation as to what the function
of mitoflashes in early B cells might be. It is conceivable that external signals such as CXCL12 in pro-B
cells [7] or successful expression of pre-BCR could activate mitoflashes by inducing signalling cascades,
resulting in increased intracellular Ca2+ [23–26]. Assuming that mitoflashes represent mitochondrial
bioenergetic phenomena that sustain the proton motive force and ATP production, the fast changes
in pHmito and Δψm may maintain quick metabolic adaption, which is vital for the activation and
differentiation processes that occur in pro- and pre-B cells. EFhd1 expression in pro- and likely very
early pre-B cells may contribute to the Ca2+-dependent control of mitoflashes, thereby, modulating
CXCL12 and pre-BCR induced metabolic survival and expansion signals (Figure 3). In the case of
the pre-BCR, it would, however, do so only transiently because surface expression of the pre-BCR
(see above; [21]) leads to downregulation of EFhd1 via as yet unknown mechanisms. We propose that
the downregulation of EFhd1 represents a sensor for optimal pre-BCR signalling strength. Pre-B cells
downregulating EFhd1 faster because they express an appropriate μHC idiotype on the cell surface
may switch to glycolysis faster and this may provide a competitive advantage. Hence, EFhd1 might
integrate mitochondrial metabolism, glycolysis and μHC selection in BM. We envision an intimate
interplay among pre-BCR-controlled genes involved in metabolism and Ca2+ sensing mechanisms,
such as efhd1. This may be important for the fitness of early B cells.
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Figure 3. Putative mechanism for EFhd1-controlled mitoflashes in early B cells. Mitoflashes
(also MitopHlashes) are bioenergetic responses to stochastic drops in the mitochondrial membrane
potential (Δψm). Their origin is unclear but research performed using pH-sensitive probes showed that
flashes represent matrix alkalinization transients and are therefore linked to pH. It has been proposed
that mitoflashes control mitochondrial metabolism and signalling in both healthy and disease states
and can be triggered by increased mitochondrial Ca2+ concentrations. EFhd1 has been shown to
mediate mitoflash activity in response to increases in mitochondrial Ca2+ concentrations via its two
EF hands. The existence and, moreover, the consequences of this event in pro-B cells, which express
EFhd1, is currently unclear. EFhd1 might translate a CXCL12 or pre-BCR induced increase in Ca2+ into
a mitoflash, thereby coupling Ca2+ to mitochondrial pH regulation and proton motive force.
7. Conclusions and Perspectives
The metabolic regulation of pro- and pre-B cell development has important consequences for the
expansion of normal and malignant pre-B cell clones. Under healthy conditions, it affects the normal
BCR repertoire and contributes directly to adaptive immunity. To understand how the growth of
normal or transformed pro- and pre-B cells is regulated, we have reviewed recent data on the regulation
of glycolysis and oxidative phosphorylation in early B cells. It has become clear that pre-BCR ultimately
induces metabolic quiescence because it leads to a reduction in glycolysis in late pre-B cells. The current
data also suggest that large pre-B cells utilize glycolysis to sustain ATP but previous extracellular flux
analyses of primary pro- and pre-B cells have missed large pre-B cells for technical reasons. Large pre-B
cells may in the future be enriched from Irf4/8 double or BLNK/SLP-65 knock-out mice to clarify this
issue. It remains unclear whether large pre-B cells (a) perform more glycolysis than is found in pro-B
cells; (b) depend solely on glycolysis for their growth or (c) require pyruvate generated by glycolysis
for ATP production via OxPhos. Hence, it remains completely unknown whether pro-B cells and
pre-B cells depend in vivo on the mitochondrial respiratory chain. It will also be important to study
metabolism in early B cells under hypoxic conditions, which occur naturally in BM. It is clear that
HIF1α plays a role in early B cell development by promoting glycolysis in B cell progenitors. Here,
we introduce the idea that recently described bioenergetic events in mitochondria (“mitoflashes”)
that have been shown to maintain the proton motive force required to generate mitochondrial ATP
may also occur in pro- and early pre-B cells. A Ca2+-binding protein that localizes on the IMM,
Swiprosin-2/EFhd1 (EFhd1), might be involved in this phenomenon because it is expressed in pro-B
cells and controls Ca2+-dependent mitoflashes. We have shown that EFhd1 becomes downregulated
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by cell surface expression of pre-BCR and that EFhd1 limits glycolysis in pro-B cells. We propose that
EFhd1 might integrate Ca2+ signals with gene regulation and metabolic activity in pro- and early B
cells and EFhd1 may thereby serve as a sensor for optimal pre-BCR signalling strength. The interplay
between pre-BCR signalling and metabolism was clearly revealed in mice lacking mTORC1 activity in
B cells. mTORC1 is required to maintain the stability of the IgM heavy chain and it therefore controls
pre-BCR signalling at this level. The mechanism behind this function remains unknown but it may
involve the generation of anaplerotic intermediate factors produced during glycolysis. In summary,
we suggest that more extensively examining the regulation of metabolism in pro- and pre-B cells
would increase our understanding of growth control and the generation of a healthy BCR repertoire.
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BLP B cell-biased lymphoid progenitor
BCR B cell receptor
BM Bone marrow
CAR cell CXCL12-abundant reticular cell
CLP Common lymphoid progenitor
ECAR Extracellular acidification rate
EFhd1 Swiprosin-2/EFhd1
EFhd1tg EFhd1 transgenic
ETC Electron transport chain
Erk Extracellular signal regulated kinase
FA Fatty acid
Flt Fms-like tyrosine kinase
Fnip1 Folliculin-interacting protein 1
HC Heavy chain
HSC Hematopoietic stem cell
Ig Immunoglobulin





Δψm Mitochondrial membrane potential





PTEN Phosphatase and Tensin homologue
ROS Reactive oxygen species
SCF Stem cell factor
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SDF-1 Stromal cell derived factor
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